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Skeletal muscle plasticity is imperative for functional adaptation to changing demands in activity.
Although a great deal is known about the structural and functional plasticity of healthy skeletal
muscle, far less is known about plasticity in diseased muscle. Here, we combined the power of
the zebrafish model with the adaptability of neuromuscular electrical stimulation (NMES) to
study the basic mechanisms of plasticity in the zebrafish model of Duchenne Muscular
Dystrophy (DMD). Four NMES paradigms, defined by their frequency, delay, and voltage, were
designed to emulate the repetition and load schemes of human resistance training programs.
Additionally, two inactivity paradigms were designed to emulate activity patterns in individuals
with DMD. Three sessions of endurance NMES improve muscle structure, increase swim
velocity and distance traveled, and extend survival. Endurance NMES significantly increased
the number and length of branching for neuromuscular junctions. Nuclear surface area and
volume also significantly increased following endurance NMES. Time-lapse imaging suggests
less degeneration and improved regeneration of the fast-twitch muscle fibers. Conversely, three
days of inactivity worsen muscle structure and decreases survival. Strikingly, inactivity followed
by a single session of endurance or power NMES obliterates muscle resilience. Therefore, our
data clearly indicate that, at least in the zebrafish model, some resistance training is beneficial

whereas inactivity is deleterious for dystrophic muscle. More importantly, though, our data
provide a new methodology with which to study muscle plasticity in healthy and diseased
muscle.
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CHAPTER 1
REVIEW OF THE LITERATURE

1.1 Introduction
My research examines the impact of inactivity versus neuromuscular electrical
stimulation (NMES) on disease progression in the zebrafish model of Duchenne muscular
dystrophy (DMD). Before diving into the significance of this research, it is worthy to discuss
skeletal muscle and the components that allow it to perform functions that are critical to
organismal health. A special emphasis is placed on the dystrophin protein and the role it plays
in maintaining the structural integrity of the muscle fiber. More importantly, though, dystrophin is
discussed in the disease context, from both clinical and molecular perspectives, since DMD is
the direct result of its absence. Lastly, an in-depth review of studies examining the role that
inactivity and activity play in DMD disease progression is provided to demonstrate the need for
more research as well as a new approach to this research question.
1.2 Skeletal Muscle Function
Unlike many organs in the body, most individuals are confident in defining what skeletal
muscle is, identifying where it is located, and describing the roles it plays in the human body.
However, the complexity of skeletal muscle’s function in human health continues to grow as
new proteins are identified, and new roles for previously identified proteins are uncovered.
Throughout the hundreds of thousands of research papers investigating skeletal muscle, it is
well-established that skeletal muscle is a highly dynamic tissue whose structural and molecular
networks actively respond to changes in the demands imposed on it. The skeletal muscle’s
ability to adapt to these demands is critical to maintaining not only muscle health but the overall
health of an individual.
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Skeletal muscle’s primary role in the human body is to generate movement. It allows us
to navigate throughout our world and to interact with our surroundings. Additionally, skeletal
muscle maintains our posture and allows us to breath. Functional independence in our daily
lives is determined by how successfully our skeletal muscle functions. However, skeletal muscle
contributes to human health beyond generating the force and power required for movement,
and these contributions are often overlooked. Over the past decade, an upsurge in ‘omic’
technologies, including proteomics and metabolomics, painted a more detailed molecular
picture of skeletal muscle. This picture now encompasses a myriad of interactions with other
body systems through numerous players [1]. Most notably, skeletal muscle is now classified as
an endocrine organ. Recently, it was established that skeletal muscle secretes cytokines and
other peptides, consequently termed myokines, that play important roles in maintaining
metabolic homeostasis [2,3] and inflammation [4,5]. Interestingly, these myokines are regulated
by skeletal muscle contractions and activity levels [2,6–8]. Skeletal muscle is also a highly
metabolic tissue. It is essential for basal energy metabolism by serving as a storage site for
carbohydrates and glucose homeostasis [9]. Additionally, skeletal muscle is a reservoir for
amino acids, housing 50-75% of proteins required by other tissues, including the skin, brain, and
heart [9]. Lastly, a major role skeletal muscle plays in energy metabolism is the production of
heat to maintain core temperature [9].
Since skeletal muscle plays an important role in human movement and a vast amount of
other key aspects of human health, it is not surprising that research continues to demonstrate
that it is one of the primary predictors of longevity and recovery from illness and injury.
Specifically, reduced skeletal muscle mass impairs the body’s ability to respond to and recover
from stress and chronic illness [9]. This is best exemplified in aging, where the loss in skeletal
muscle mass contributes to an overall decline in physical functioning, increased disability, and
mortality [10]. Therefore, robust skeletal muscle mass is essential for whole-body homeostasis
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[11], and it is important that research focuses on preserving this tissue in healthy and diseased
states.
1.3 Skeletal Muscle Structure
There are over 650 named skeletal muscles within the human body, and each of them
share the same underlying structure. Skeletal muscle structure is highly intricate but can be
broken down into four main components: the nerves that signal muscle contraction, the
individual muscle fibers that contract, the vasculature that delivers oxygen, and the metabolic
machinery that supplies energy to power movement [1]. Each of these four components contain
many subcomponents with intricate structures that play a critical role in maintaining the overall
structure of the muscle and allow it to perform its many functions. Understanding the underlying
structure of skeletal muscle brings to light how a small perturbation, such as the presence of a
partially formed protein, can spiral into a vicious cycle of degeneration and weakness.
Skeletal muscle is best described as a cylindrical bundle of cylindrical bundles that are
separated from one another by connective tissue sheaths. For example, if we build a biceps
muscle, the muscle responsible for flexion of the elbow, we begin first with the myofilaments,
which are actin and myosin. Actin and myosin are long cylindrical proteins that are found in
series along the length of the muscle fiber. Together, they are surrounded by a plasma
membrane, known as the sarcolemma. Individual muscle fibers are wrapped by a second
connective tissue sheath, called the endomysium, and are arranged into bundles, called
fascicles. Each individual fascicle is surrounded by a connective sheath, called the perimysium.
Finally, these fascicles are bundled together to form the biceps muscle, which is surrounded by
another layer of connective tissue known as the epimysium.
Skeletal muscle is not only highly organized but is highly vascularized and highly
innervated. An elaborate network of arteries and veins create a rich lattice of vasculature that
enmeshes the bundles of muscle fibers [1]. These networks ensure that muscle fibers are
supplied with ample amounts of oxygen for energy production. Notably, the density of the
3

vasculature varies within and between muscles, and adapts to changes in energy demand [1].
Motor neurons innervate the muscle, carrying signals from the brain to the muscle. Unlike the
vasculature, there is a one-to-one relationship between a muscle and the motor neurons
innervating it [12]. That is, a motor neuron can only innervate one muscle. However, a single
motor neuron can innervate multiple muscle fibers within that muscle, but a muscle fiber cannot
be innervated by more than one motor neuron [12]. The muscle fibers innervated by a single
motor neuron is collectively called a motor unit [12]. The size of the motor unit, or the number of
muscle fibers innervated by the motor neuron, is dependent upon the movements performed by
the muscle. For example, motor units are small for muscles of the hands and fingers in order to
carry out their highly coordinated, more delicate movements. Conversely, motor units are
extremely large for the muscles of the thigh since highly coordinated movements are not
required [12].
1.3.1 The Muscle Fiber
Individual muscle fibers themselves are highly organized and contain a plethora of
intricate structural and regulatory components. Unlike other cells in the body, muscle fibers are
multi-nucleated and post-mitotic [9], meaning multiple nuclei are found along the length of an
individual muscle fiber and the muscle fiber is unable to divide to form a sister cell. Muscle fibers
exhibit a range of diameters and lengths, but are, on average, 100 micrometers in diameter and
1 cm in length [9]. Therefore, having nuclei spread along the length of the muscle fiber ensures
that specific proteins are synthesized and readily available to meet the demands of the muscle
fiber within each region [13]. Similar to the nuclei, mitochondria are located strategically
throughout the entire muscle fiber to allow for maximum oxygen delivery to the mitochondria,
which in turn, allows for maximum energy production by the mitochondria [14]. Specifically,
individual mitochondria are positioned close to the sarcolemma to reduce oxygen’s diffusion
distance from the vasculature as well as in the intermyofibrillar space to enhance the delivery of
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ATP to the contractile machinery. Notably, changes in the demands imposed on skeletal muscle
result in significant changes to these three structural components [9].
Individual muscle fibers drive skeletal muscle contraction and force generation required
for locomotion, breathing, and postural stability. Muscle contraction is carried out and supported
by five basic units: the neuromuscular junction (NMJ), the excitation-contraction coupling
machinery, the sarcomere, the extracellular matrix (ECM), and the cytoskeleton [1]. The NMJ
serves as the junction between the innervating motor neuron carrying the signal for contraction,
the excitation-contraction coupling machinery then transforms the electrical impulse from this
neuron into a mechanical contraction, the sarcomere is the contractile apparatus responsible for
force generation while the ECM and cytoskeleton protect the muscle by providing mechanical
support and force transmission. Together, this units allow the muscle to sustain rapid cycles of
contraction and relaxation. The following sections below provide more detail on the these
structural components.
1.3.2 The Neuromuscular Junction
The NMJ is the chemical synapse that transmits the electrical impulse from the
innervating motor neuron to the muscle fiber. It is comprised of three major regions: the
presynaptic region, the synaptic space, and the postsynaptic region. Within the presynaptic
region is the nerve terminal that houses synaptic vesicles containing the neurotransmitter,
acetylcholine [15,16]. Synaptic vesicles fuse to the presynaptic membrane and release
acetylcholine into the synaptic space [17]. The synaptic space is the space between the preand post-synaptic membranes through which acetylcholine diffuses. Within the postsynaptic
region are the junctional folds, which serve to amplify both the space occupied by and the
volume of the postsynaptic membrane area [1]. The crests of these junctional folds are packed
with nicotinic acetylcholine receptors [18], which become activated by the diffusing
acetylcholine. Muscle contraction is discussed in more detail in 1.4.
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1.3.3 The Excitation-Contraction Coupling Machinery
The excitation-contraction coupling machinery is composed of the transverse tubular (T
tubule) system and the sarcoplasmic reticulum [9]. The T tubule system conducts the electrical
signal received from the motor neuron to the interior of the muscle fiber [19]. T tubules are
invaginations of the sarcolemma that ensure information from the innervating neuron is spread
uniformly throughout the fiber [19] and that contractions are coordinated events. The
sarcoplasmic reticulum is responsible for the storage, release and reuptake of calcium during
muscle contractions [9]. The ends of the sarcoplasmic reticulum, termed terminal cisternae, are
responsible for storing calcium and form triads with the T tubule system [9].
1.3.4 The Sarcomere
The sarcomere is the basic unit of the muscle fiber and it is the site of rapid force
generation that brings above movement. Sarcomeres are intricate structures composed of two
main alternating sets of protein filaments: thin filaments and thick filaments. Thin and thick
filaments run parallel to the muscle fiber axis and are made up of actin and myosin,
respectively, as well as their associated proteins [1]. Using transmission electron microscopy,
the hallmark features of the sarcomere are easily visualized and distinguished by their light and
dark appearance. At each end of the sarcomere is a dark narrow line called the Z disk, which is
shared between adjacent sarcomeres and bisects the lighter I band [1]. The Z disk is
responsible for holding together the thin filaments. Conversely, at the center of the sarcomere is
a dark narrow line called the M line, which bisects the darker A band [1]. The M line is
responsible for holding together the thick filaments [1].
The sarcomere is home to a diverse array of proteins whose roles include structural
stability, excitation-contraction coupling, energy release, and the generation of force and power
[20]. For example the troponin complex (including troponins C, I and T, which are the calcium,
inhibitory, and tropomyosin binding subunits, respectively) and tropomyosin are associated with
the actin filament and play a major regulatory role in the activation of excitation-contraction
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coupling and force generation [9]. Two major structural proteins are titin and nebulin [20]. Titin is
a large elastic protein anchored to the Z disk and the myosin filaments while nebulin is
integrated within the actin filaments [21]. Both titin and nebulin serve as molecular templates,
ensuring the precise length and organization of the myosin and actin filaments, respectively
[22]. Additionally, titin and nebulin stabilize the sarcomere and maintain its integrity [20] through
their contribution to the ever evolving passive tension and stiffness required by individual
muscle fibers [9]. Myomesin is present at the M-line to serve as an additional strain sensor [23],
while creatine kinase serves as a spatial ATP buffer and maintains energy homeostasis [24,25].
1.3.5 The Extracellular Matrix
As mentioned in the discussion of skeletal muscle structure, there are three discrete but
interconnected connective tissue sheaths that surround and protein the muscle fibers, fascicles,
and whole muscle: the endomysium, the perimysium, and the epimysium, respectively. These
sheaths represent the extracellular matrices within skeletal muscle. The focus of this section,
though, is on the endomysium and its interface with the sarcolemma. At the heart of this
interface, is a specialized basement membrane [1], which is becoming more appreciated as
research continues to demonstrate its multi-functional roles in protecting the integrity of the
muscle fiber. For the remainder of this section and dissertation, ECM will be used to refer to this
interface.
The ECM is highly involved in the modulation of mechanical homeostasis and cell-matrix
interactions [26,27]. It provides the necessary uniform distribution and transmission of force
across muscle fibers, which is mostly achieved through its cytoskeleton-ECM linkage via the
dystrophin glycoprotein complex [26]. Additionally, the ECM serves as a scaffold for focal
adhesions that are necessary for initiating biological responses to changes in the cellular
environment [27]. Most importantly, though, several proteins residing in the ECM serve as
important signaling mediators during recovery from injury and regeneration [28–30].
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The multitude of proteins that construct the ECM primarily fall within one of three main
classes: collagens, non-collagenous glycoproteins, and proteoglycans [1]. Collagens are the
largest fraction of ECM proteins within skeletal muscle [31,32], and play major roles in structural
stability. Specifically, collagen I exhibits a range of biomechanical properties, including tensile
strength and load bearing [1], while collagen VI and IV create a network of fine filaments and
integrate laminins, nidogens and other proteins into a stable structure [33,34]. Lastly, collagens
I, III, V, and XI form fibrils to further enhance the structural stability of the ECM [1]. Working
alongside the collagens, is fibronectin. Fibronectin is described as a master organizer, playing a
major role in aiding fibril organization and serving as a bridge for proteins such as integrins,
collagen IV, and other focal adhesion molecules [35]. Matrix assembly and modulation of cellmatrix interactions are regulated by several ECM proteins, including nidogens, periostin, and
osteopontin [1]. Additionally, matrix metalloproteinases (MMPs) and their inhibitors (TIMP1 and
TIMP2) are ECM-associated enzymes that maintain the integrity of the ECM by regulating ECM
protein degradation [36,37]. The ECM is a dynamic structure in the sense that it responds to
changes to the intra- and extracellular environments via a host of growth factors that signal the
production or maintenance of ECM proteins [38]. The dynamic nature of the ECM is especially
important for monitoring and responding to changes in muscle activity.
1.3.6 The Cytoskeleton and the Dystrophin Glycoprotein Complex
Sarcomeres are supported structurally by the muscle cytoskeleton [1]. This cytoskeleton
is composed of various protein networks that form a lattice called the costamere [39]. The
costamere functions to transmit force produced by the sarcomere both laterally and
longitudinally [40–42]. Ultimately, this allows contractions to be unified from one tendon to the
other while maintaining the integrity of the muscle fiber. It is estimated that as much as 70% of
the force produced by the sarcomere is transmitted laterally through the costamere [42–44].
One of the most important components of the costamere, and arguably one of the most
important structural complexes within the entirety of the skeletal muscle, is a multi-protein
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complex known as the dystrophin glycoprotein complex (DGC) or the dystrophin-associated
protein complex (DAPC). The DGC is physically connected to the internal myofilament structure
through filamentous actin as well as the external extracellular matrix through laminin [45,46].
Proteins that make up the DGC are divided into three groups based on their cellular localization
[47,48]. Cytoplasmic proteins include dystrophin, a-dystrobrevin, syntrophins, and nNOS.
Transmembrane proteins include b-dystroglycan, sarcoglycans, sarcospan, and caveolin-3.
Finally, the extracellular proteins include a-dystroglycan and laminin. The DGC is extremely
important for maintaining the structural integrity of the muscle fiber, which is clearly
demonstrated by how the partial or complete absence of a single protein within the complex
results in muscular dystrophy [49,50]. Additionally, through the multiple binding sites and
domains present within the individual proteins that construct it, the DGC serves as a scaffold for
various signaling and channel proteins as well as an anchoring point for signaling molecules
near their sites of action [47]. A more detailed discussion about the roles of these individual
proteins is provided below.
Dystrophin is an extremely large (427 kDa) sub-sarcolemmal cytoskeletal protein
organized into four distinct domains: (1) the actin-binding amino-terminal domain; (2) the central
rod domain; (3) the cysteine-rich domain; and (4) the carboxy-terminal domain [48]. The actinbinding amino terminal domain houses binding sites for filamentous actin [51], connecting
dystrophin to the sub-sarcolemmal actin network [52]. Additionally, this domain supports
dystrophin’s interaction with cytokeratin-19, a costamere-enriched intermediate filament [53,54],
connecting dystrophin to the sarcomere. The central rod domain is made up of 24 spectrin
repeats consisting of homologous triple helical repeats and four hinge domains [55]. A second
actin-binding motif [56] and interaction sites for microtubules [57,58] are located within this
domain, creating a strong lateral association with actin filaments [59] and providing an
organizational framework for the microtubules [57,58]. The hinge domains provide elasticity to
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the overall structure of the protein [55]. The cysteine-rich domain resides between the central
rod and the carboxy terminus domains. This domain houses binding sites for beta-dystroglycan
and calmodulin [60–63] as well as ankyrin-B [64] and synemin [65]. Ankyrin-B is an adaptor
protein that helps retain dystrophin at the sarcolemma [64], while synemin is an intermediate
filament protein, whose interaction with dystrophin helps strengthen the link between the
costameres and myofibrils [65]. Lastly, the carboxy-terminus domain harbors binding sites for adystrobrevin and the syntrophins [66,67], which assists in their localization to the sarcolemma
[68]. Ultimately, these intra- and extracellular linkages allow dystrophin to play a crucial role in
stabilizing the sarcolemma against mechanical forces endured during muscle contraction
[39,69–77] and in serving as a molecular shock absorber duration muscle contractions [78].
a-Dystroglycan is an extensively glycosylated extracellular protein [79,80] with a
dumbbell-like shape from its two globular domains that are connected by an extensible portion
[81,82]. One of these globular domains houses binding sites for multiple extracellular matrix
components including laminins, agrin, perlecan, and biglycan [83], while the other houses a
binding domain for b-dystroglycan [84,85]. b-dystroglycan is a single transmembrane protein
with an extracellular amino-terminal domain that binds with a-dystroglycan and a carboxyterminal domain that binds with dystrophin [86,87] and caveolin-3 [88]. The dystroglycan
complex is responsible for transducing extracellular-mediated signals that direct cell polarity,
matrix organization, and mechanical stability of tissues to the cytoskeleton [89–91]. Additionally,
b-dystroglycan binds agrin at the NMJ, suggesting a role for b-dystroglycan in acetylcholine
receptor clustering [92].
Syntrophins are intracellular membrane-associated adaptor proteins believed to recruit
and regulate signal-transduction complexes [93]. Specifically, the syntrophins harbor numerous
binding sites for dystrophin, a-dystrobrevin [94], calmodulin [95,96], heterotrimeric G-proteins
[97], nNOS [98–100], voltage-gated sodium channels [101], non-voltage gated calcium channels
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(specifically TRPC) [102], and aquaporin-4 [93]. Therefore, it is suggested that syntrophins play
an important role in recruiting, organizing and anchoring a signaling complex to the dystrophin
scaffold [93].
The sarcoglycan complex is composed of four sarcoglycan isoforms [103–106] and
sarcospan [107]. Each of the sarcoglycan proteins are single transmembrane glycoproteins
whose amino-terminal domains are housed either extracellularly (a-sarcoglycan) or
intracellularly (b-, g-, d-sarcoglycan) [103–106]. While the purpose of the sarcoglycan complex is
not fully understood, early studies predict that it has both mechanical and non-mechanical roles.
Specifically, this complex may strengthen the interaction between b- and a-dystroglycan as well
as b-dystroglycan and dystrophin [108]. Further, the sarcolgycan complex may regulate cell-cell
adhesion through its interactions with the integrin complex and focal adhesion proteins
[109,110]. Tightly associated with the sarcoglycan complex is sarcospan, which houses four
transmembrane spanning helices [111]. Studies suggest an important role for sarcospan in
upregulating the cell surface expression of the major laminin-binding complexes in the muscle,
including the DGC, the utrophin-glycoprotein complex and integrin-a7b1 complexes [112].
Utrophin is a dystrophin-related protein with significant sequence homology to dystrophin and
shares structural similarities with dystrophin that allow it to provide mechanical protection to
skeletal muscle [66,113,114]. Integrin-a7b1 and its associated proteins, including talin, viniculin,
and paxillin [1], are critical components of the costamere.
a-Dystrobrevin is a cytoplasmic dystrophin-related protein that binds directly to
dystrophin, utrophin, and the syntrophins [115,116]. Unlike other members of the DGC whose
roles are critical to sarcolemmal integrity and signaling, a-dystrobrevin may be critical to the
distribution and stability of acetylcholine receptors at the NMJ [117,118]. Specifically, adystrobrevin may serve as a hub for assembling signaling complexes that are critical to the
organization of the postsynaptic machinery, specifically the acetylcholine receptors [119].
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Caveolin-3 is a critical structural protein located within flask-shaped invaginations of the plasma
membrane, or caveolae [120]. Caveolin-3 interacts with a number of signaling molecules,
including heterotrimeric G-proteins, c-SRC and SRC-like kinases [121], and may play a role in
the formation of the T tubule system during muscle development [122] as well as in the
regulation of energy metabolism [123]. Additionally, caveolin-3 interacts with nNOS and may
negatively regulate its enzymatic activity [124,125]. nNOS is associated with the DGC through
dystrophin and controls local blood flow [126].
1.3.7 Skeletal Muscle Fiber Types
Skeletal muscle fibers exhibit a high degree of heterogeneity, harboring unique
biochemical, mechanical and metabolic phenotypes that allow them to meet the demands
imposed on them [9]. Ultimately, this allows muscles within the human body to participate in
activities that require different metabolic and mechanical demands, such as running a marathon
or holding a plank, due to the unique distributions of various fiber types [9].
For the past few decades the classification of muscle fibers has evolved to incorporate
new research that defines multiple subtypes or isoforms of specific proteins. Traditionally,
muscle fibers are classified based on color (red vs white), which correlates to myoglobin
content, or contraction speed during a single muscle twitch (fast vs slow) [127]. Muscle fibers
are further classified based on their degree of fatigability during sustained activation (fatigable
vs fatigue-resistant), their dominating metabolic pathway (oxidative vs glycolytic), as well as
their histochemical stain reactions (ATPase or succinate dehydrogenase) [127]. More recently,
muscle fibers are classified based on their calcium handling properties by the sarcoplasmic
reticulum (slow vs fast) [128] and protein isoform expression, such as troponin T isoforms [129]
and myosin isoforms. Regardless, human skeletal muscle is most frequently described as
having three muscle fiber types: type I (slow, oxidative, fatigue-resistant), type IIa, (fast,
oxidative, intermediate metabolic properties), and type IIb (fast, glycolytic, fatigable). Here, the
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speed of contraction (fast vs slow) correlates with the sarcoplasmic reticulum and calcium
handling, while the metabolic properties (oxidative vs glycolytic) and tolerability of fatigue
(fatigue-resistant vs fatigable) correlate with the mitochondrial content [9]. Phenotypically, type I
muscle fibers are highly vascularized and saturated with mitochondria, which allow them to
remain active for longer periods of time but with low force output [1]. Muscles from elite
endurance athletes, such as marathon runners, have a higher type I muscle fiber composition.
Alternatively, type II fibers contract faster and fatigue much easier than type I fibers as a result
of their higher glycolytic capacity and accelerated ATP hydrolysis [1]. Muscles from elite
sprinters and power lifters have a higher proportion of type II fibers.
1.4 Skeletal Muscle Contraction
The stability and integrity of the skeletal muscle structure is critical to the survivability of
the muscle fiber during muscle contraction. The absence or partial functioning of the above
mentioned proteins in the ECM or DGC negatively affects the fiber’s ability to withstand the
movement and force generated during contraction. Muscle contraction occurs via a series of
coordinated events that are repeated until movement ceases or until the muscle can no longer
supply energy to support contraction. This series of events is properly named excitationcontraction coupling (ECC) and consists of three main events: the transmission of the nerve
impulse to the muscle, the release of calcium from the sarcoplasmic reticulum, and the
formation of a cross-bridge between myosin and actin [9]. Visually, we see the whole muscle
contract, such as the biceps contracting to lift a cup of coffee to the mouth. However, the whole
muscle contracts as a result of what occurs at the molecular level between the myosin heads
and the actin filaments.
First, an action potential from the innervating motor neuron arrives at the presynaptic
membrane, or nerve terminal. The arrival of the action potential stimulates the fusion of synaptic
vesicles housing acetylcholine to the presynaptic membrane at the active zones, or visually
dense zones at the presynaptic membrane that contain specialized proteins associated with
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vesicle docking and fusion, exocytosis and vesicle recovery [130]. Exocytosis of acetylcholine
into the synaptic space is tightly orchestrated by Ca+2 and its respective voltage-gated calcium
channels [1]. This entire process is suggested to depend on both the muscle type and the
stimulus [131,132]. Acetylcholine then readily diffuses across the synaptic space and binds with
nicotinic acetylcholine receptors on the sarcolemma, creating a local depolarization event [1].
Following exocytosis, the synaptic vesicles and the associated vesicular membrane proteins are
rapidly recycled via endocytosis to sustain further exocytosis [1]. Additionally,
acetylcholinesterase immediately begins to hydrolyze the diffusing acetylcholine, promoting the
cessation of this signal [133].
The local depolarization event at the sarcolemma activates the voltage-gated sodium
channels that are concentrated within the junctional folds, which drives an action potential along
the length of the muscle fiber and through its interior via the T tubule system [134]. When this
action potential arrives at the triad, a voltage sensor subunit of the dihydropyridine receptor on
the T tubule opens, allowing a flood of calcium to enter [135], which consequently triggers the
ryanodine receptors within the terminal cisternae of the sarcoplasmic reticulum to open and
large amounts of Ca+2 to enter the sarcoplasm. Ca+2 then binds to troponin C, a regulatory
protein located on the actin filaments, which initiates a series of conformational changes that
moves tropomyosin away from the myosin active sites on the actin filament [136]. With the
active site now exposed, the head of the myosin molecule binds to actin at a 45 degree angle
relative to actin [137]. This position is called the rigor state [137]. ATP molecules located near
the myosin head bind to myosin, briefly dissociating myosin from actin [137]. These ATP
molecules immediately become hydrolyzed by ATPase to ADP and inorganic phosphate, which
facilitates the re-binding of the myosin head to actin but at a 90 degree angle relative to actin,
forming a cross-bridge [137]. Upon release of inorganic phosphate, the power stroke is initiated,
and the myosin head rotates on its hinge, pushing the actin filament towards the M-band. This
sliding of actin and myosin generates muscle force [138,139]. Once the power stroke is
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completed, ADP is released from the myosin head and the myosin head is repositioned into its
rigor state at a new position along the actin filament [137]. This cycle continues until ATP is no
longer available.
Since cross-bridges are formed along the entire length of the muscle fiber, forces are
transmitted longitudinally and laterally throughout the fiber via the costameres [9]. However,
movement is not produced until these forces reach the myotendinous junction, where the
muscle and tendon interact, and then transmitted through the tendon to the bone [9]. The force
that a muscle generates is dependent on several factors including the extent of activation of the
innervating motor neuron, the size of the muscle fibers, the number of cross-bridges formed, the
force generated by each cross-bridge, and most importantly, the space between the
myofilaments [9]. The space between actin and myosin is extremely important, as highlighted by
the force-length relationship, which states that at lengths longer and shorter than the optimal
length of the sarcomere, there is sub-optimal overlap between actin and myosin during crossbridge formation, which limits force generation.
Even though muscles generate force using the same mechanisms detailed above,
muscles are capable of producing three types of contractions: isometric, concentric and
eccentric [9]. During an isometric contraction, force is generated but there is no movement of
the joint or limb. An example of an isometric contraction is pushing against a wall, where the
resistance of the wall is greater than the force generated. Concentric and eccentric contractions
occur to complete a full range of motion. Specifically, concentric contractions result in the
shortening of the muscle and the movement brings the muscle’s origin and insertion points
closer together. An example of a concentric contraction is the biceps muscle contracting to flex
the elbow. In contrast, eccentric contractions result in lengthening of the muscle as its origin and
insertion points move away from each other. An example of an eccentric contraction is the
biceps muscle lengthening to extend the elbow and return it to resting position. The lengthening
of the muscle during an eccentric contraction can be associated with muscle damage [140].
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As demonstrated above, muscle contraction requires ATP for cross-bridge formation. A
contracting muscle fiber receives energy through three basic pathways: ATP and creatine
phosphate (CP) stored in the muscle, anaerobic glycolysis, and oxidative phosphorylation [9].
The energy pathway used is dependent on the intensity and duration of the activity. It should be
noted, though, that these pathways are not an all-or-none phenomenon but actively overlap at
different time points throughout the activity. ATP and CP stored in the muscle provide energy for
the first few seconds of activity since these reserves are extremely limited. Once ATP and CP
stores are depleted, anaerobic glycolysis produces ATP quickly to sustain muscle contractions.
The primary fuel source that supports this pathway is plasma glucose [141]. However,
anaerobic glycolysis can only provide energy for a couple of minutes since glycolysis also
produces H+ and lactate, both of which impair muscle function and are associated with muscle
fatigue [9]. The final energy pathway that produces ATP is oxidative phosphorylation. Oxidative
phosphorylation occurs within the mitochondrial network and ATP is shuttled throughout the
muscle fiber to sustain muscle contractions for minutes to hours. The primary fuel sources that
support this pathway free fatty acids within the plasma as well as glycogen and triglycerides
stored within the muscle [141].
1.5 Skeletal Muscle Repair and Regeneration
Skeletal muscle undergoes multiple bouts of damage throughout its lifetime from daily
use and injury. For example, the physical movement of actin sliding past myosin may result in
microlesions within the sarcolemma of a single muscle fiber while acute ischemia may result in
widespread damage throughout the entire muscle. The muscle fiber’s ability to reseal its
sarcolemma to prevent cell death as well as the entire muscle’s ability to regenerate following
extensive damage are hallmarks of skeletal muscle tissue [1]. Below are brief overviews of the
repair and regenerative processes following injury to the sarcolemma and to the whole muscle,
respectively.
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A highly-orchestrated membrane repair machinery patches microlesions endured by the
sarcolemma during contraction-relaxation cycles, and allow the muscle fiber to continue meeting
the functional demands of the muscle. This membrane-repair machinery is constructed by
various proteins, including dysferlin [142–145], caveolin-3 [146], calpain-3 [147], AHNAK
[148,149], and annexin A1 and A2 [148,150]. Immediately after a tear in the sarcolemma
occurs, calcium rapidly enters the muscle fiber, activating and strengthening the binding
properties of these repair proteins [151] such that the annexins bind with dysferlin and
phospholipids while dysferlin binds additional phospholipids [152]. These binding events
encourage the recruitment of intracellular vesicles, such as lysosomes and enlargeosomes, to
the sarcolemma [153,154]. An additional protein, mitsgumin 53, also plays a role in translocating
these vesicles [155–159]. These intracellular vesicles accumulate beneath the damaged
sarcolemma, and then undergo exocytosis to fuse with the sarcolemma, creating a patch of new
membrane and sealing the damaged area [152]. Intracellular vesicle fusion is made possible by
the SNARE proteins [160] and synaptotagmins [161]. Finally, the membrane repair complex is
deactivated through calpain-dependent cleavage of the annexins and AHNAK [151]. This rapid
membrane repair mechanism occurs within seconds of activation [162].
In the event that the membrane damage is too extensive and cannot be repaired via the
patch repair mechanism, sarcolemmal injuries may trigger an inflammatory response [163–165]
and activate the satellite cells. Satellite cells are located along the length of the muscle fiber
tucked between the sarcolemma and the basal lamina [166,167]. These cells represent the
adult stem cell niche in skeletal muscle and are responsible for muscle growth and regeneration
[166,167]. Upon unresolved injury, fiber necrosis occurs, which activates the complement
cascade, stimulating the infiltration of leukocytes, neutrophils, and eventually macrophages [1].
These macrophages clear the damaged muscle fibers and send the initial signals for satellite
cell migration and proliferation [168]. The ability to regenerate is governed not only by the
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satellite cells [169] but by the microenvironment [170]. This microenvironment, or niche, is home
to growth factors, extracellular matrix proteins, fibro-adipogenic progenitors (FAPs),
chemokines, and MMPs [1]. Additional components within and around this niche include the
local interstitial cells, motor neurons, the vasculature [171,172], and chemo-attractants and
cytokines from local and infiltrating inflammatory cells [173–179]. These components provide
scaffolding for cell migration and cues for the regenerative processes. There are many shared
components between embryonic myogenesis and muscle regeneration [180], including the
transcription factors and signaling molecules that orchestrate the activation and migration of
satellite cells to the site of injury as well as their proliferation and differentiation into muscle
fibers [1]. Within days of the initial injury, damaged muscle is completely regenerated [151].
Most importantly, though, skeletal muscle’s regenerative capacity is governed by its ability to
reactivate the satellite cell pool when necessary [151].
1.6 Skeletal Muscle Plasticity
Alongside the muscle’s ability to repair and regenerate is its profound ability to respond
to changes in its physiological environment. In fact, skeletal muscle is one of the most dynamic
and plastic tissues within the human body [9]. Skeletal muscle fibers are capable of changing
their size and type, metabolic profiles, calcium handling properties, and more. Skeletal muscle is
constantly sensing, transducing, and integrating neuronal, mechanical, metabolic and hormonal
signals in order to produce a systemic physiological adaptation that would allow it to perform
more optimally, whether it is to maintain new postures, to run longer distances or to perform
finer movements with the fingers. These adaptations occur at the level of gene activation,
mRNA processing, as well as protein synthesis and assembly (reviewed in [181]).
Skeletal muscle plasticity is best understood in the context of skeletal muscle size in
response to completing a resistance training program versus enduring bedrest or limb
immobilization. The maintenance of skeletal muscle size is the direct result of the synergy of the
signaling pathways for anabolic and catabolic processes such that myofibrillar proteins are
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continuously being synthesized and degraded. However, when the functional demands change,
one pathway dominates over the other. For example, during periods of increased contractile
activity, such as during an exercise program, muscle growth, or hypertrophy, is initiated by
enhancing protein synthesis. Conversely, during periods of decreased contractile activity, such
as during bed rest, muscle wasting, or atrophy, is initiated by enhancing protein degradation.
Interestingly, studying these two mechanisms on a cellular and molecular level has proven
difficult because there is not one specific signaling pathway that initiates a hypertrophic versus
atrophic program, but rather an overlap between inhibition and activation of various molecular
players [181]. For example, growth hormone, IGF-1 and insulin are recognized most in the
initiation of muscle growth, while myostatin is the primary initiator of muscle wasting, but these
proteins act via the same molecular mediators [181]. In lieu of discussing these pathways, a
discussion on the phenotypic changes observed in response to exercise training and inactivity
will be provided below.
1.6.1 Benefits of Exercise
There are more than 100,000 studies showing positive associations between the terms
‘exercise’ and ‘health’ [182]. In fact, health-related physical fitness is among the most powerful
predictors of morbidity and mortality [183–185], and lifelong exercise is associated with a longer
health span by targeting the four components of physical fitness: (1) cardiovascular fitness, (2)
musculoskeletal fitness, (3) body composition and (4) metabolism. Exercise training leads to
extensively documented improvements in a myriad of systems with the most profound being in
cardiorespiratory function, muscle oxidative capacity, metabolic health, glucose and lipid
homeostasis, adiposity, inflammatory burden, muscle mass and strength, joint pain, bone
density, mobility function, depression, anxiety, and cognition [186,187]. These clear and
profound benefits of exercise allow it to be prescribed as the primary prevention and secondary
intervention strategies for over 40 conditions and chronic diseases, including cardiovascular
disease, chronic obstructive pulmonary disease, obesity, diabetes, cancer, and sarcopenia
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[182]. Many individuals assume that all exercise is created equal. However, the body’s response
to exercise is highly specific to the type of exercise that it is performed. This is especially true for
skeletal muscle, which will be the focus of the discussion below.
1.6.2 Aerobic Exercise
Aerobic exercise training targets cardiorespiratory fitness by activating large muscle
groups to perform continuous, rhythmical movements for a prolonged period of time [9,186]. It is
designed to improve the capacity and efficiency of the aerobic energy-producing systems,
specifically oxidative phosphorylation [186]. Examples of aerobic exercises include running,
biking, or swimming.
Disruptions in cellular homeostasis occur during aerobic exercise and these disruptions
are responsible for driving the positive adaptations [188,189] that ultimately lead to enhanced
metabolic capacity [9]. Specifically, there is an increase in the capillary supply to the active
muscles to facilitate oxygen delivery [190]. The number and size of the mitochondria are also
increased to enhance the production of ATP [190]. Additionally, fat and glycogen storage as well
as the availability of oxidative enzymes are increased to further enhance ATP production
[191,192]. It should be noted that aerobic exercise most often does not result in changes in
muscle size or force generating capacity [9].
1.6.3 Resistance Training
In contrast to aerobic training, resistance training is a series of exercises that require
individual muscles or targeted muscle groups to exert or resist force using free weights, weight
machines, or elastic bands [186]. Resistance training is broken down into four types that are
defined by their targeted goals for muscular fitness: local muscular endurance training,
hypertrophy training, strength training, and power training. Local muscular endurance training
utilizes high repetitions and submaximal loads with short rest intervals to improve the muscle’s
resistance to fatigue. Hypertrophy training utilizes moderate repetitions and moderate to heavy
loads to increase the size of the muscle. Strength and power training are very similar, utilizing a
20

very low number of repetitions and maximal loads to increase the amount of resistance that the
muscle can effectively move and to improve the speed at which this load is moved, respectively.
Within the four training programs, there are acute variables that influence training
adaptations further [193,194]. These physiological adaptations are specific to the muscle
actions involved [195], the speed of movement [196], the range of motion [197], the muscle
groups trained [198], the energy systems involved [199,200], and the intensity and volume of
training [201–203]. Regardless, though, these adaptations occur as a result of the cross talk
between the nervous and muscular systems. Specifically, the early increases in strength are
brought about by improvements in motor unit recruitment, firing rate, and synchronization [204].
Then, within about 4 to 8 weeks of training, muscle hypertrophy becomes evident [205–207] as
a result of changes in the quality of proteins [207], transitioning between fiber types [205,207],
and the rate of protein synthesis [206]. As training progresses, there is further interplay between
neural adaptations and muscular hypertrophy that drive acute changes in muscular strength
[204].
1.6.4 Inactivity
Physical inactivity is arguably one of the most important concerns to human health in the
21st century [208]. Even more so, it was a great concern for early Greek philosophers. Plato
once said that the "lack of activity destroys the good condition of every human being, while
movement and methodical physical exercise save it and preserve it." Similarly, Socrates once
stated that “and is not the bodily habit spoiled by rest and idleness, but preserved for a long time
by motion and exercise?” These negative impacts of physical inactivity on overall health are
now well-established. Specifically, it is one of the main risk factors of a number of diseases
including obesity, cardiovascular diseases, stroke, diabetes, and colon cancer [209,210], and is
the largest preventable risk factors for Alzheimer’s disease in the United States [211,212].
Unfortunately, skeletal muscle is one of the major body systems that is influenced immediately
by inactivity.
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Physical inactivity is modeled in humans using strict bed rest, 24 hours a day, in a headdown position at -6 degrees [213]. Short-term bed rest for 2, 8 or 12 days does not result in
significant effects on muscle mass or strength [214], but long-term bed rest for 35 or 90 days
results in a large decrease in muscle force and power generation of the lower limb muscles
[215,216]. These decreases are caused by muscle atrophy of both type I and type II muscle
fibers [217]. Additionally, inactivity leads to lower work capacity (peak oxygen consumption)
[218], hypovolemia and negative water balance [219–221], decreased orthostatic tolerance
[222], changes in resting metabolic rate, poor body composition, including decreased lean body
mass, increased fat mass, and reduced bone mineral density [223–229], limited muscular
strength and endurance [222,224,225], changes in thermoregulation [230,231], impaired
immune response [226], and altered mood and neuropsychological performance [232]. Further,
proteolysis pathways are significantly upregulated, especially the ubiquitin-proteasome pathway
and autophagy [233,234], which negatively affects the quality of the muscle proteins [235].
Similarly, in rodent models, inactivity is achieved through hindlimb suspension, where the
hindlimbs are elevated to produce a 30-degree head-down tilt [236]. This position restricts
animals to using only their forelimbs [236]. Regardless, hindlimb suspension for 1 to 2 weeks
negatively affects body and muscle mass [237], myosin heavy chain expression and fiber type
switching [238,239], functional muscle strength [240], protein synthesis and degradation
pathways [241], and bone mechanical strength [242]. Most importantly, though, these negative
consequences may be reversed upon resuming normal activity [243].
1.7 Muscular Dystrophy
Knowing the complexity of muscle structure and function as well as its response to
exercise and inactivity, what happens when a protein is not present or functioning properly and
how does the muscle now respond to changing demands imposed on it? A slight perturbation in
muscle structure due to the absence of a protein, or even the presence of a partially formed
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protein, can wreak havoc on the entire muscular system. This is often visualized as the loss in
muscle fibers and reduced motor output [1]. One of the most common groups of diseases
affecting skeletal muscle is muscular dystrophy. Muscular dystrophy is caused by the absence
or dysfunction of a muscle protein involved in maintaining the integrity of the sarcolemma,
repairing the sarcolemma after damage, or constructing the extracellular matrix or nuclear
envelope. Muscular dystrophies are inheritable (or occasionally spontaneous) diseases that
vary in their severity and age of onset, but share the same two features: progressive loss of
muscle mass and function. There are over 50 genetically distinct muscular dystrophies [244]
that can affect both males and/or females. Unfortunately, though, many individuals are
diagnosed as having an unknown variant, meaning the missing or non-functional protein
wreaking havoc on their muscular system has not been identified. Regardless, because
muscular dystrophy leads to skeletal muscle degeneration, walking, breathing, and swallowing
become extremely difficult and functional independence is lost.
1.7.1 Duchenne Muscular Dystrophy
In the realm of muscular dystrophy research, DMD is the most common type of muscular
dystrophy and most frequent genetic disease of childhood, affecting 1 in 5000 male births [245].
Sadly, it is also the most lethal genetic disease of childhood [246]. Individuals with DMD harbor
mutations in the gene encoding the protein dystrophin, which is located on the X chromosome,
hence why females carry the mutation and are asymptomatic while males are symptomatic. The
dystrophin gene is the largest known gene in the human genome spanning at least 2,300
kilobases [247–249]. Remarkably, though, 99.4% of this gene is comprised of introns while only
a tiny percentage, representing 14 kilobases make up the 79 exons that encode the protein
[61,247,250]. Most notably, it takes approximately 12 hours to transcribe 1,770 kilobases via
RT-PCR, estimating at least 16 hours to complete the entire gene [251]. Further, the high
molecular weight protein that is formed spans 3685 amino acids [61]. Mutations in the
dystrophin gene lead to a truncated, non-functional dystrophin protein. Exon deletions and
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duplications account for about 65% and between 6 to 11%, respectively, of all mutations while
deep intronic mutations account for less than 7% of mutations [245].
1.7.2 Clinical Presentation of DMD
DMD is first diagnosed between the ages of 2 and 5 years. Symptoms are typically
manifested as delayed milestones, including delayed onset of ambulation, difficulty standing
unaided [252], and gait abnormalities [245]. When parents alert clinicians of these motor delays,
the next step is testing for serum creatine kinase levels [245]. Elevated levels of serum creatine
kinase is a major indicator of muscular dystrophy, and begins the genetic testing process. As
the disease progresses, muscle wasting overpowers the regenerative capacity of the muscle,
and performing activities of daily living become difficult [252]. As the paravertebral muscles
weaken, individuals will exhibit a progressive lumbar curvature of the spine [246]. This curvature
results in postural compensations as well as a change in the distribution of weight bearing from
the heels to the toes [246]. Additionally, the calf muscles experience extensive fibrosis, leading
to the development of contractures that limit plantar flexion [246]. Fibrosis and fatty tissue
overwhelm the calf muscles, creating a pseudohypertrophy [246]. As a consequence of these
changes, most individuals with DMD become wheelchair bound between the ages of 11 and 13
years old [252]. The progressive loss in muscle mass and strength is not only present in the
limb muscles but also in respiratory and bulbar muscles, increasing the risk for respiratory
failure [245]. Cardiac muscle is also affected by the absence of dystrophin, and exhibits
progressive fibrosis, leading to subclinical and eventually dilated cardiomyopathy and heart
failure [245]. These complications and the extremely progressive nature of this disease result in
premature death before the age of 30 [253].
DMD muscle experiences increased fatigability, fibrosis, and fat deposition as well as
defects in regeneration, vasoregulation, metabolism and synaptic structure and function
[126,254–264]. Magnetic resonance spectroscopy of multiple muscles from individuals with
DMD highlight the extensive reductions in muscle mass, and the infiltration of fatty tissue [265].
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Further, muscle biopsies stained with hematoxylin and eosin reveal large accumulations of
connective tissue separating the individual muscle fibers as well as the infiltration of immune
cells within the interstitial tissue and near the blood vessels [266]. Individual muscle fibers also
show a significant variability in their cross-sectional areas [266]. Electron microscopy shows an
extensive number of lesions in the sarcolemma, some large enough to permit unrestricted
movement of molecules into the muscle fiber [267].
1.7.3 Molecular Mechanisms of DMD
Dystrophin provides a link between the actin cytoskeleton and the extracellular matrix
and serves as a scaffold for the assembly of the DGC within the sarcolemma. The mechanical
defect hypothesis states that the progressive muscle weakness and wasting in DMD is caused
by the lack of this link and the disruption of the DGC, which mechanically weakens the
sarcolemma [268,269]. Stress placed on a mechanically weakened sarcolemma can cause
microlesions to develop along the sarcolemma [270]. These microlesion allow excessive
calcium entry, altering calcium homeostasis [271,272]. An increase in calcium permeability
impairs different cellular processes, such as excitation-contraction coupling [272], and ultimately
activates proteases to breakdown different cellular components. Therefore, the end result is an
increase in muscle protein degradation, muscle fiber necrosis, and significant decreases in
muscle strength and tolerance for physical activity [272,273].
However, some features of disease pathology in individuals with DMD cannot be
explained by the mechanical defect hypothesis [246]. The immune system also plays a major
role in amplifying the pathology of DMD as well as in determining disease severity [246]. Upon
damage to healthy muscle, an inflammatory response is initiated to clear the damaged muscle
fibers and begin regeneration. This response subsides within several hours or days, depending
on the extent of damage. However, in DMD muscle, the inflammatory response is prolonged,
and the microenvironment is more conducive to further promoting an inflammatory response. By
manipulating specific inflammatory cell populations, studies suggest that these cells are
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responsible for an extensive amount of damage to DMD muscle [274]. Specifically, proinflammatory macrophages accumulate, and there is an increase in pro-inflammatory cytokines,
including TNF-a and TGF-b, as well as free radicals that lead to further muscle damage and
fibrosis [275]. Therefore, the initial invasion of macrophages in response to acute muscle
damage may actually amplify such damage and promote a chronic immune response [246].
Additional immune cells, including cytotoxic T lymphocytes, eosinophils, mast cells, and
neutrophils, further exacerbate this immune response (reviewed in [246]). Ultimately, these
ongoing cycles of degeneration and limited regeneration lead to premature senescence of
muscle stem cells and the inability for muscle to repair itself when further damaged [272,276].
More recent studies suggest a critical role of nNOS in the progression of DMD. Nitric
oxide (NO) is a potent vasodilator during exercise and is involved in the metabolism of free
radicals. Its function is highly dependent on the dynamic regulation of its enzyme, nitric oxide
synthase. In individuals with DMD, NO levels are decreased. It is suggested that, in the absence
of dystrophin, nNOS is not recruited to the sub-sarcolemmal space, leading to aberrant nNOS
signaling [274]. This aberrant signaling negatively impacts the maintenance of muscle mass as
well as force generation and fatigability [277], which may be the result of the increased oxidative
stress in dystrophic muscle [260,278]. Notably, overexpression of nNOS ameliorates the
dystrophic phenotype [274].
1.7.4 Current Treatment Options for DMD
The first clinical description of DMD was recorded in the 1860s. In 1986, the DMD gene
was identified, and in 1987, the protein product was identified [279–281]. Unfortunately,
scientific advances are not paralleled by discoveries of effective therapeutic tools thus far as
there is still no cure for DMD. One of the major obstacles in designing gene therapies for DMD
is the size of the dystrophin gene itself as well as the protein product. Much attention is given to
the development of gene delivery, gene editing, exon skipping, and stem cell-based approaches
that restore the full-length or truncated, but functional, dystrophin protein constructs [282].
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However, a number of hurdles have been reached, including tissue delivery, low efficiency, and
an inability to target all DMD mutations [282]. Currently, there are three different microdystrophin gene therapies (sponsored by Solid Biosciences, Sarepta Therapeutics, and Pfizer)
undergoing clinical testing [283]. Each of these therapies use a viral cDNA construct that code
for a truncated micro-dystrophin protein. This micro-dystrophin lacks the internal repeating
motifs but retain the critical binding domains for filamentous actin and b-dystroglycan [283,284].
This theoretically allows the micro-dystrophin protein to anchor the actin cytoskeleton to the
sarcolemma and ECM, providing a greater level of stability to the muscle fibers. Additionally,
antisense phosphorodiamidate morpholino oligomers (PMOs), such as eteplirsen, are
promising. Eteplirsen is designed to alter the splicing of the dystrophin mRNA such that exon 51
is excluded, making it applicable to multiple mutations [245]. Current research demonstrates
that eteplirsen restores a relatively small amount of dystrophin, but improves ambulation and
respiratory effects [285,286].
It should be highlighted that dystrophic muscle maintains a limited ability to adapt to
muscle contractions and this is through the compensatory upregulation of various proteins such
as integrin-a7b1, utrophin, talin, vinculin, and g-actin [287–289]. The upregulation of these
proteins suggests a compensatory mechanism to reinforce the compromised costamere and
preserve muscle structure [290]. Therefore, these proteins are emerging as targets for potential
therapies [290]. Additionally, surrogate genes that may serve as a substitute for dystrophin
function are being developed as an alternate mechanism for viral gene therapy. For example,
GALGT2 is a protein responsible for the terminal glycosylation of dystroglycan [291]. As
described previously, dystroglycan is a member of the DGC, and is critical to the maintenance
of the NMJ and myotendinous junctions. The exogenous delivery of GALGT2 via a viral vector
in mdx mouse models increased utrophin’s expression throughout the muscle fiber and
improved overall muscle health [292,293]. Pilot studies in humans are now underway [245].
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More recently, genetic modifiers have been identified in human data and subsequent follow up
studies using the mdx mouse model suggest they may also serve as potential therapeutic
targets to modulate disease [294]. Genetic modifiers alter the clinical severity of DMD, including
muscle strength and ambulation [294]. These modifiers include myostatin, osteopontin, latent
transforming growth factor b binding protein 4, and annexin A6 [294]. Ultimately, these
pathways represent additional mechanisms to improve sarcolemmal stability and repair as well
as to reduce fibrosis in DMD [294].
Currently, individuals with DMD must rely on symptomatic treatments that aim to
preserve functional abilities for as long as possible [295]. Specifically, the main goals for
symptomatic treatment are to maintain ambulation, prevent scoliosis, delay the development of
respiratory problems, and prolong survival [296]. The first international guidelines for the care
and management of DMD were published in 2010 [252,297]. One popular treatment is chronic
corticosteroid use, such as prednisone and deflazacort [298–300]. Corticosteroids act as
immunosuppressors, and multiple studies confirmed that their use increases muscle strength
and delays the progression of muscle weakness, allowing individuals with DMD to remain
ambulatory for 2 to 5 years longer compared to non-treated individuals [252,297,301–304]. This
supports the above hypothesis that inflammation promotes DMD pathology [246]. However,
corticosteroids, especially chronic use of corticosteroids, are accompanied by a variety of sideeffects that may be detrimental to disease progression, including weight gain,
immunosuppression, hypertension, bone loss, and behavior changes [299,305]. These sideeffects may ultimately lead to an increased energy demand to maintain muscle function. More
importantly, though, the optimal dosing regimen that maximizes the beneficial effects while
minimizing the negative side effects has not been established and research continues to
address the importance of this [306–308].
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As a component of the symptomatic treatment plan, physical activity has been under
intense consideration since DMD was first characterized. In healthy children, muscle strength
increases with age but in individuals with DMD, this relationship is not sustained [309]. The
progressive decrease in muscle strength and endurance in individuals with DMD results in the
partial and then complete loss of functional abilities [310]. Interestingly, lower-limb strength is
one of the most important predictors of functional ambulation and independence in individuals
with DMD [311,312]. Few studies have looked at activity levels, but all of them demonstrate that
these individuals have lower physical activity levels compared to healthy counterparts beginning
at a very young age [313,314]. Specifically, boys aged 5 to 13 years old wore a step activity
monitor on the right ankle to track right steps or complete gait cycles. Those with DMD spent
40% fewer minutes performing high levels of activity (>30 steps/minute) compared to agematched controls and spent a greater proportion of their days inactive or performing low levels
of activity (<15 steps/minute). Further, these individuals spend fewer minutes at a moderate and
high step rate compared to their healthy counterparts [313,314]. Gait velocity is a strong
predictor of the amount of time before an individual becomes wheelchair dependent [312].
Specifically, in 51 individuals with DMD, 89% of boys who walked 10 meters in less than 6
seconds did not become wheelchair dependent for 2 or more years while 100% of those who
walked 10 meters in greater than 12 seconds were wheelchair dependent in less than 1 year
[312]. These reduced levels of activity are often the consequence of loss of functional muscle
tissue, muscle disuse, overuse injury, cardiopulmonary involvement, increased fat mass,
contractures, reduced efficiency of locomotion, reduced motivation, less social reinforcement for
activity, increased depression, and increased societal barriers [315]. Ultimately, this progressive
disuse of both the musculoskeletal and cardiorespiratory systems may lead to secondary
deterioration of the muscle [315,316], similar to what is observed in healthy individuals.
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1.8 Current Understanding of Exercise and Inactivity in DMD
While skeletal muscle plasticity is well-studied in healthy muscle, very little research is
available on the adaptability of dystrophic muscle to exercise or inactivity. Currently, there are
five proposed mechanisms described in the literature that render dystrophic muscle vulnerable
to exercise [317]. These include weakening of the sarcolemma, increased calcium influx and
oxidative stress, recurrent muscle ischemia, and aberrant signaling to both the nerves and
immune cells (reviewed in more detail in [317]). Further, it is postulated that weaker muscles are
more susceptible to exercise-induced damage because their maximal limits may be reduced
[318]. The experiments performed in this dissertation were designed to investigate the role that
exercise and inactivity play in the progression of DMD. Before discussing these experiments, a
detailed review of studies addressing this same question is provided to shed light on the
limitations of these studies and the need for more research.
1.8.1 Exercise in Human DMD
Current international care guidelines recommend that individuals with DMD participate in
regular submaximal activities [297]. However, no randomized control trials are available that
discuss what these activities entail or the timeframe for performing these activities. The first
study that explores the effect of exercise on DMD was conducted by Vignos and Watkins in
1966 [319]. Twenty-eight boys with DMD, ages 5 to 10 years old, participated in a 12-month at
home exercise program (n = 14 in exercise group; n = 14 in non-exercise control group) that
included active-assistive or active-resistive movements. Individuals underwent monthly
assessments that included a manual muscle test, a series of functional tests, and serum
adolase and urinary creatine-creatinine excretion measurements. In the year leading up to the
study, muscle strength was also measured, declining with time in both the exercise and nonexercised groups. Within the first four months of exercise, muscle strength improved each
month, but functional tests did not parallel these improvements. However, at the conclusion of
one year, the exercise group significantly improved overall strength, while the non-exercised
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group continued to lose muscle strength. Ultimately, the authors conclude that a resistance
exercise program is most effective if instituted early in the disease and the degree of
improvement is dependent on the initial strength of the exercised muscle. In 1979, de Lateur
and Giaconi [320] measured changes in maximal isokinetic strength across a 24-month period.
Participants used a Cybex isokinetic exerciser to perform controlled extension of a single knee
from 90 degrees to full extension. The contralateral leg served as the control. A greater maximal
torque in the exercised leg was recorded both during and after training, and the authors
conclude that submaximal exercise does not negatively affect strength in DMD muscle but may
be of limited value for increasing strength. In 1981, Scott and colleagues [321] investigated the
impact of two exercise programs on multiple outcome measures for muscle strength and
function in 18 boys with DMD. For 6 months, Group 1 performed a series of exercises against
manually applied resistance for 15 minutes each day while Group 2 performed a series of
exercises in response to oral commands for 15 minutes each day. Total muscle strength, torque
output, locomotor ability and walking times were negatively affected by both exercise programs,
with Group 1 exhibiting greater difficulty in performing movements and taking longer to walk the
predetermined distance. Here, the authors conclude that a pre-treatment phase is necessary to
establish the rate of physical deterioration and that the study should be extended to determine
the long-term impact of exercise. Regardless of the outcomes of these studies, exercise
continued to be frowned upon and further studies using human subjects were not conducted.
However, in 2013, Jansen et al. [310] studied the impact of assisted bicycle training on
various functional measures, range-of-motion, and strength. In this study, 30 boys with DMD
were divided into either the intervention (n = 17) or control group (n = 13). The intervention
group included 8 weeks of baseline measurements followed by 24 weeks of training, and 28
weeks of post-training measurements. Conversely, the control group included 8 weeks of
baseline measurements, followed by 24 weeks of control (normal activity), and then 24 weeks of
intervention and 4 weeks of post-training measurements. During the intervention period,
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participants completed a 15-minute session on an assisted bicycle ergometer using both arms
and legs. Sessions were completed 5 days per week. The authors confidently conclude that
their results contradict the longstanding consensus that exercise accelerates disease
progression but support the notion that dystrophic muscle obeys the adage “use it or lose it.”
Lastly, in 2015, Alemdaroglu and colleagues [296] examined the effects of upper extremity
exercise training on disease progression. Twenty-four boys, ages 8 to 15 years, were separated
into the study group (n = 12) or control group (n = 12). The study group exercised with an
electronic arm ergometer for 45 minutes each day, 3 days per week, while the control group
performed strengthening range-of-motion exercises. Function performance, strength and
endurance of the upper extremity were assessed as well as ambulatory status. Muscle strength
was significantly improved for the right wrist flexor muscle as well as for the total forearm
muscles of the right side in the control group. Grip strength also improved in the right hand of
the control group. However, functional tests and timed performance tests were significantly
different, in favor of the study group. The authors conclude that arm ergometer training had
positive effects on muscular endurance, performance of daily activities, arm function, and
ambulation status and should be included in rehabilitation programs early in the disease course.
While these studies suggest a positive effect of exercise, they are extremely limited not
only in number but the overall design of the studies. First, these studies have extremely small
sample sizes, and participants exhibited a range of severities and ages at the time of
intervention. Studies also lacked valid experimental controls. For example, in one study,
participants performed a movement using their limbs on one side of their body while their
contralateral limbs served as a control. However, voluntary strength on the contralateral side
can increase due to a phenomenon known as cross-education [322]. Secondly, the exercise
regimes across the studies are different, including the type of exercise and the duration of the
intervention, making it hard to compare these studies. Lastly, the outcome measures used to
assess the impact of exercise varied across studies as well as the timeframe in which
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measurements were taken. All of these variables markedly influence changes in muscle
strength and function, and may not uphold to a population effect.
1.8.2 Exercise in mdx Mouse Model
To overcome the limitations of human studies, some researchers turned to the mdx
mouse model. Pre-clinical animal models are critical for understanding a disease and unraveling
mechanistic pathways. The mdx mouse model is the most researched DMD model. It arose
from a spontaneous mutation in the premature stop codon which terminated exon 23 in the
C57BL/10ScSnJ mouse over 30 years ago [323,324]. The mdx mouse displays the hallmark
symptoms of DMD, including muscle weakness, respiratory insufficiency, cardiomyopathy, and
changes in skeletal muscle histology [325,326]. Therefore, it is used to understand the
pathophysiology of DMD and test therapeutic strategies, including the impact of exercise on
dystrophic muscle. However, it should be noted that the mdx mouse model does not completely
recapitulate the human disease, and the severity of its pathology is much less compared to
humans [325].
Due to the large number of studies examining the effects of exercise on mdx muscle,
detailed descriptions of each study will not be provided here but are highlighted in Tables 1
through 4. Instead, the major conclusions from these studies will be discussed. Notably, the
purpose of these studies were in and of the same, with authors describing their goal or goals to
determine the impact of exercise on muscle force and fatigue, oxidative stress, and evaluate the
extent of trauma endured by the muscle. Based on these studies, exercise in mdx mice is
beneficial or detrimental depending on the mode, duration, age at intervention, and intensity of
the exercise protocol. Studies used either treadmill running, voluntary wheel running, or
swimming as the mode of exercise. The duration of a single session, independent of the mode
of exercise, ranged from 10 minutes to 2 hours, while the duration of experiments ranged from 1
week to 52 weeks. The age at which exercise began ranged from 3 weeks to 96 weeks old. This
is important to highlight because mdx mice exhibit very little muscle weakness during the first
33

year of life, yet this is the time frame in which most studies are conducted, making it difficult to
extrapolate these results to humans [327]. The intensity of exercise ranged from at will for
voluntary wheel running to between 4 and 23 meters per minute for treadmill running at a
decline between 0 and 18 degrees. Collectively, studies demonstrate either improvements in
twitch tension and decreased necrosis [328], or reduced muscle strength and increased edema
and inflammation [329]. Similarly, studies either demonstrate improvements in anti-oxidant
capacities and oxidative enzyme activities [330–332] or detrimental increases in reactive oxygen
species [333] and lipid peroxidation [334]. Further, most studies measured specific outcomes on
individual muscles of the hindlimb, the diaphragm, or the heart. Unfortunately, these muscles
are not equally affected by the absence of dystrophin [335], and therefore, likely respond
differently to exercise.
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Table 1: Studies examining treadmill exercise in mdx mice.
Study

Age

Duration Exercise Program
of Study

[328]

3 weeks 3 weeks

7 days/week
Time = 25 min
Incline = 18 degrees
Speed = 4 m/min

Results

Study’s Conclusions

Compared to WT, MDX-ex
exhibited:
↓ BW
↓ muscle size
↓ twitch tension in EDL and
SOL
↓ rate of relaxation
↑ mean fiber size, degree of
hypertrophy, fiber variability in
SOL type I fibers
↔ mean fiber size in SOL
type II fibers
↓ internal nuclei in EDL and
SOL
↓ inflammation in EDL
↓ fibrosis in SOL
↓ split fibers in SOL

Exercise is beneficial based
on clinical performance,
contractile properties of the
SOL, and histochemical
analysis in both SOL and
EDL muscles.

MDX exhibited less dragging
of hind limbs and appeared
less cachectic and atrophied.
[336]

2
months

3 days

3 days

MDX-sed:
14.9 ± 0.62% TB damage
Time = 10 min
5.54 ± 0.27% BB damage
Incline = -15 degrees >13% EDL and GASTROC
Speed = 10 m/min
damage
<3% SOL and TA damage

Sarcolemma damage
correlated with magnitude
of mechanical stress during
contraction rather than the
number of activations

Exercise could cause
Compared to MDX-sed,
muscle wasting, weakness,
MDX-ex exhibited:
dystrophy, fibrosis, and
↑muscle fiber damage in SOL degeneration
(+10.04%), GASTROC
(+9.92%), BB (+24.37%), TB
(+8.02%)
↑ 27% DIA damage
distribution of damaged fibers
was similar
limited hindlimb injuries
(↑<11%)
[334]

4 weeks 6 weeks
or 16
weeks

7 days/week
Time = 2 x 30 min
Incline = 0 degrees
Speed = 8.3 m/min
(8 day adaptation
period prior to
training):
Time = 2 x 5 min
Speed = 4 m/min
then 8 m/min

4 weeks
Compared to MDX-sed,
MDX-ex exhibited:
↑ plasma CK (+85%)
↑ lipofuscin accumulation
(+29%)
↑ TBARS (+48%)
↔ P/O ratios
↔ SOD activity
↓ O2 uptake state 3+4 (-52%
and -23% respectively)
↓ RCI ratio (-27%)
↓ alpha-tocopherol
↓ GSH-Px activity (-12%; but
↑ in WT-ex (+60%))
↓ alpha-tocopherol
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Exercise affects mdx
mitochondria differently
based on age.
Low intensity treadmill
exercise is detrimental to
muscle mitochondria of 4
week mdx mice.
Adult mdx mice exhibited a
higher mitochondrial
adaptive capacity to lowintensity exercise and this
could be due to increase in
regenerating fibers.

Table 1 continued
16 weeks
Compared to MDX-sed,
MDX-ex exhibited:
↔ plasma CK activity
↔ RCI and P/O ratios
No differences in other
measures.
[337]

6 weeks 10 weeks 2x/week
Exercised
First 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 15 m/min
Last 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 23 m/min
Non-exercised
Time = 60 min
Incline = 0 degrees
Speed = 2 m/min

Compared to MDX nonexercise, MDX-ex exhibited:
↑ heart weight (not significant)
↑ ratio heart:body weight
↑interstitial fibrosis and
adipose tissue in cardiac
muscle (fiber disorganization
observed)
↑ infiltration of inflammatory
cells
↑% dystrophic lesion in
myocardium
↑basal level of [p-ERK1/2 and
calcineurin]
↔ body weight
↓p-JNK1 in cardiac muscle
↑p-38 MAPK in heart

Physical exercise induces
dystrophic features in mdx
cardiac muscle.
Future studies should look
at the effects of inhibitors of
p38 MAPK, ERK or
calcineurin on exercised
mdx mice in order to
elucidate mechanism of
progression of the
dystrophic change in heart
muscle

MDX-ex + non-exercise:
↑immunoreactivity with
antibodies against p-p38
MAPK, p-ERK1/2, calcineurin
in degenerative fibers around
the fibrotic change, infiltration
of inflammatory cells
Nakamur
a et al.
2005
[338]

6 weeks 10 weeks 2x/week
Exercised
First 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 15 m/min
Last 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 23 m/min

↔ overt necrosis, fibrosis,
inflammatory cell invasion in
skeletal muscle in MDX-ex.
MDX-ex compared to MDXsed:
↑ratio protein level of pERK1/2 to pan ERK1/2 (4
fold)
↑ratio of p-p38 MAPK to pan
p38 MAPK (1.8 fold)
↑ratio of protein level of pJNK2 to pan JNK2 (2.3 fold)
↑ MMP-9 (1.3 fold)
↔ ratio of protein level of pJNK1 to pan JNK1 among
any group

Treadmill exercise training ↑
phosphorylation of ERK1/2,
p38 MAPK, and JNK2 in
mdx GASTROC muscle.
This may play a role in the
degeneration and
regeneration process of
dystrophic features.
No pathological change
compared to previous
results in cardiac muscle.
Difference may be
explained by the
degeneration-regeneration
cycle after exercise or by
factors which modify muscle
degeneration in mdx
skeletal muscle but not
cardiac muscle.
JNK2 and p38 MAPK may
be associated with the
degeneration mechanism of
dystrophin-deficient skeletal
muscle.
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Table 1 continued
MMP-9- possible role in
disruption of the integrity of
muscle fibers or in the
inflammatory response and
the activation of satellite
cells associated with
regeneration. Not known if
upregulation after exercise
is associated with
degeneration or
regeneration in mdx skeletal
muscle.
[339]

6 weeks 10 weeks 2x/week
First 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 15 m/min

N = 10
mdx
male
mice

Last 5 weeks
Time = 60 min
Incline = 7 degrees
Speed = 23 m/min

MDX had difficulty completing MDX skeletal muscles
protocol (fatigued, need for
temporarily cope with workgentle stimulation or rest)
induced injury by enhancing
muscle regeneration and
MDX-Ex compared to MDXrepair. Chronic exercise
sed:
may accelerate active cycle
↔ fiber size distribution
of degeneration↔ intramuscular collagen
regeneration, which may be
(suggesting ↔ perimysial and an advantage for coping
endomysial fibrosis)
with exercise.
↑ population of smaller sized
fibers (<20 um)
Early ↓ of IGF-1 will
↓ # of large-sized DRG in
accelerate age-dependent
sol/gas/quadriceps
muscle wasting and
↓ level of Igf-1 expression
weakness in the later stage
↓ level of myod1 expression
of life.
Type III collagen mainly
localized in perimysium
IGF-1 localized to early
regenerating fibers with large
round nuclei (moderately or
fully regenerated, centrally
nucleated fibers were not
positively stained)
IGF-1 absent in small
regenerated fibers with
compacted, centrally located
nuclei

Mdx mice vulnerable to
exercise, which may result
in fiber necrosis
earlier/more drastically;
however, data show that
necrosis can be repaired in
exercise mice.
Exercise may shorten the
active degenerationregeneration period in mdx
mice and mdx muscle fibers
more resistant to necrosis
after undergoing one cycle
of regeneration.
Chronic exercise in the
active degenerativeregenerative period will
accelerate age-dependent
dystrophic processes in
mdx mice, leading to a
shortening of the natural
course of mdx skeletal
muscles.

[273]

28 days

8 weeks

2x/week
Time = 30 min
Incline = 0 degrees
Speed = 9 m/min

Oxidative Damage
↔ MDA, protein carbonyls in
MDX-ex
↓MDA (38%) in MDX-ex
↓protein carbonyl (44%) in
white muscle of MDX-ex
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Low intensity exercise
training decreases oxidative
stress markers (protein
carbonyls and MDA) in
white GASTROC of mdx
mice and does not

Table 1 continued
Antioxidant Enzymes
No effects of exercise on
SOD, MnSOD, or CAT in
MDX-ex

detrimentally affect mdx
mice.

Oxidative stress may
contribute to muscle
degeneration in mdx mice
Mitochondrial Enzymes
but low intensity exercise
↔COX between MDX-ex and training decreases ROS
MDX-sed
generation in skeletal
muscle of trained mdx mice.
Muscle Damage
↔ internalized muscle nuclei Propose that when calcium
per total muscle fiber area
homeostasis is improved,
between MDX-ex and MDXROS generation is
SED
decreased which causes a
decline in markers of
oxidative stress in skeletal
muscle MDX-ex.
Lower protein carbonyls
and MDA levels following
exercise in MDX suggest
that several pathways are
involved in alleviating the
effect:
1. Activation of nNOS
and up-regulation of
NO formation that
results in lower
generation of
peroxynitrite
2. Improved calcium
homeostasis that
results in decreased
ROS generation
3. Acceleration of the
regeneration phase
and transformation
from fast to slow
twitch fibers
4. Other unknown
factors
[340]

8 weeks 1 session Protocol A
for 4
vs 4
single 30 minute
week
weeks
session
study
Protocol B
12
2x/week for 4 weeks
weeks
for
Treadmill Settings
single
Warm Up:
session
Time = 2 min
Incline = 0 degrees
Speed = 4 m/min
Followed by:
Time = 8 min
Incline = 0 degrees
Speed = 8 m/min
Main Exercise:
Time = 30 min

Protocol A
~45% of 12-week old
untrained mdx mice could not
complete main exercise
despite 5 rest times.

Protocol A is a suitable
screening protocol for
assessing therapeutic
interventions in adult mdx
mice.

MDX-ex and MDX-sed had
high variation in the amount
of myofiber necrosis but
exercise significantly
increased amount in both 24h
and 48h samples

To visualize the increase in
myofiber necrosis following
treadmill exercise, the
muscles must be sampled
between 24 and 48 h.

↑ mRNA levels of IL-1beta in
MDX-ex after at 2h and IL-6
at 0h + 2h but ↔ at 24h
↓mRNA levels of TNF in
MDX-ex
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Large n is needed due to
variation, and muscle
choice is critical to
assessing impact of
exercise induced damage.

Table 1 continued
Incline = 0 degrees
Speed = 12 m/min
If one mouse
fatigued, all four
mice on treadmill
were allowed to rest
for 2 min then
gradually increased
speed

↑protein thiol oxidation in
MDX-ex at 0h + 2h but ↔ at
24h
↔ MDA in MDX-ex
Protocol B
↓ avg # of rests needed to
complete exercise throughout
4week period
↑rests for in Protocol A
compared to Protocol B
↓ absolute and normalized
change in forelimb grip
strength in MDX-ex

Protocol A was damaging
enough to render myofibers
leaky, but not damaging
enough to cause
widespread myofiber
necrosis in muscles except
for the quadriceps.
The mdx mice may have
adapted to the treadmill
exercise overtime, as
shown by relatively stable
IL-6 mRNA.
Increased IL-6 following
exercise may inhibit TNF,
which is involved with the
pathology of mdx mice and
blockade of TNF can
reduce necrosis.

↑myofiber necrosis in QUAD,
TB, DIA, and TA in MDX-ex
at 24h and ↑necrosis in MDXex at 0h
Potential therapeutic drugs
for DMD should be
↔ myofiber necrosis in MDX- chronically tested in order to
ex 96h post exercise
examine efficiency and
possible negative effects
↑blood serum CK levels in
MDX-ex at 24h but ↔ at 96h
↔ mRNA for IL-1beta or IL-6
in MDX-ex at 0h and ↓ at 96h
↓TNF mRNA in MDX-ex at 0h
but ↔ for at 24h
↑protein thiol oxidation in
MDX-ex at 0h but ↔ at 24h
[341]

4-5
weeks

4 weeks 2x/week
(T4) or
12 weeks Time = 30 min
(T12)
Incline = 0 degrees
Speed = 12 m/min

↔ BM in MDX-ex

GASTROC muscle was
studied due to the
↓absolute and normalized
resemblances in
strength in T4 in MDX-ex and composition with human
maintained up to T12
muscle.

48 or 72 hr break
between each
exercise session

↓ distance (30-40%) in MDXex at T4 + T12 compared to
WT-ex

Exercised for either
4 or 12 weeks

↑ fatigue in MDX-ex at T4 and
T12
Genes primarily involved in
harmful signaling in
Exercise-Related Genes
dystrophic skeletal muscles
↔ Pgc-1alpha gene in MDX- are kept deregulated in
ex at T4
MDX-ex, while the
↓Pgc-1alpha gene in MDX-ex expression of genes
at T12
involved in protective
↔Sirt1 in MDX-ex at T4, but programs and upregulated
↓in MDX-ex at T12
in basal conditions is
↓Ppar-gamma in MDX-ex at
markedly impaired.
T12
Exercise that is able to
Pgc-1alpha Target Genes
produce a myofiber
adaptation in WT muscle
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Exercise protocol does not
produce metabolic
adaptation in healthy
muscle

Table 1 continued
↔ in Cox4 and Cs for MDXex at T4
↔ in utrophin in MDX-ex at
T4 or T12 exercise

may cause more damage in
mdx muscle.

Myofiber Phenotype Genes
↔ Mhc isoforms in MDX-ex at
T4
↓Mhc1 in MDX-ex at T12
↑Mhc2b in MDX-ex at T12
↔ Serca1 in MDX-ex at T4 or
T12
↔ Serca2 in MDX-ex T4 but
↓Serca2 in MDX-ex at T12
↑Mef2c (not significant) in
MDX-ex at T12
↓Hdac5 in MDX-ex at T4 and
T12
Regeneration-Related
Genes
↓Myog and Fst in MDX-ex at
T12
↔ Igf-1 in MDX-ex at T12
Muscle Damage Related
Genes
↓Mstn in mdx mus at both
ages (no effects of exercise)
↔ Atrogin1 in any
experimental condition
↓adiponectin in MDX-ex at
T12
Autophagy Genes
↓Bnip3 in MDX-ex at T12
↓Pgc-1alpha, Sirt1, Fst, and
Mhc1 in EDL of MDX-ex
[342]

4 weeks 4 weeks

2x/week
Time = 30 min
Incline = 0 degrees
Speed = 12 m/min
No more than 48-72
h between each
session
Excluded mice that
did not complete all
sessions

MDX-ex compared to mdx
SED:
↓TTEs and basal O2
consumption
↔max O2 consumption
↑oxidative stress in QUAD
and AB
↑hydroxyproline deposition in
QUAD and heart tissues
↔hydroxyproline in AB
↑collagen scarring in heart
↑collagen-I scar amounts
↑levels of dying myocytes
(not significant) (indicated by
intracellular IgG
accumulation)
↔IgG staining in QUAD
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Exercise is deleterious to
mdx mice, and exacerbates
disease pathology and
alters exercise capacity.
Forced treadmill exercise
increases dystrophic
severity.
Intensity and modality of
exercise affect how
dystrophic muscle responds
to exercise. This protocol
exacerbated the pathology
of mdx mice.
Decrease in basal oxygen
consumption could indicate
that exercise produced
disruptive changes in O2
consumption.

Table 1 continued
Unlike the anti-fibrotic
effects observed in healthy
muscle following exercise,
exercise increases fibrotic
scar damage in quadriceps
muscles, abdominal
muscles, and heart in
dystrophic muscle.
No control conditions were
used to assess the
possibility that mdx mice
incurred muscle damage
during the maximal exercise
test, which might further
confound indices of muscle
damage.
Dystrophic muscle does not
favorably adapt to exercise
in regard to oxidant
buffering and redox
homeostasis.
[343]

8 weeks 60 days

3x/week
Low intensity
training
Time = 30 min
Incline = 0 degrees
Speed = 9 m/min

[344]

4-5
months

6 months 3x/week
Time = 30 min
Incline = 0 degrees
Speed = 4 m/min
(low intensity) vs 8
m/min (moderate
intensity). Speed
gradually increased
over the first 7.5 min
to reach training
speeds.

MDX-ex compared to MDXsed:
↑intramuscular area of
collagen III (and ↑ than WT)
↔ BM
↔ % of centrally-located
nuclei
↔ minimal Feret’s diameter
↔ intramuscular area of
collagen I
↓ collagen fibers mean values
(but similar to WT)

Exercise did not influence
muscle injuries resulting
from membrane fragility in
MDX mice.

MDX-low and MDX-mod
compared to MDX-sed:
↑grip strength
↑max force generated by TA
↔ TA cross sectional
analysis among groups
dose-dependent ↑ in
proportion of type IIa fibers
↑Pgc1a gene expression
GASTROC
↑minute volume with aerobic
exercise
↔ HR between groups
↔QRS duration throughout
the study
↓rate of decline in fractional
shortening and stroke volume

Progression of
cardiomyopathy was
delayed with aerobic
exercise with no adverse
effects on electrical function
of dystrophic heart.
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Exercise provoked
adaptations on extracellular
matrix bringing higher
elastic features to mdx
muscle tissue.
Exercise delayed the
aberrant muscle repair at
the studied age.
At 16 weeks old,
regeneration was more
present than fibrosis in both
MDX-sed and MDX-ex but
exercise decreased the
progression of muscular
fibrosis.

Function of dystrophic heart
and muscle was improved
with exercise without a
significant increase in
fibrosis, centrally nucleated
fibers, or serum CK
Translate into human
setting by defining
biomarkers for skeletal and

Table 1 continued
in an exercise dependent
cardiac dystrophic muscle
manner
to help define low and
↓heart mass with ↑ exercise
moderate exercises.
intensity
↑Pgc1a in the hearts
↔picrosirius red staining (#
and size of fibrotic regions in
heart, DIA, GASTROC)
↔% of centrally located
nuclei
↔serum CK during exercise
program
↑serum and adipocyte
concentrations of adiponectin
↓cross sectional area of
adipocytes
↓in left ventricle internal
diameter thickness during
diastole and the left ventricle
posterior wall thickness at
month 6
Inspiratory time (Ti):
↑7% in MDX-sed
↑1% in MDX-mod
↓6% in MDX-low
Expiratory time (Te):
↑43% in MDX-sed
↑13% in MDX-mod and MDXlow
Ti and Te inversely related to
disease progression
↑avg activity level (months
4+5) in MDX-mod compared
to MDX-sed and MDX-low
[345]

4-5
weeks
16
weeks
for
single
session

~4 weeks 2x/week
vs >12
weeks vs Time = 30 min
30 min
Incline = 0 degrees
Speed = 12 m/min

MDX-short and MDX-long
compared to MDX-sed:
↓absolute and normalized
strength after 4 week and
impairment maintained up to
12 weeks

Long (>12 weeks),
short (~4 weeks) and ↓twitch and tetanic force of
acute (1 session)
mdx DIA but no DIA fatigue
protocols
↓contractile force (to 10%) of
EDL in MDX-short and
becomes significant in MDXlong
↔ effects of eccentric
contractions of EDL
↓PCG-1alpha, ↓MYH1, and ↓
basal upregulation of SIRT1
↑AChR1 (twofold) in MDXlong protocol
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There is a complex
equilibrium between
adaptation and
maladaptation in MDX mice.

Table 1 continued
↑NOX2 and Tuba-1b and ↓ in
Fst
↑total damage (40%) in MDXlong protocol (sum of
necrosis, infiltration and nonmuscle area)
↔% of centrally located
nuclei
↔mmp9
In response to single bout of
exercise:
↓normalized twitch and
tetanic tension in MDX-acute
↔contraction kinetics or
fatigue
↓twitch and tetanic
contractions of EDL in MDXacute
↓time to peak tension and
half-relaxation time for MDXacute
↔ fatigue
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Table 2: Studies examining ad libitum wheel running in mdx mice.
Study

Age

Duration Results
of Study

[346]

Young
group
~4
weeks

4 weeks

Adult
group
~6
months

Study’s Conclusions

Adult Mice
Force does not ↑ at same rate as
↓running in MDX-ex compared to WT- the CSA. Could be because
ex
strangely branched and/or split
fibers in MDX and/or ↑ in % of nonCK ↓65% in MDX-ex
contractile elements such as
connective tissue
↑BW for MDX-ex ↓BW for WT-ex
EDL and SOL from young and adult
↑SOL weight for MDX-ex and WT-ex MDX showed slight injury b/c of
but ↔EDL weight
exercise.
↑CSA in SOL and EDL for MDX-ex
and WT-ex
↓tetanic tension in SOL and EDL of
MDX-ex and WT-ex
↔fatigue response in SOL of MDX-ex
Young Mice
↔ running in MDX-ex and WT-ex due
to high inter-mouse variability
↔CK levels in MDX-ex
↔ in BW between MDX-ex and WTex
↑SOL weight for MDX-ex and WT-ex
but ↔EDL weight
↑CSA in SOL of MDX-ex but ↔EDL
↓tetanic tension in SOL and EDL in
MDX-ex
↔fatigue response in SOL of MDX-ex
↔ on histology of MDX-ex

[347]

4 weeks 16 weeks ↔ avg week distance + daily speed
for 2 weeks. Then ↓ avg distance and
daily speed for MDX-ex compared to
WT-ex in all weeks after 3 weeks
except week 8

↓ in distance run MDX-ex vs WT-ex
due to ↓ speed in MDX

After exercise, ↑ fatigue resistance,
proportion of oxidative fibers +
improvement in muscle force
↔ avg run hours per week in MDX-ex production
vs WT-ex
running ↑ abs. mass of SOL in MDXex but
↔ in EDL + PL
↔ in EDL + PL contractile properties
in MDX-ex
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Table 2 continued
↑ abs. twitch + tetanic tensions of
SOL in MDX-ex
↑ resistance to fatigue in EDL + SOL
of MDX-ex but ↔ fatigue resistance
in PL of MDX-ex
↑ type I + ↓ type IIa fibers in SOL but
↑ type IIa + ↓ type IIb in EDL of MDXex
[348]

6
months

1 year

MDX-ex ran 55% of daily distance of
WT-ex
↔ EDL weight but ↑ SOL weight in
MDX-ex
↔ tetanic tension for EDL or SOL in
MDX-ex
↑ fatigue resistance in EDL of MDXex

Hypothesis that long-term ad libitum
exercise having beneficial effects on
WT and deleterious effects on MDX
was not supported by data
MDX-sed show high muscle
damage but MDX-ex respond
beneficially to low levels of voluntary
running
Reason for atrophy in MDX mice is
unknown but ould be due to ↓
physical activity, ↓ satellite cell
proliferation., and/or ↑ catabolism
Long-term exercise does not have
deleterious effects on MDX EDL,
and slightly improves SOL

[330]

21 days
male

3 weeks

Run distance dependent on diet:
MDX-ex-GTE ran total distance 128%
↑ than MDX-ex over course of study.
Interestingly, MDX-ex-GTE total
distance was equal to WT-ex

GTE, MDX-ex and MDX-ex-GTE
was beneficial and no obvious
deleterious outcomes
EX + GTE diet ↑ muscle function in
MDX

↑ tetanic stress in MDX-ex and MDXex-GTE and ↑active stiffness in MDX- ↑ EDL tetanic stress output could be
ex and MDX-ex-GTE
due to ↑ stability of contractile
proteins, shift in fiber type, and ↑
↑abs. myosin content, total muscle
membrane integrity
protein to muscle mass, total
contractile protein to total muscle
protein in EDL of MDX-ex and MDXex-GTE
↑ type I and IIa fibers and ↓ type IIb
fibers of EDL in MDX-ex but ↔ in
MDX-ex-GTE
↑ antioxidant capacity in MDX-ex and
MDX-ex-GTE
↓ Lipid peroxidation in GASTROC
and heart of MDX-ex and MDX-exGTE
↓CK levels in MDX-ex and MDX-exGTE
↑CS activity in QUAD and heart of
MDX-ex and MDX-ex-GTE
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Table 2 continued
↑ B-oxidation activity in QUAD and
heart of MDX-ex and MDX-ex-GTE

[349]

4 weeks 8 weeks

↓ distance + time on wheel in MDX-ex MDX can remodel in response to
than WT-ex
exercise.
↔ BM in MDX-ex

MDX mice engage in physical
activity when given the opportunity.

↑percentage of type IIa fibers and ↓
percentage of type type IIb in EDL of
MDX-ex
Leftward shift in CSA distribution of
EDL and SOL in MDX-ex

Exercise may prevent secondary
unwanted consequences.
Appears to be an intensity threshold
for inducing beneficial vs deleterious
adaptations.

↔ in central nuclei in MDX-ex
[290]

4-5
weeks

12 weeks ↓ BM in MDX-ex (no resistance) and
MDX-resist (resistance increased by
1 g per week)
↓ mean daily distance in MDX-resist
vs MDX-ex
↑ external work per week in MDXresist vs MDX-ex during weeks 2-12
↔ max. dorsiflexion torque in MDXresist vs MDX-ex but ↑ during
duration of study
↑ grip strength in MDX-ex + MDXresist
↔ whole body tension in MDX-ex +
MDX-resist
↔ abs. twitch, tetanic, or eccentric
forces by SOL in MDX-ex + MDXresist
↔ passive + active stiffness in in
MDX-ex + MDX-resist
↔ in force loss during + following
eccentric injury in in MDX-ex + MDXresist
↔ in muscle masses in MDX-ex +
MDX-resist
↔ CK in MDX-ex + MDX-resist
↑ beta-dystroglycan content in
GASTROC of MDX-ex
↑ vinculin content in SOL of MDX-ex
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↔ in functional measurements by
wheel running
12 weeks of voluntary wheel running
↑ muscle strength in SOL and ↑ grip
strength
2 modes of exercise differing in
intensity are capable of inducing
comparable adaptations in skeletal
muscle of MDX mice.
Dystrophic muscle can adapt to a
resistance-type exercise
Hypertrophy was not the underlying
cause of improvement.
Minimal changes in cytoskeletal
proteins with wheel running.
Did not observe a benefit with
regard to susceptibility to injury.
Data collected indicates that a
threshold must be surpassed
regarding cytoskeletal protein
expression to observe functional
benefits, and wheel running did not
overtly elicit this adaptation in mice.

Table 2 continued
[332]

4 weeks 12 weeks Voluntary wheel running does not
in vivo muscle strength + fatigue
induce physical inactivity in MDX-ex
resistance ↑ in MDX-ex.
but mice ↓ voluntary activity during 30
min after forced running on wheel.
Mitochondrial adaptations contribute
to the beneficial exercise-induced
↔ CK in MDX-ex
skeletal muscle remodeling.
↔ BM in MDX-ex
↑heart mass but ↔ GASTROC and
TA in MDX-ex
↑ maximal isometric torque in MDXex

Strength gains occurred at
functionally-relevant, sub-maximal
frequencies.
Duration is an important exercise
design parameter. Mode + intensity
are also important.

Plantarflexor muscles beneficially
adapted to daily running with ↑ submaximal torque MDX-ex but ↔ in
concentric torques
↑% of peak torque in MDX-ex
↑ PCG-1alpha protein in GASTROC
of MDX-ex
↑ COX IV protein in GASTROC of
MDX-ex
↔ percent of central nuclei in TA or
diaphragm but ↓ in central nuclei in
GASTROC of MDX-ex
[350]

10-12
weeks

2 weeks

Daily distances run by individual mice
diverged over time.
Mouse 1
Pattern: intermittent running + resting
throughout most of the dark hours
Mouse 2
Pattern: intermittent running + resting
throughout most of the dark hours
Mouse 3
Pattern: intermittent running + resting
throughout most of the dark hours
Mouse 4
Pattern: intermittent running + resting
throughout most of the dark hours
Mouse 5
Pattern: intermittent running + resting
throughout most of the dark hours.
More breaks in last 4-6 hours of night
Mouse 6
Pattern: ran intermediate-high
overnight distances, although these
were variable by up to 3 km per night
Ran mostly in first 6 hours per night,
with almost no running activity in
second 6 hours
Mouse 7
Pattern: intermittent running + resting
throughout most of the dark hours
Total Distance: 0.04 km
Mouse 8
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Extensive variation in voluntary
wheel running in MDX adults.
↓# of bouts + ↑ bout distance
promoted muscle damage.
Data strongly indicates that a
detailed analysis of individual mouse
running behavior is essential when
utilizing voluntary wheel running.

Table 2 continued
Pattern: intermittent running + resting
throughout most of the dark hours
Total Distance: 7.65 km
Mouse 9
Pattern: ran intermediate-high
overnight distances, although these
were variable by up to 3 km per night
Ran mostly in first 6 hours per night,
with almost no running activity in
second 6 hours
Mouse 10
Pattern: intermittent running + resting
throughout most of the dark hours.
More breaks in last 4-6 hours of night
Total Distance: 67.24 km
Mouse 11
Pattern: ran intermediate-high
overnight distances, although these
were variable by up to 3 km per night
Ran mostly in first 6 hours per night,
with almost no running activity in
second 6 hours
Total Distance: 62.68 km
Avg time spent running on running
wheel per bout ranged from 1.04 min
(mouse 7) to 10.52 min (mouse 11)
Running bouts ↓ for mouse 4, 7, and
8, and ↑ for mouse 11 in comparison
with group avg
Mouse 7 + 11 had rest times ↑ than
all other mice
From slowest to fastest average
running rate: mouse 7 + 8, mouse 1 +
4, mouse 2 +3, mouse 5 + 6, and
mice 9-11.
Mouse 8 ran ↑ # of bouts but ↓ avg
rate. Mice 6 + 9-11 ran ↓ # of bouts
but ↑ avg rate.
↑ in tissue necrosis in QUAD of mdxex.
Shift towards larger fiber CSA in
QUAD and GASTROC in MDX-ex.
Mean distance covered in individual
running bouts showed a positive
correlation with percent of tissue
necrosis in QUAD.
Total # of running bouts showed an
inverse correlation with tissue
necrosis.
Mean nightly + total # of running
bouts also showed an inverse
correlation with necrosis in
GASTROC.
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Table 2 continued
Mean running bout distance
correlated with percent of centrally
nucleated myofibers.
Total + mean rest times showed
positive correlation with necrosis in
GASTROC.
Total run time had negative
correlation with necrosis in
GASTROC.
Only running parameter that was a
significant positive indicator for
myofiber CSA was total cumulative
rest time.
[351]

Sed
MDX: 5
months

Sed
MDX: 2
weeks

Run
Run
MDX: 4- MDX: 45 weeks 4.5
months
Run CT:
4 weeks Run CT:
3 months

Inactivity
↓ specific maximal force in
MDX+staple

inactivity aggravates muscle
weakness + susceptibility to
contraction-induced injury.

↓ absolute maximal force in CT +
MDX.

Possible that GDF8 decreases
contractile protein contents because
it is known to inhibit protein
synthesis.

↓ force after 3rd, 6th, and 9th
lengthening contraction in MDXstaple, indicating increased
susceptibility to contraction-induced
injury with inactivity
↑ expression of MHC-2b protein and
GDF8, Stim1 and Jph1 gene
expression in MDX+staple
↔ in Bnip3, LC3, and astrogin-1
expression in MDX-staple
Activity
↑ specific maximal force, abs.
maximal force, and muscle weight in
MDX-ex
lower force ↓ after 3rd, 6th, and 9th
lengthening contraction in MDX-ex,
indicating a decreased susceptibility
to contraction-induced injury

Fast fibers have ↑ fragile than slow
fibers
Inactivity can worsen dystrophic
features and be more harmful to
DMD vs healthy muscle.
Activity ↓ muscle weakness +
susceptibility to contraction-induced
injury.
Data suggests that muscle
weakness + susceptibility to
contraction-induced injury in
dystrophic muscle could be partly
attributable to inactivity.

↔ in gene expression except for ↑ in
MHC-2a protein + ↓ in Actg1
↔ fibrosis in MDX-ex
[352]

4 weeks 52 weeks ↑ BM in MDX-ex
Running distance peaked at weeks
3+4 of study, and steeply declined
after.
↑abs. plantarflexor, GASTROC and
SOL, and heart masses in MDX-ex
↑CSA and tetanic force in SOL of
MDX-ex
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1 year of wheel running caused
heart remodeling but diaphragm
function was severely impaired in
MDX-ex. Likely that ↑ rate of
respiration + workload required to
support exercise accelerated
disease progression in diaphragm.
Mice tend to perform intermittent
sprints instead of maintaining a

Table 2 continued
↑heart

steady pace which could ↑
diaphragm injury +↓ function

↑ Left ventricular end diastolic and
systolic dimensions, and systolic
volume in MDX-ex
↑stroke volume + cardiac output in
MDX-ex
[353]

Note: mice are from Baltgalvis et al.
2012
↑ total utrophin protein in QUAD of
MDX-ex but ↔ in SOL

Previous reports show utrophin
protein translation is regulated by
signaling pathways activated by
aerobic exercise.

↔CSA or muscle fiber CSA variability
↑percentage of small central nuclei %
in MDX-ex
[354]

7
months

3 months ↔ in running between male + female
MDX-ex
↔ force drop after 9 lengthening
contractions
↔ in specific maximal force
↑ abs. maximal force in female MDXex but ↔ in males
↔ left ventricular function + structural
heart dimensions
↔ in expression in cardiac gene
markers of inflammation/fibrosis
(Col1a1, Col3a1, Ctgf, and TgfB1)
and cardiac remodeling (Bnp and
Myh7)
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Voluntary activity initiated at 7
months was not detrimental for
hindlimb skeletal muscle in MDX
mice and does not improve
susceptibility contraction-induced
injury in female MDX mice.

Table 3: Studies examining swimming in mdx mice.
Study Age
[355]

[356]

Duration Exercise Program
of Study

Results

5 weeks 15 weeks Time was ↑ daily until
total swim time was 2
hours continuously.

MDX-ex compared to MDXsed:
↓ mass of SOL + EDL
↓ SOL CSA
Program continues by ↓ EDL CSA
attaching weights (5% ↑ normalized twitch tension
of body weight) to tail ↑ fatigue resistance in SOL
during 2 hour swimand EDL
period. Resisted swim ↑ type I fibers in EDL
continued for 5 more
weeks until 20 weeks
of age was reached

same
15 weeks same mice + protocol
mice
from Hayes et al.
from
1993
Hayes et
al. 1993

Study’s Conclusions
Improvement in fatigue
resistance of skeletal
muscles in MDX-ex,
improvements in muscle
oxidative capacity, and
transformation towards lessfatigable fibers renders
muscle less vulnerable to
damage.
Combining exercise and an
anabolic agent may improve
muscle mass and offer
greater benefits.

MDX-ex compared to MDXSwimming affected some
sed:
contractile properties of MDX
↓ # of type IIa fibers and ↑ # of skeletal muscle fibers.
intermediate fibers
Fast-twitch fibers isolated
EDL
from MDX-ex had ↓ sensitivity
Type IIa fibers displayed
to Ca2+ and Sr2+. This ↓in
steeper force-pCa and forcesensitivity to activating ions
pSr
may be a protective
mechanism that prevents the
Type IIb fibers showed ↓
↑ resting Ca2+ in these fibers
threshold for contraction by
from exceeding contraction
Ca2+ and a ↓ Ca2+ sensitivity threshold.
SOL
↔ differences existed for
Ca2+, sensitivity of type I
fibers to Ca2+, or force-pCa
curve steepness
Type IIa fibers had force-pCa
curves that were significantly
right shifted and displayed
higher values for contraction
threshold and sensitivity.
↓ force-pCa curve steepness
values

[327]

8-10
months
or 24
months

10 weeks Free swimming for as
long as possible once
daily. Rest day after 2
consecutive days of
swimming.

24-month mice were unable to Contractile properties of old
swim continuously for > 25
MDX mice can still be altered
min.
by very low-intensity
swimming.
For swimming,
↔BM or muscle mass in 24Low levels of controlled, nonmonth mdx mice
weight-bearing activity can be
beneficial for dystrophic
↔ absolute forces produced
muscle.
but ↑ in peak tension
normalized to muscle mass
and tetanic tension normalized
to muscle mass in 8-10 month
mdx mice vs 24-month mdx
mice
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Table 3 continued
↑ force-generating capacity in
24-month mdx mice
↔ fatigue properties of 24month mdx mice
[357]

4 weeks 4 weeks

exercised 4 days per
week (M, T, Th, F) for
30 min/day. Mice
were not forced to
swim and were free to
stand.

MDX-ex compared to MDXsed:
↑ grip strength
↔ total protein carbonylation
level but ↓ carbonylation of
voltage-dependent anionselective channel protein 1,
fast isoforms of troponin T +
MyBP-C, and
phosphoglucomutase-1

Proteins involved in muscle
contraction and glycogen
metabolism were both over
carbonylated and
downregulated in MDX Sed.

Swimming rescued, at least
in part, MDX muscle at
protein level. Specifically,
proteins from mitochondria,
muscle contraction, and
glycogen metabolism that
↑ expression of respiratory
were highly carbonylated and
chain proteins, fast isoforms of downregulated in MDX-sed
troponin T and MyBP-C, UTP- muscle were less
glucose-1-phosphate
carbonylated and highly
uridylytransferase and
expressed in MDX-ex.
carbonic anhydrase 3
This suggests that protein
↓carbonylation of ATP
carbonylation could cause a
synthase subunit alpha, fast
functional impairment in mdx
isoform of troponin T and GP
muscle.
↑expression of tubulin,
vimentin, and associated
proteins, and stress response
proteins.
Two ATP synthase complexes
absent in MDX-sed muscle
were restored in MDX-ex.
↑ expression of slow isoforms
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Table 4: Studies examining Rota-Rod training in mdx mice.
Study

Age

Duration Exercise Program
of Study

[358]

8 weeks 6 weeks

5 days/week at
progressively
increase number of
rotations (16 to 24
rotations/minute) and
duration (15 to 60
minutes).

Results

Study’s Conclusions

MDX-ex compared to MDXsed:
between 1 and 3 weeks of
training, ↓forelimb strength
and insignificant ↓ of forelimb
fatigue at weeks 3 and 4 of
training.

Exercise did not improve
muscle function in MDX-ex
but there is improvements
in muscle morphology

↔ fatigue resistance
↓ inflammatory-necrotic areas
in GASTRO and QUAD (not
significant for mice that
exercised for 15 days but
significant for mice that
exercised for 30 and 45 days)

Exercise intensity could
have been too low to induce
significant physiological
adaptation in MDX-ex.

↓ Cx39 protein in GASTRO
and QUAD (not significant for
mice that exercised for 15
days but significant for mice
that exercised for 30 + 45
days)
[359]

Same mice as first
study.

4 spots showed modulation in
protein levels in MDX-ex,
including 3 CA3 isoforms and
SODC. Levels appeared to
return to WT levels.
↓ CA3 in MDX-ex
↑ SODC in MDX-ex

Reduced expression of CA3
and parallel increase in
expression of SODC protein
suggest improved oxidative
stress and restored antioxidative response,
indicating a possible
mechanism by which
exercise may reduce
muscle degeneration in
MDX
Exercise may in part
contribute to lower muscle
degeneration in MDX
muscles.

[360]

Same mice as first
study.

↔ in total area of necrosisregeneration in DIA in MDXex but ↑ area of active
regeneration and ↓ area of
necrosis when evaluated
separately at both 30 and 45
days

Trend for regeneration
areas to be larger than
necrosis areas in
diaphragm of MDX-ex.

Similar Cx39 protein levels
in diaphragm of MDX-sed
and MDX-ex cannot be
↔ difference in Cx39, Hsp60, explained by inflammation
Hsp70 at 30 and 45 days
in regenerating areas but
stable levels of Cx39 and
↓ NF-kB levels at 45 days in
NF-kB may indicate that
MDX-ex
training was not detrimental
to the diaphragm of MDX
mice.
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Early investigations on exercise and dystrophic muscle centered on determining the
susceptibility of dystrophic muscle to eccentric contraction-induced injury. These studies
subjected mice to a single or multiple sessions of eccentric exercise, either via electrically
stimulated lengthening contractions or downhill treadmill running. In healthy muscle, it is well
established that eccentric contractions produce greater exercise-induced damage and promote
negative functional consequences [361]. Damage arises from the higher force required by the
reduced number of activated muscle fibers, leading to high mechanical stresses and
microlesions within the sarcolemma [362] as well as disruptions in the components of the
extracellular matrix and connective tissue [363,364]. This is important to highlight because these
studies clearly demonstrate that dystrophic muscles endure more damage from eccentric
contraction compared to their wild-type counterparts [69,70,74,76,365–367]. Specifically, there
is an increase in membrane breakdown in the rectus femoris and EDL muscles [365,366], and
serum creatine kinase [74,368]. Thus, authors urged researchers and clinicians that because a
single bout of eccentric contractions negatively affects dystrophic muscle, exercise should be
completely avoided by those with DMD [76].
These studies led researchers to propose that eccentric exercise regimens could be
used to make the mdx mouse model a better clinical model for DMD and become a more
reliable model for testing novel therapies [74]. Specifically, because of the lesser severity in mdx
muscle, many studies have used exercise to exacerbate the phenotype prior to administering
the therapy. Since these studies further supported the above hypothesis that exercise
exacerbates disease progression, researchers and clinicians air on the side of caution and
advise their patients to not participate in exercise. It should be noted, though, the only
conclusion that can be drawn from these experiments is that inappropriate exercise and forceful
muscle contractions are, in fact, detrimental to mdx muscle [317].
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Lastly, due to the biomechanical differences between mouse and humans, there is only
one study that evaluated the impact of “resistance training” on mdx muscle. To emulate
resistance training, Call and colleagues (2010) [290] progressively increased the resistance of
the running wheel by adding weights to the running wheel. For 12 weeks, mdx mice where given
access to a running wheel ad libitum. Resistance increased each week from 1 gram (which is
6% of body mass) to 7 grams. Additionally, a second group of mdx mice had ad libitum access
to a running wheel whose resistance remained set at 1 gram and a third group that did not have
access to a running wheel but maintained normal cage activities. Mice running on the resistance
wheel did not display increased skeletal muscle damage nor higher creatine kinase levels when
compared with mice that ran on the normal running wheel. From these results, the authors
conclude that dystrophic skeletal muscle can positively adapt to resistance training.
The major shortcomings of studies on exercise and individuals with DMD are also
evident in the mdx research. The lack of uniformity among the protocols of these studies
severely hinders the ability to draw conclusions and translate results to humans [369]. In 2008,
TREAT-NMD published standard operating procedures for experiments evaluating dystrophic
muscle’s response to activity in order to improve comparability between studies
(http://www.treat-nmd.eu/research/preclinical/dmd-sops/). These documents provide detailed
protocols for both the mode, intensity, and duration of exercise. For example, to worsen the mdx
phenotype and/or to evaluate the efficacy of therapeutic interventions, mdx mice should run at a
speed of 12 meters per minute for 30 minutes twice a week (SOP DMD_M.2.1.001).
Additionally, this SOP states that mdx mice can barely tolerate downhill running and this should
only be used for proof-of-concept approaches. However, there is no published SOP for studying
the impact of aerobic exercise on disease progression. Lastly, while similar studies use the
same outcome measures, such as maximum twitch or tetanic tension and fatigue resistance,
the protocols used to collect these data were extremely different. Differences in these
parameters make it difficult to compare results across studies, leading to contradicting results
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and further delay in understanding how exercise impacts the progression of DMD. SOPs are
now available in order to limit these differences across all preclinical studies.
Voluntary wheel running as the primary mode of exercise for mdx mice should be
addressed as a study limitation, especially because it leads to inconsistent results in the
literature. For studies that used voluntary wheel running with various lengths of ad libitum
access (4 weeks vs 16 weeks vs 1 year), force-generating capacity and fatigue resistance of the
soleus and EDL muscles differed across studies [346–348,370]. For example, following 16
weeks and 1 year of voluntary running, the soleus muscles demonstrated greater forcegenerating capacities while the EDL muscle exhibited a greater fatigue resistance compared to
sedentary mdx mice [347,348]. Conversely, no effect was observed on these same properties
following 4 weeks and 1 year of voluntary wheel running in another set of studies [346,370].
These differences most likely arise from differences in the running activity of individual mice
across the four studies. Specifically, in the two studies reporting positive benefits from wheel
running, mdx mice ran an average weekly distance of 29.8 ± 2.6 km [347] and about 25.2 km
based on the reported average daily distance [348]. For the two studies reporting no effects of
wheel running, the average weekly distance ran by mdx mice was estimated to be 33 km based
on data presented in the graphs [370] and an estimated 4.5 km based on data presented in the
graphs [346]. Recently, Smythe and White (2012) [350], demonstrated that voluntary wheel
running differentially affects the muscles depending on the time interval between and the
duration of each individual bout of running, rather than on the total daily or weekly distance.
Ultimately, when using wheel running as the mode of exercise, a large number of animals is
required to tease apart these inter-individual differences.
1.8.3 Inactivity in DMD
Even with extremely low activity levels in boys with DMD and a limited understanding of
the potential role that exercise plays in disease progression, very few studies have been done to
understand the role that inactivity plays in disease progression. While there are no human data,
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studies using the mdx mouse model are available [73,75,351] and their conclusions are
contradicting. Following an injection of tetanus toxin into the right gastrocnemius muscle, 3week-old mdx mice were subjected to sustained dorsiflexion of the right ankle joint for 2 to 56
days [73]. Compared with un-injected control mdx mice, the soleus and EDL muscles exhibited
a significantly reduced number of muscle fibers with centrally located nuclei, leading the authors
to suggest that muscle necrosis is facilitated by muscle movement and can be prevented
through immobilization. Similarly, in 3-week-old mdx mice, when a metal splint was applied to
the right hindlimb to prevent contractions for 14 days, evidence of early stage necrosis in the
soleus and EDL muscle was absent [75]. Additionally, the cross sectional areas of muscle fibers
were noticeably reduced [75]. Here, the authors conclude that, while muscle necrosis may occur
from muscle contractions, early atrophy from immobilization and the requirement of the
respiratory muscles to be permanently active eliminates any therapeutic potential of these
results to slow the progression of disease in individuals with DMD [75]. Lastly, following 2 weeks
of leg immobilization, inactivity was found to aggravate muscle weakness and increase its
susceptibility to contraction-induced injury in 5-month-old mdx mice [351]. These deficits could
not be explained by changes in the expression of genes involved in autophagy, proteolysis or
fibrosis [351]. Here, the authors conclude that inactivity may be more harmful for dystrophic
muscle than for healthy muscle [351]. Unfortunately, none of these studies examined the longterm impact of inactive periods on disease progression.
1.9 Recommendations for Future Research
Many authors who conduct reviews on the potential impact of exercise on DMD muscle
draw the same conclusions: more research is necessary and study design must be improved
[317,369,371–373]. To improve study design, authors suggests that studies include not only
participants of similar age but with similar disease severity, be of longitudinal design rather than
cross-sectional design, be of sufficient duration to capture all potential effects, implement
outcome measures that are standardized, reliable and systematic across studies [371,372], and
57

assess respiratory, cardiac, and limb muscles simultaneously [369,372]. This is of utmost
concern because there are several major questions that still need to be addressed, including:
does exercise lessen or exacerbate muscle loss and contractures in DMD patients, when is
exercise more likely to beneficial or injurious during the disease, how does exercise interact with
other treatment modalities, what are the short (initial days or weeks), the intermediate (several
weeks to months) and the long term (many months to years) effects of exercise on disease
progression, and to what extent does exercise influence tissue reorganization [372]? More
importantly, though, there is a need for establishing a model that not only allows the
assessment of various exercise interventions both safely and effectively but permits longitudinal
assessment of dynamic variables [372].
1.10 Purpose of our Research
Skeletal muscle plasticity in diseased muscle, specifically in muscle lacking dystrophin,
is incredibly understudied. While healthy individuals are capable of adapting and overcoming
changes in muscle activity, how exercise or the phenomenon “use it or lose it” applies to
dystrophic muscle are not clear. Therefore, it is critical that research goes back to step one, and
fundamentally assesses the short- and long-term impact of muscle contractions on the
structure, function and survivability of dystrophic muscle.
The purpose of our research is to evaluate the impact of inactivity and NMES on muscle
structure, function and survival using the zebrafish model of DMD in order to gain insight into
the delicate equilibrium between adaptation and maladaptation in DMD muscle. Zebrafish are a
well-established model for studying muscle diseases and offer several advantages to
understanding disease progression, which are highlighted throughout our experiments. More
importantly, though, studying the impact of activity on DMD muscle must go beyond measures
of muscle strength and function and delve deeper into the molecular and cellular changes
occurring across multiple systems that interact and support muscle health. As demonstrated
above, most studies on humans and mouse models are limited in these assessments.
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Leveraging the zebrafish model of DMD allows us to address many of these limitations both in
vivo and across time. We hypothesize that inactivity lowers the threshold for contraction-induced
injury in dystrophic muscle and accelerates disease progression. Conversely, we hypothesize
that there is an intensity threshold for NMES, where it crosses from a therapeutic intervention to
one of accelerated pathology. As novel treatment strategies become available and allow
individuals with DMD to become more active, it is critical that we understand the basic
mechanisms of skeletal muscle plasticity and define these thresholds.
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CHAPTER 2
VARIATION IN DISEASE PROGRESSION IN A ZEBRAFISH MODEL OF DMD

2.1 Relevant Background
2.1.1 Zebrafish as a Model to Understand the Pathological Mechanisms of Muscular Dystrophy
Zebrafish harbor orthologous genes with more than 70% of all human genes and more
than 80% of human disease-causing genes [374]. Included in these genes are those
responsible for various types of muscular dystrophy (reviewed by [375,376]). Interestingly,
multiple zebrafish models for these muscular dystrophies more closely resemble the severity of
the pathology observed in humans than the corresponding mouse models [376–378]. Zebrafish
are an attractive model for studying skeletal muscle and muscle diseases, especially because
they generate a large number of offspring, develop rapidly ex utero, have optically transparent
embryos and larvae, and can be genetically manipulated more easily [379,380]. Additionally,
skeletal muscle is the largest and most prominent system in zebrafish larvae, allowing it to be
easily visualized and accessible [375]. Further, many molecular, ultrastructural and histological
features are shared between zebrafish and human muscle, including components of the DGC,
the excitation-contraction coupling machinery, and the contractile apparatus [381–385].
However, one fundamental difference between zebrafish and human muscle is the anatomical
separation of the fast- and slow-twitch muscle fibers. Specifically, the bulk of the fast muscle
fibers are located close to the axis while the slow muscle fibers reside just under the skin. A
second fundamental difference is that zebrafish harbor short muscle fibers attached serially to
the myotendinous junctions. This structural difference increases the relative number of possible
failure points per unit muscle length compared to mammalian limb muscles [386]. Lastly,
zebrafish exhibit reproducible, quantitative motor behaviors beginning at 1 dpf [387], providing
simple and non-invasive measures of muscle function. Therefore, numerous studies have
leveraged the zebrafish model to perform large drug screening assays to identify potential
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therapies for muscular dystrophies as well as to investigate potential mechanisms of disease
progression.
2.1.2 The Zebrafish Model of DMD
Dystrophin-deficient zebrafish, known as sapjeta222a/ta222a, and referred to as dmd mutants
throughout this dissertation, are the smallest vertebrate model of DMD. These zebrafish were
isolated in a forward genetic screen [388] and subsequently identified as carrying a non-sense
mutation in exon 4 of the dystrophin gene. This mutation is autosomal recessive, affecting about
25% of the offspring from a heterozygous cross. Zebrafish dmd mutants are an excellent
example of how the zebrafish model better captures the severity of the human disease than the
mouse model [324,389]. For example, zebrafish larvae exhibit severe structural and functional
deficits by 4 days post fertilization (dpf), and die prematurely by their second week [377,390].
Conversely, mdx mice have very mild structural and motor deficits with little impact on survival
[324,389]. Upon histological characterization of dmd mutants, there is extensive muscle fiber
degeneration and fibrosis, as well as infiltration of inflammatory cells and activation of muscle
satellite cells [377]. Additionally, muscle fiber cross-sectional areas exhibit significant variation,
with the proportion of small muscle fibers being significantly higher compared to wild-type
siblings. However, at 7, 14, and 21 dpf, the area covered by muscle fibers with large crosssectional areas is significantly greater in dmd mutants compared to wild-type siblings, and the
percentage of muscle fibers with centrally-located nuclei is significantly reduced [377]. BrdU and
Pax7 labeling also reveal significantly higher levels of proliferation throughout development in
dmd mutants, especially for the satellite cell population [377]. Lastly, twitch and tetanic forces
are significantly decreased in dmd mutants compared to wild-type siblings, with a 50% deficit in
normalized twitch force and a 40% deficit in normalized tetanic force [386]. Therefore, while
dmd mutants are well-characterized as a whole, longitudinal studies to elucidate variation in the
severity of muscle degeneration as well as the dynamics of degeneration-regeneration cycles in

61

individual zebrafish have not been conducted. The goal for this chapter is to test a longitudinal
approach for studying variation in the zebrafish model of DMD.
2.2 Experiment Overview
Unlike most zebrafish studies in which embryos are treated as a collective whole, we
followed embryos individually throughout each experiment so that disease progression could be
monitored throughout time. Experiments began at disease onset, which is 2 dpf. At disease
onset, zebrafish were identified via birefringence as a dmd mutant or healthy wild-type sibling.
Wild-type siblings had myotomes with organized, parallel muscle fibers that appear bright white
while dmd mutants had myotomes with disorganized and detached muscle fibers that appear
gray to black [389]. After separating dmd mutants from wild-type siblings, zebrafish were
prepared for birefringence imaging (protocol in Appendix B.2). Zebrafish were imaged one by
one, and housed one fish per well in 12-well plates with 3 mL of 1X ERM per well. Upon
imaging, each individual zebrafish was assigned a number that was used to track the zebrafish
and its corresponding birefringence images throughout the entire study. Birefringence images
were taken at the same time every day beginning at 2 dpf. In addition to birefringence,
DanioVision was used to analyze swimming activity as a metric of muscle function (protocol in
Appendix B.3). Following birefringence imaging at 3, 5 and 8 dpf, swimming was analyzed.
DanioVision was not performed at 2 dpf since zebrafish exhibit extremely low activity levels. At
the conclusion of the experiment, birefringence images and DanioVision data were analyzed for
each individual zebrafish. An overview of the experimental workflow is shown in Figure 1A.
2.3 Results
2.3.1 Longitudinal Studies Indicate that Muscle Structure, Degeneration, and Regeneration in
dmd Mutant Zebrafish are Variable
All birefringence data were also normalized to the average WT birefringence in each
imaging session (Fig. 1A). Birefringence clearly visualizes healthy muscle in WT larvae (Figure
1B, white arrowhead in B3 denotes a healthy muscle segment). While the average mean gray
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value for a group of wild-type embryos is always 100% (see Figure 1E1), mean gray value of
individual wild-type embryos varies day-by-day but hovers around 100% (see Figure 1E2). At
the onset of muscle degeneration in dmd mutants, there was drastic variation in muscle
structure: ranging from 35% to 135% of the average wild-type values (in Figure 1E1, note the
large standard deviation; see Figure 14 for individual values). Mutants were categorized as
either mild or severe at the onset of muscle degeneration (2 dpf) with mild dmd mutants having
a mean gray value of ≥ 86% of wild-type birefringence and severe dmd mutants having a mean
gray value of ≤ 85.99%. Although mild and severe mutants had indistinguishable muscle
degeneration at 8 dpf (Figure 1E1), they took different paths to get there. Mild dmd mutants had
better muscle structure at 2 and 3dpf than severe mutants (compare Figure 1C2, red
arrowheads point to a couple muscle segments with degeneration versus the near complete
degeneration in severe mutants in Figure 1D1). This improved muscle structure was reflected in
significantly higher mean gray values at 2 and 3 dpf compared to severe dmd mutants, but at 5
and 6 dpf, severe dmd mutants had significantly higher mean gray values. These data indicate
that dmd mild mutants undergo extensive degeneration for the first three days after
disease onset followed by a period of slight regeneration. In contrast, muscle in severe dmd
mutants regenerated throughout the study. These data clearly indicate that there is phenotypic
variation in the zebrafish dmd mutants and that this variation can be quantified with
birefringence.
2.3.2 Longitudinal Studies Indicate that Muscle Function in dmd Mutants is Variable
The above birefringence data indicate that general muscle structure at 8 dpf was not
significantly different in mild versus severe dmd mutants. However, the path to muscle structure
at 8 dpf differed between mild and severe mutants with mild mutants undergoing
degeneration/slight regeneration and severe mutants regenerating. We thus asked whether
muscle function, as assayed by swimming activity, was different in mild versus severe mutants.
We analyzed motility with DanioVision and found that mild mutants swam a significantly greater
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distance with significantly faster velocity than severe mutants at 3 and 5 dpf (Figure 15).
Surprisingly, even though birefringence was similar between mild and severe mutants at 8 dpf,
swimming activity remained significantly higher in mild dmd mutants at this time (Figure 1F).
These results suggest that muscle structure early in development (2 dpf) correlates with function
throughout development (8 dpf). Additionally, these data suggest that improving muscle
structure may not coincide with improving function.

Figure 1: Variation in the dmd mutant phenotype determines disease progression.
(A) We created an experiment workflow to assess disease progression from 2 to 8 dpf. At 2 dpf,
birefringence is used to separate dmd mutants from WT siblings. Zebrafish are placed in
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individual wells of a 12-well plate and assigned a number, which is used to track individual
zebrafish for the duration of the experiment. Each day, from 2 dpf to 8 dpf, birefringence images
are taken. Birefringence (white) reflects normally organized muscle tissue. Loss of birefringence
(grey to black) reflects areas of degeneration and myotomes with detached muscle fibers. Mean
gray value is used to quantify birefringence and is presented as a percentage of WT sibling
controls. Following birefringence imaging at 8 dpf, swimming activity is recorded using
DanioVision. Total distance and mean velocity is calculated during the active (dark) periods. (B D) Anterior left, dorsal top, side mounted. (B) Birefringence and bright field images of a WT
sibling from 2 to 7 dpf. (C - D) At disease onset, zebrafish exhibit two levels of severity. (C)
Birefringence and bright field images for a mild dmd mutant. Mild dmd mutants have mean gray
values greater than 86% of WT siblings at 2 dpf. (D) Birefringence and bright field images for a
severe dmd mutant. Severe dmd mutants have mean gray values less than 85.99% of WT
siblings at 2 dpf. (E) Mild and severe dmd mutants exhibit variation in disease progression. (E1)
Average mean gray values for WT siblings (black circles) do not change across time, remaining
at 100%. However, mild dmd mutants (blue upward facing triangles) undergo extensive
degeneration for the first three days followed by a period of slight regeneration. Conversely,
severe dmd mutants (red downward facing triangles) regenerate throughout the study. (E2)
Individual mean gray values for zebrafish presented in B - D highlight the vast degeneration that
mild dmd mutants experience compared to the regeneration that occurs in severe dmd mutants.
(F) Swimming activity is significantly different in mild versus severe dmd mutants. Total distance
(F1) and mean velocity (F2) are significantly lower in severe dmd mutants compared to mild
dmd mutants and WT siblings at 8 dpf. Each data point represents a single time point for an
individual zebrafish. Each zebrafish has a total of 15 points. DanioVision data were analyzed
using an ordinary one-way ANOVA with Tukey’s multiple comparisons test. *** p < 0.001, **** p
< 0.0001.
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2.4 Perspective
The clinical presentation of muscular dystrophies is frequently variable: ranging from
severe, congenital muscle weakness to mild, adult-onset limb girdle muscular dystrophies.
Similarly, variability across individuals with the same disease-causing allele is common. This
variability likely keeps clinicians from accurately informing patients as to how their disease will
progress and/or respond to therapies. One roadblock to understanding the phenotypic spectrum
of muscular dystrophies is that the basic biological mechanisms of variability in musculoskeletal
development and disease are not well understood. This is especially true for DMD, which is one
of the most studied types of muscular dystrophies, but still has no cure. The development of
effective disease-modifying therapies that withstand the critical evaluation and exhaustive
testing at the pre-clinical and clinical levels proves difficult. These difficulties likely arise from
variation in disease severity, which is often not addressed in preliminary drug-screening studies
due to the failure of identifying variation in these animal models. Additionally, due to the
variation in both severity and disease progression in dmd mutants, it is possible that gene
expression profiles may be different at these different stages, which could impact response to
treatment. A preliminary study to unveil potential mechanisms for variation is addressed in
Chapter 6.
Recognizing that there are differences in muscle homeostasis between mild and severe
dmd mutants, we chose to conduct future studies identically so that variables such as treatment
duration, disease stage at time of treatment, and disease stage at time of evaluation do not
change. We also chose to examine mild and severe dmd mutants separately to identify that
observed changes are occurring simultaneously in both phenotypes. Further, the above study
demonstrates that changes in muscle structure, whether beneficial or detrimental, are not
always reflected in muscle function. That is, muscle regeneration may be evident but these
regenerating fibers may not improve muscle function, which was observed in severe dmd
mutants. Conversely, muscle degeneration may be evident but these degenerating fibers may
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not worsen muscle function, which is evident in mild dmd mutants. Therefore, it is critical that
our future studies addressed muscle health using a combinatorial approach rather than focusing
on demonstrating improvements/detriments in structure versus function.
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CHAPTER 3
IMPACT OF INACTIVITY IN DMD MUTANT ZEBRAFISH

3.1 Relevant Background
In healthy individuals, prolonged inactivity stimulates muscle atrophy and hinders
multiple components of overall health, especially muscular strength and endurance. Limitations
in muscular strength and endurance lead to further inactivity, which leads to heightened muscle
wasting and larger reductions in muscle strength and endurance. Ultimately, diminished muscle
strength and endurance lead to persistent inactivity. However, even though muscle wasting and
weakness are hallmarks of DMD, the impacts of inactivity on DMD disease progression are not
entirely known. Of the three studies looking at the immediate effects of inactivity in mdx mice,
meaning that the limb was immobilized until analyses began, two studies suggest that inactivity
may prevent muscle damage that occurs as result of the absence of dystrophin [73,75], while
the third study suggests that inactivity may increase susceptibility to this same damage [351].
No study to our knowledge examines how a prolonged period of inactivity, however this may be
defined, followed by the resumption of normal activity affects disease progression in dystrophindeficient muscle. As individuals with DMD are being advised to refrain from activities beyond
that of their daily living, it is possible that they may be entering the vicious cycle of muscle
wasting and weakness seen in inactive, healthy individuals. The goal of this chapter is to
evaluate the longitudinal effects of two inactivity paradigms on neuromuscular plasticity in dmd
mutants.
3.2 Experiment Overview
For intermittent inactivity, zebrafish were placed in a low dose of tricaine (MS-222; 306
µM in 1X ERM) overnight for 12 hours each day for three days beginning at disease onset (2, 3,
and 4 dpf) (Figure 2A1). The total time that zebrafish were inactive was 36 hours. For extended
inactivity, zebrafish were placed in the same dose of tricaine for 72 hours beginning at disease
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onset (2, 3, and 4 dpf), and were removed from tricaine at the start of 5 dpf (Figure 2B1).
Birefringence images were taken at disease onset, immediately prior to removal from tricaine at
5 dpf, and three days following removal at 8 dpf. DanioVision was used to evaluate swim
function in response to intermittent or extended inactivity, and was performed 4 hours and 3
days following removal from tricaine (5 and 8 dpf, respectively). Following DanioVision,
zebrafish were either fixed for further analyses of muscle health via immunostaining or followed
daily for survival. Throughout the experiment, zebrafish were single-housed in individual wells of
a 12-well plate with 3 mL of 1X ERM (or 3 mL of tricaine solution). A more detailed description
of these methods is found in Appendix B.2 and B.3.
3.3 Results
3.3.1 Intermittent Inactivity Negatively Impacts Swimming Activity but no Effect on Structure or
Survival
Birefringence was used as a metric to assess changes in muscle structure across time.
Inactive dmd mutants exhibit lower mean gray values beginning at 4 dpf compared to control
dmd mutants but follow similar trend of regeneration from 5 to 8 dpf (Figure 2A4). We chose to
look specifically at the change in mean gray value from 5 to 8 dpf as a measure of recovery
from inactivity. These data indicate that three intermittent periods of inactivity did not affect
muscle structure (Figure 2A6). We fixed and stained dmd mutants with phalloidin at the end of
the experiment (8 dpf) to determine whether there were any dramatic changes in muscle fiber
structure, specifically the percent of muscle segments with detachments. These analyses also
indicated that intermittent inactivity did not have major effects on muscle fiber organization (data
not shown). Interestingly, however, dmd mutants subjected to intermittent inactivity swam more
slowly and covered less distance at 8 dpf (Figure 2A8 and A9). These data indicate that early
intermittent inactivity can have negative impacts on swimming activity later in development.
However, survival was not negatively impacted (Figure 2A10).
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3.3.2 Extended Inactivity Improves Swimming but Decreases Muscle Structure and Lifespan
In contrast to intermittent inactivity, extended inactivity from 2 dpf through the morning of
5 dpf had deleterious impacts later in development. Immobilized larvae initially show improved
muscle structure at 5dpf (compare Fig. 2B3a to Fig. 2B2a, and Fig. 2B3b to Fig. 2B2b,
quantification in Fig. 2B4). However, this improvement was short lived. Specifically, there was a
significant decline in birefringence of inactive dmd mutants 3 days after removal from tricaine
(compare Figure 2B3 5 dpf to 8 dpf, quantified in Figure 2B4). These data indicate that while
muscle structure was preserved during the inactive period, it became more susceptible to
damage upon reinstatement of normal activity, which is indicated by the significant decrease in
mean gray value from 5 to 8 dpf (Figure 2B6) and poor muscle fiber organization (Fig. 2B7d, red
arrowheads denote short disorganized muscle segments, red arrow points to a degenerating
fiber). Surprisingly, even though muscle structure was improved upon removal from tricaine,
inactive dmd mutants swam a significantly lower total distance and at a significantly slower
mean velocity compared to control dmd mutants 4 hours after removal from tricaine (Figure 15).
However, after three days of recovery in ERM, swim function in inactive dmd mutants was
significantly improved, and dmd mutants that were inactive for three days swam a significantly
higher total distance and at a significantly faster mean velocity compared to dmd mutant
controls (Figure 2B8 and B9). Strikingly, this improved swim function did not correlate with
survival: although extended inactivity increased swimming at 8 dpf, survival was negatively
impacted in inactive dmd mutants (Figure 2B10). Thus, despite overall neutral effects on muscle
structure at 8 dpf and improved swimming at 8 dpf, extended inactivity decreases lifespan.
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Figure 2: Inactivity in dmd mutants differentially affects muscle structure, function, and
survival.
(A1) Experiment overview for intermittent inactivity. Zebrafish are housed in a low dose of
tricaine for 12 hours overnight (orange boxes) at 2, 3, and 4 dpf. Upon removal from tricaine at 5
dpf, zebrafish are allowed to recover in ERM (white box) for the remainder of the experiment.
(A2 - A3) Anterior left, dorsal top, side mounted. (A2) Birefringence images at 2, 5, and 8 dpf for
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mild (A2a) and severe (A2b) dmd mutant controls housed in ERM. (A3) Birefringence images at
2, 5, and 8 dpf for mild (A3a) and severe (A3b) dmd mutants housed in tricaine for 12 hours
overnight for 3 nights. (A4) Average mean gray values for WT sibling controls (black circles)
remain consistent across time. However, WT siblings that were inactive (orange circles)
experience a decrease in mean gray values at 4, 5 and 6 dpf, but recover to WT sibling control
values by 8 dpf. Conversely, dmd mutants that were inactive (orange squares) experience a
decrease in mean gray values compared to dmd mutant controls (gray squares) beginning at 4
dpf but do not recover to dmd control values at 8 dpf. (A5) Mild (blue upward facing triangles)
and severe (red downward facing triangles) dmd mutants that were inactive (dashed lines) have
lower mean gray values compared to their respective controls (solid lines) beginning at 4 dpf.
Inactive mild dmd mutants experience a more dramatic decrease in mean gray values
compared to mild control and inactive severe dmd mutants. (A6) Change in mean gray value
from 5 to 8 dpf is not different in control versus inactive dmd mutants. (A7) Anterior left, dorsal
top, side mounted. Scale bar is 50 micrometers. Phalloidin staining at 8 dpf suggests no change
in muscle fiber structure following inactivity in dmd mutants (A7d) compared to dmd mutant
controls (A7c). Total distance (A8) and mean velocity (A9) at 8 dpf are significantly lower in
inactive dmd mutants compared to dmd mutant controls. Each data point represents a single
time point for an individual zebrafish. Each zebrafish has a total of 15 points. (A10) Survival is
not affected by intermittent inactivity. (B1) Experiment overview for extended inactivity.
Zebrafish are housed in a low dose of tricaine (dark red box) for 72 hours beginning at 2 dpf.
Upon removal from tricaine at 5 dpf, zebrafish recover in ERM (white box) for the remainder of
the experiment. (B2) Birefringence images at 2, 5, and 8 dpf for mild (B2a) and severe (B2b)
dmd mutant controls housed in ERM. (B3) Birefringence images at 2, 5, and 8 dpf for mild (B3a)
and severe (B3b) dmd mutants housed in tricaine for 72 hours. (B4) Average mean gray values
for WT sibling controls (black circles) remain consistent across time at 100%. However, WT
siblings that were inactive (dark red circles) experience a dramatic decrease in mean gray value
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beginning at 4 dpf and continuing through 7 dpf, but return to control values by 8 dpf.
Conversely, dmd mutants that were inactive (dark red squares) have higher mean gray values
at 4 and 5 dpf compared to dmd mutant controls (gray squares). However, upon return to ERM,
inactive dmd mutants experience a decrease in mean gray values but regenerate to dmd mutant
control values. (B5) Mild (blue upward facing triangles) and severe (red downward facing
triangles) dmd mutants that were inactive (dashed lines) have higher mean gray values
compared to control dmd mutants (solid lines) at 4 and 5 dpf. Inactive mild dmd mutants
experience a more dramatic decrease in mean gray values compared to inactive severe dmd
mutants at 6 dpf. (B6) Change in mean gray value from 5 to 8 dpf is significantly lower in
inactive versus control dmd mutants. (B7) Anterior left, dorsal top, side mounted. Scale bar is 50
micrometers. Phalloidin staining at 8 dpf suggests that inactivity negatively affects muscle
structure in dmd mutants (B7d) compared to dmd mutant controls (B7c). Total distance (B8) and
mean velocity (B9) at 8 dpf are significantly higher in inactive dmd mutants compared to dmd
mutant controls. Each data point represents a single time point for an individual zebrafish. Each
zebrafish has a total of 15 points. (B10) Survival is negatively affected by extended inactivity.
Birefringence and DanioVision data were analyzed using two-sided t tests. Survival data were
analyzed using a Mantel-Cox test. *** p < 0.001, **** p < 0.0001.

3.3.3 Extended Inactivity Diminishes dmd Muscle Resilience to Neuromuscular Electrical
Stimulation
The above data confirm previous data that inactivity improves muscle structure in dmd
mutants while they remain inactive [377]. However, our data show that this beneficial effect
does not perdure. These results raise the question of why the seemingly improved muscle
structure is not stable and immediately affects muscle function upon reinstatement of normal
activity at 5 dpf. To answer this question we turned to NMES, which was previously adapted for
use in zebrafish larvae [391]. NMES uses trains of electrical pulses to evoke muscle
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contractions and thus allows comparison of muscle structure in multiple larvae subjected to the
same stimulus. Specifically, NMES would allow us to determine whether extended inactivity (1)
obscured latent defects in muscle resilience because the muscle was not being used and thus
did not degenerate, or (2) improved muscle fiber resilience but the resilience was not
maintained for the next few days. In order to distinguish between these possibilities, we asked
whether inactive larvae were uniquely susceptible to activity (NMES) immediately upon removal
from tricaine.
For this experiment, dmd mutants were placed in tricaine for three days. In the morning
of 5 dpf, a birefringence image was taken as a baseline measure of muscle structure (see
Figure 3A). Next, larvae were subjected to a session of NMES using one of two stimulation
paradigms. These stimulation paradigms were defined as high frequency, low voltage (NMES
Paradigm 1), which requires the muscle to contract continuously but very subtly, or low
frequency, high voltage (NMES Paradigm 2), which requires the muscle to contract more
forcefully but less frequently. Birefringence images were taken immediately following this NMES
session. A detailed description of how NMES was performed is provided in Appendix B.5.
Finally, larvae resumed normal activity in 1X ERM for three days similar to the above
experiment. At the end of this recovery period (8 dpf), birefringence images were taken and
zebrafish were fixed for further structural analyses (see Figure 3A for experiment overview).
Control dmd mutants, which were removed from tricaine and allowed to swim while
experimental larvae were receiving NMES, sometimes showed increased degeneration just
after swimming (Fig. 3B2b after) compared to immediately prior to removal from tricaine (Fig.
3B2a before). However, at a population level although there was a slight trend that inactive
larvae showed more damage, there was not a significant increase in degeneration (Fig. 3B3). In
contrast, both NMES paradigms significantly worsened mean gray values immediately after
stimulation (Fig. 3C2, D2, yellow arrows denote new areas of degeneration after NMES, Fig. C3
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and D3). Larvae that underwent three days of inactivity were unable to recover from this single
session of NMES (Figure), and exhibited more fiber detachments, especially following NMES
Paradigm 2 (Figure 3H2). More importantly, though, dmd mutants that underwent three days of
inactivity were unable to recover from this single session of NMES. Specifically, dmd mutants
exhibited a negative change in mean gray value from the birefringence measurement after
NMES to three days following NMES, indicating extensive muscle deterioration (data not
shown). Further, these larvae exhibited more fiber detachments especially following NMES
Paradigm 2 (Figure 3H2). Therefore, these data suggest that inactivity for an extended period of
time may cause dmd muscle to become more susceptible to contraction-induced injury.

Figure 3: Extended inactivity increases susceptibility to injury in dmd mutants.
(A) Experiment overview. Zebrafish are housed in a low dose of tricaine for 72 hours (dark red
box) beginning at 2 dpf. At 5 dpf, zebrafish receive a single session of NMES (either Paradigm 1
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or Paradigm 2) and are then allowed to recover in ERM (white box) for the remainder of the
experiment. (B, C, D) Anterior left, dorsal top, side mounted birefringence images. (B1)
Birefringence for the first (a) and second (b) imaging session, and at 6 (c) and 8 (d) dpf for a
dmd mutant control that did not receive NMES. (B1e) Individual mean gray values for dmd
mutant controls for the first and second imaging session. (B2) Birefringence for the first (a) and
second (b) imaging session, and at 6 (c) and 8 (d) dpf for an inactive dmd mutant that did not
receive NMES. (B2e) Individual mean gray values for inactive dmd mutants for the first and
second imaging sessions. (B3) Change in mean gray values between the first and second
imaging session are lower in the inactive dmd mutants, indicating that upon removal from
tricaine, muscle immediately begins degenerating. (C1) Birefringence before (a) and after (b)
NMES Paradigm 1, and at 6 (c) and 8 (d) dpf for a dmd mutant control. (C1e) Individual mean
gray values for dmd mutant controls before and after NMES Paradigm 1. (C2) Birefringence
before (a) and after (b) NMES Paradigm 1, and at 6 (c) and 8 (d) dpf for an inactive dmd mutant.
(C2e) Individual mean gray values for inactive dmd mutants before and after NMES Paradigm 1.
(C3) Change in mean gray values before versus after NMES Paradigm 1 are significantly lower
in inactive dmd mutants, indicating dmd muscle fibers are less resilient following extended
inactivity. (D1) Birefringence before (a) and after (b) NMES Paradigm 2, and at 6 (c) and 8 (d)
dpf for a dmd mutant control. (D1e) Individual mean gray values for dmd mutant controls before
and after stimulation. (D2) Birefringence before (a) and after (b) NMES Paradigm 2, and at 6 (c)
and 8 (d) dpf for an inactive dmd mutant. (D2e) Individual mean gray values for inactive dmd
mutants before and after NMES Paradigm 2. (D3) Change in mean gray values before versus
after NMES Paradigm 2 are significantly lower in inactive dmd mutants, further indicating that
muscle fibers are less resilient after inactivity. (E-G) Anterior left, dorsal top, side mounted
phalloidin staining. Scale bar is 50 micrometers. A single session of NMES Paradigm 1
negatively affects muscle structure in inactive dmd mutants (F) compared to inactive dmd
mutants that did not receive stimulation (E). Similarly, a single session of NMES Paradigm 2
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negatively affects muscle structure in inactive dmd mutants by increasing the number of visibly
detached fibers (G) compared to inactive dmd mutant controls. Each data point represents a
single zebrafish. Birefringence data were analyzed using two-sided t tests. * p < 0.05, ** p <
0.01.
3.4 Perspective
Step activity patterns from individuals with DMD indicate that activity levels are
extremely low and infrequent in the years leading up to wheelchair dependency. This loss in
activity is addressed as a clear consequence of muscle wasting in the absence of dystrophin.
Based on the above data, it is critical that the consequences of prolonged reductions in activity
are evaluated in human patients, especially in the realm of muscle resilience. This is especially
a major concern for those individuals who participate in physical therapy or aquatic therapy
programs on non-consecutive days throughout the week or sporadically throughout the month,
where there may be large periods of reduced activity followed by a short, more intense session
of activity.
In terms of neuromuscular plasticity in diseased muscle, these studies suggest that dmd
muscle exhibits a more delicate, intricate equilibrium with more factors at play compared to
healthy muscle. In healthy muscle we see improvements in structure correspond with
improvements in function and these functional improvements prolong survival. Similarly, the
consequences of muscle structure breakdown are decreases in function and reduced survival.
Therefore, neuromuscular plasticity is linear and the consequences of change are easily
predicted. However, based on the above data, neuromuscular plasticity in dmd muscle is not
linear. That is, muscle structure does not predict function and function does not predict survival.
There are more factors at play, and we need to identify these factors in order to better
understand disease progression and elucidate mechanistic pathways that target improvements
in structure, function, and survival. To begin to elucidate these mechanisms, it is important to
ask what are the underlying mechanisms protecting (or preserving) muscle structure in dmd
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muscle during extended inactivity but simultaneously breaking down muscle in healthy wild-type
siblings? What mechanisms occur immediately upon return to ERM and normal activity, and
how do these influence improvements in structure but reduced function? A more in-depth
discussion of these questions is provided in Chapter 6 as inactivity and activity are discussed
together.
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CHAPTER 4
NMES AS A MODEL OF NEUROMUSCULAR PLASTICITY IN DMD MUTANT ZEBRAFISH

4.1 Relevant Background
Knowing that extended inactivity negatively impacts muscle health and survival in dmd
mutants, we next asked whether there is there a better recommendation for care as researchers
continue searching for a cure. Resistance training is an excellent approach to combatting
muscle wasting and weakness in healthy individuals. Using zebrafish larvae as a model for
lifting weights is not feasible, so we asked whether we could use NMES as an alternate means
to stimulate muscle activity and combat muscle wasting and weakness in dmd mutants.
Numerous studies have demonstrated that skeletal muscle fibers are highly influenced
by the activity pattern imposed upon them, whether via the innervating neuron or electrical
stimulation [392]. Neuronal activity plays a vital role in determining both the biochemical and
physiological characteristics of individual skeletal muscles and their muscle fibers [393]. NMES
was introduced in the clinical setting to maintain and preserve neuromuscular function during
disuse or the aging process, to restore neuromuscular function after disuse, or to enhance
neuromuscular function in able-bodied individuals, especially athletes [394–409]. NMES delivers
a series of waveforms of electrical current that is characterized by frequency, amplitude, and
pulse width (or pulse duration) [410]. Frequency defines the rate at which the pulses are
delivered and determines the pattern of temporal summation [410]. Both amplitude and pulse
width describe how much voltage (or current) and for how long the pulse is being delivered and
determines the number of muscle fibers that are activated [410]. These three parameters dictate
the strength of the muscle contraction and the amount of force that is generated. Specifically, by
increasing the pulse duration or the amplitude, the amount of muscle force generated will be
greater [410]. The main advantage of NMES is its ability to activate muscle fibers, regardless of
their type, without requiring high-effort voluntary force generation [403,411].
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4.1.1 NMES in DMD
Guilluame Benjamin Amand Duchenne, the French neurologist who first described DMD,
suggested NMES as a potential therapy for dystrophic muscle [412]. Immature muscle [413] and
prolonged contraction and relaxation times [413–416] are characteristic features observed in
individuals with DMD. Therefore, it was proposed that super-imposing slow frequency electrical
stimulation on the muscles would initiate maturation of existing muscle fibers and support newly
regenerated muscle fibers [417,418], and ultimately delay disease severity and progression.
However, only a few studies have examined the impact of NMES on muscle strength and
function in both humans and the mouse model of DMD.
In 14 boys with DMD, ages 5 to 12 years old, the TA muscle was stimulated
(contralateral leg served as control) at 5 to 8 Hz continuously or intermittently (1.5 seconds on,
1.5 seconds off) for 1 hour each session with 3 sessions per day for 7 to 11 weeks [309].
Following the stimulation period, older boys exhibited no significant change in maximum
voluntary contraction, but younger boys showed a mean increase of 47%. Notably, the
stimulated muscles in the younger children were significantly stronger one month after
stimulation was stopped. However, during a 6 month follow up, significant declines in physical
characteristics and functional ability were evident. The authors conclude that DMD muscles
respond positively to electrical stimulation if it is applied early in the disease. In a follow up
study, Scott and colleagues (1990) [393] investigated the long-term effects of electrical
stimulation on the quadriceps femoris muscle. Fifteen boys with DMD, ages 2 to 13 years old,
received 3 hours of electrical stimulation 6 days per week for 7 to 11 weeks. After 10 weeks of
stimulation, stimulated muscles exhibited a small but significant increase in overall strength but
no functional improvements were observed. When stimulation was applied to the TA muscles
intermittently (6 seconds on, 6 seconds off) for 1 hour twice a day with a frequency of 8 Hz in 7
boys with DMD and 2 boys with BMD between the ages of 6 and 10 years old, 4 participants
exhibited no significant changes after 3 months and stopped the program while 5 participants
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exhibited favorable changes and continued the program for 9 months [419]. These favorable
changes included greater torque measurements of the stimulated muscles. The author
concludes that electrical stimulation cannot prevent muscle degeneration but may slow its
progression. In a follow-up study, similar results were found, including an average increase in
torque of 17.1% on the stimulated leg and a decrease of 3.4% on the non-stimulated leg.
Interestingly, the largest benefits were observed in the youngest participants [420].
Similarly, in the mdx model, NMES may exert beneficial effects on stimulated muscles.
In mdx mice, ages 3 to 5 months, electrical stimulation was applied through implanted
electrodes on either side of the lateral popliteal nerve of the hindlimb at 10 Hz for 30 minutes, 6
times per day for 9 and 28 days. Stimulation visibly improved ankle dorsiflexion and gait [421].
These improvements were accompanied by higher maximum tension development in the
stimulated TA and EDL muscles, an increase in the number of muscle fibers in the stimulated
EDL muscles, and an increase in the intensity of SDH staining in the stimulated muscles [421].
Vrbova & Ward (1981) [422] applied the same methods and found similar improvements in
tension development of the TA muscles and increased fatigue resistance in the EDL muscles.
However, the authors noticed that these functional improvements were only observed in
severely affected muscles [422], contradicting what was observed in humans. More importantly,
in a study examining the short- and long-term effects of electrical stimulation, these positive
benefits disappeared once the NMES program ended. Specifically, four weeks after the
completion of electrical stimulation, the maximum force generated by TA muscles was similar to
the initial forces generated by the muscles of the contralateral side, indicating that any force
output that was gained during the program was no longer present [423]. However, this was not
observed in the EDL muscles for these muscles displayed significantly greater force compared
to the unstimulated, contralateral side [423], suggesting that muscles may respond differently to
stimulation. Ultimately, the mechanisms by which electrical stimulation may benefit dystrophic
muscle are unknown, but authors suggest that it may slow degeneration of the existing muscle
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fibers, support the growth of regenerating fibers, and develop and maintain characteristics of the
slow fiber phenotype.
Given these beneficial effects observed in humans and mdx mice, we asked whether
NMES could benefit muscle in dmd mutants, especially in comparison to inactivity. There are
four types of strength training - endurance, hypertrophy, strength and power - and each are
designed to elicit specific responses in the muscle by altering the number of repetitions
performed and the load, or resistance, used. We designed four unique NMES paradigms
ranging from high frequency/low voltage pulse trains to lower frequency/higher voltage pulse
trains (Figure 4C and D). To easily differentiate these paradigms from each other, and because
they were conceptually based on strength training paradigms, we named these paradigms
endurance-NMES (eNMES), hypertrophy-NMES (hNMES), strength-NMES (sNMES), and
power-NMES (pNMES). The goal for this chapter is to understand how dystrophic muscle
responds to these four NMES paradigms at the structural and functional levels.
4.2 Experiment Overview
To assess the impact of each NMES program without introducing confounding variables,
we created a training program, similar to the experimental workflow used to study the impact of
inactivity on dmd muscle. Specifically, this training program was divided into two periods: the
training period and the recovery period (Figure 5A). During the training period zebrafish
completed three sessions of NMES, each session lasting one minute, on three consecutive
days (2, 3, and 4 dpf). Following these three training days, zebrafish entered the recovery
period (5, 6, 7 and 8 dpf). A complete protocol for how NMES was performed is provided in
Appendix B.5. Throughout the training program, birefringence was used to assess muscle
structure while DanioVision was used to measure swim function. Terminal outcome measures
were performed at the conclusion of the recovery period, including various immunostaining to
look at components of muscle health. The recovery period was also extended to track survival.
Therefore, only the NMES paradigms changed during these studies.
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4.3 Results
4.3.1 NMES Does Not Result in Immediate Damage to the Sarcolemma
Our first question was whether these four NMES paradigms elicit unique tail bend
patterns that vary in how many times the tail bends as well as how hard it bends. As would be
expected, eNMES with high frequency/low voltage pulse trains elicited a fast but subtle tail beat.
Conversely, with pNMES, the tail beat infrequently but bent to a much greater degree. Next, we
next asked if our NMES paradigms result in dramatic damage to the sarcolemma. As mentioned
previously, one of the major reasons why strength training is not recommended for individuals
with DMD is due to the fragility of the sarcolemma and its susceptibility to contraction-induced
damage. We did this by asking whether increased Evans Blue Dye (EBD) was observed in
muscle after one session of NMES. EBD is a membrane impermeable dye commonly used for
examining sarcolemmal damage in skeletal muscle fibers. If the sarcolemma is damaged during
NMES, it will become permeable to EBD and its accumulation can be easily quantified. At 2 dpf,
EBD was injected into the peri-cardial space at disease onset and allowed to circulate for 4
hours (protocol in Appendix B.4). Then, images of EBD in the zebrafish musculature were taken
immediately prior to and after one session of NMES (Figure 4A). Birefringence and EBD images
of the same embryos before and after NMES are shown in Figure 4. The yellow stars denote the
same position in the embryo before and after stimulation. Mean gray values were calculated to
determine the amount of EBD entry into the muscle fibers. Both wild-type and dmd mutant
control larvae are similar when imaged prior to and after the experimental larvae received
NMES (Figure 4E, F, K1, and K2). None of the NMES paradigms consistently caused a
dramatic change in either birefringence (data not shown) or EBD infiltration after one session
(Figure 4G-K). These results indicate that the four NMES paradigms do not cause immediate
dramatic damage to the sarcolemma.
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Figure 4: Four NMES paradigms do not result in immediate damage to the sarcolemma.
(A) Experiment overview. At 2 dpf, WT siblings and dmd mutants were injected with EBD. Four
hours later, zebrafish were imaged for birefringence and EBD before and after a single session
of NMES. (B) For NMES, zebrafish are placed in a 3D printed gym with their heads towards the
positive electrode and tails towards the negative electrode. (C - D) NMES delivers a series of
square wave pulses that vary in frequency and voltage. We named these paradigms after
weightlifting regimes. (E-J) Anterior left, dorsal top, side mounted birefringence and EBD
fluorescent images. Yellow asterisks denote the same position in embryos before and after
NMES. (E) WT sibling control exhibits healthy muscle segments (E1, E2) and no dye entry in
the muscle (E1’, E2’) during the first and second imaging session. (F) dmd mutant control has
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significant areas of degenerated muscle (F1) and dye entry (F1’) but no new areas of
degeneration or dye entry during the second imaging session (F2, F2’). (G-J) Similar to the dmd
mutant control, dmd mutants that receive NMES have significant areas of degenerated muscle
and dye entry prior to NMES but no new areas of degeneration or dye entry during following
NMES. (K) Quantification of EBD during the first and second imaging session.

4.3.2 Different NMES Differentially Impacts dmd Muscle Structure, Function, and Survival
During our initial assessment of each NMES paradigm, we took birefringence images of
each zebrafish prior to the first NMES session at 2 dpf, 24 hours after the third NMES session at
5 dpf, and four days after this third session at 8 dpf, and calculated mean gray value to assess
the extent of degeneration/regeneration. As was done for inactivity, we focused on the change
in mean gray value from 5 to 8 dpf because that change represents how the muscle responds to
and recovers from 3 sessions of NMES. Wild-type larvae with all 4 NMES paradigms were
unaffected (Figure 5B1, C1, D1, E1 and data not shown). Control dmd larvae for each NMES
paradigm were similar to larvae shown in Figure 1, with mild larvae degenerating between 2 and
5 dpf (Fig. 5B2,C2,D2,E2, red arrowheads denote degeneration from the previous time point,
green arrowheads denote regeneration from the previous time point) and severe larvae
regenerating between 2 and 5 dpf (Fig. 5 B3,C3,D3,E3). Between 5 and 8 dpf, as shown in
Figure 1, birefringence levels for both mild and severe larvae trend towards slight improvement
(Fig. 5B6, C6, D6, E6). The eNMES and pNMES paradigms improved muscle structure in dmd
mutants. pNMES resulted in a slight but significant increase in birefringence compared to
controls (Fig. 5B6, note also green arrows in Fig. 5B4 and 5B5). eNMES also increased
regeneration between 5 and 8 dpf (Fig. 5E6, note green arrows in Fig. 5E4, E5). In contrast,
dmd mutants that underwent sNMES exhibited significantly lower changes in mean gray values
compared to control dmd mutants (Figure 5C6) while hNMES trended towards lowering
birefringence (Figure 5D6). These data indicate that, at least at a gross level, different NMES
85

paradigms do have different effects on muscle structure in zebrafish larvae. To further look at
the extent of deterioration in our NMES groups, we calculated the percentage of fish that deproved, meaning the fish exhibited a negative change in birefringence from 5 to 8 dpf (Figure
16). These data further indicate that the percent of dmd mutants in the endurance and power
NMES groups deteriorating between 5 and 8 dpf is much lower than that of control dmd
mutants. Conversely, sNMES and inactivity have higher percentages of dmd mutants that deprove and undergo muscle deterioration during this 5 to 8 dpf period.

Figure 5: Birefringence is used as an initial measure of muscle structure following NMES.
(A) Experiment overview and calculation of change in mean gray value from 5 to 8 dpf. At 2 dpf,
birefringence images are taken followed by the first session of NMES. At 3 and 4 dpf, zebrafish
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undergo the second and third sessions of NMES, respectively. Birefringence images are taken
at 5 and 8 dpf. The training program is divided into the training period (2 to 4 dpf) and the
recovery period (5 to 8 dpf). (B - E) Anterior left, dorsal top, side mounted birefringence images
for WT sibling controls (B1 - E1), mild (B2 - E2) and severe (B3 - E3) dmd mutant controls, and
mild and severe dmd mutants that received pNMES (B4 and B5), sNMES (C4 and C5), hNMES
(D4 and D5), or eNMES (E4 and E5). (B6, C6, D6, and E6) Change in mean gray values from 5
dpf to 8 dpf represent how the muscle responds to and recovers from 3 sessions of NMES.
Positive changes indicate improvements in muscle structure while negative changes indicate
deterioration in muscle structure. Red arrowheads denote degeneration from the previous point,
green arrowheads denote regeneration from the previous time point. Power (B6, maroon
squares) and endurance (E6, blue squares) NMES significantly improve muscle structure in
dmd mutants compared to dmd mutant controls (gray circles). Strength (C6, purple squares)
NMES significantly worsens muscle structure in dmd mutants while hypertrophy NMES (D6,
green squares) trends to decrease muscle structure compared to dmd mutant controls. Each
data point represents a single zebrafish. Birefringence data were analyzed using two-sided t
tests. * < 0.05, ** p < 0.01.

To gain a better understanding of the impacts of NMES on muscle structure, we stained
zebrafish for phalloidin, which binds to f actin, allowing individual muscle fibers to be visualized.
Muscle fibers in WT zebrafish are highly organized and linear (Figure 6A). In contrast, many
fibers in dmd mutants are disorganized while others are compressed and/or detached from their
extracellular matrix (Figure 6B). We quantified the percentage of muscle segments with fiber
detachments and found that, similar to the results observed with birefringence, eNMES and
pNMES resulted in fewer fiber detachments compared to control dmd mutants (Figure 6C2 and
F2). Taken together, the above data indicate that eNMES and pNMES improve muscle structure
in dmd larvae.
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Figure 6: Phalloidin staining provides more details on how dmd muscle responds to
NMES at the structural level.
Phalloidin staining for F-actin at 8 dpf allows for visualization of individual muscle fibers and the
ability to count detached fibers in dmd mutants. Anterior left, dorsal top, side mounted. Scale
bar is 50 micrometers. (A) Representative image of WT sibling demonstrates organized muscle
fibers with well-defined myotome boundaries. (B) Representative image of dmd mutants
demonstrates disorganized, wavy muscle fibers with poorly defined myotome boundaries and
empty space between individual muscle fibers. (C1) Representative image of dmd mutant that
received pNMES demonstrates less muscle fiber waviness, lack of empty space between
muscle fibers but visible detached fibers. (D1) Representative image of dmd mutant that
received sNMES demonstrates massive deterioration of muscle fiber structure, disorganized
myotomes with poorly defined boundaries. (E1) Representative image of dmd mutant that
received hNMES demonstrates improved muscle fiber organization with more defined myotome
boundaries but visibly detached muscle fibers and empty space between fibers. (F1)
Representative image of dmd mutant that received eNMES demonstrates healthy myotomes
with clearly defined boundaries, organized muscle fibers with very few wavy fibers, and lack of
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empty space between fibers. Quantification of the percentage of muscle segments with
detachments indicates that pNMES (C2) and eNMES (F2) significantly reduce fiber
detachments in dmd mutants. Strength NMES (D2) and hNMES (E2) do not impact the percent
of muscle segments with detachments. Each data point represents a single fish. A muscle
segment is defined as half of a myotome. Muscle detachment data were analyzed using twosided t tests.* p < 0.05, ** p < 0.01.

We hypothesized that improved muscle structure would correlate with improved function.
We tested this hypothesis by assessing swim activity as a gross readout of muscle function.
Swim activity was tested using DanioVision at 8 dpf. As predicted, eNMES resulted in increased
distance and mean velocity compared to control dmd larvae (Figure 7A4 and B4). Surprisingly,
though, pNMES negatively affected swimming activity (Figure 7A1 and B1). Similarly, sNMES
significantly reduced total distance and mean velocity (Figure 7A2 and B2) while hNMES did not
affect these two measures (Figure 7A3 and B3).
Because improvements in muscle structure in response to different NMES paradigms
did not strictly correlate to changes in swimming, we asked whether neuromuscular junction
(NMJ) morphology changed with NMES. We analyzed NMJ morphology by using the SV2
antibody to label presynaptic structures and alpha-bungarotoxin to stain postsynaptic AChR. We
focused on analyzing fast-twitch muscle fiber innervation, which is called distributed innervation
(the rich network of NMJs in between the chevron shaped slow-twitch muscle innervation at the
myotendinous junctions (MTJs), Figure 7C1).
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Figure 7: NMJ abundance does not correlate with swim function.
DanioVision was used to assess the impact of NMES on total distance (A) and (B) mean
velocity. Measurements were made at 8 dpf. (A1, B1) dmd mutants that completed pNMES
exhibited significant reductions in total distance and mean velocity compared to dmd mutants in
the control group. (A2, B2) Strength NMES also negatively affected swimming activity in dmd
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mutants compared to control dmd mutants. (A3, B3) No change in total distance or mean
velocity is observed following hNMES. (A4, B4) dmd mutants that completed eNMES swam a
significantly greater total distance and at a significantly faster mean velocity compared to dmd
mutants in the control group. Each data point represents a single time point for an individual
zebrafish. Each zebrafish has a total of 15 points. (C) anti-SV2 (cyan) and a-Bungarotoxin
(AChR; magenta) antibodies are used to visualize the pre- and post-synaptic components of the
NMJ. (C1) Representative image of WT sibling has muscle segments that are vastly innervated
by both SV2 and AChR. (C2) Representative image of dmd mutant demonstrates a visible
reduction in innervation, with relatively large portions of the muscle segments lacking
innervation, especially by SV2. (C3, C4, C5, and C6) Representative images of dmd mutants
that completed three sessions of pNMES, sNMES, hNMES, or eNMES demonstrate visible
increases in innervation by both SV2 and AChR. The number of NMJs (skeleton number) within
the muscle segments is significantly increased in dmd mutants compared to both WT siblings
and dmd mutant controls following sNMES (C4’), hNMES (C5’’), and eNMES (C6’). Skeleton
length is also increased in dmd mutants that completed three sessions of hNMES (C5’’) and
eNMES (C6’’) compared to both WT siblings and dmd mutant controls. (C3’, C3’’) Power NMES
did not change the number or length of skeletons compared to dmd mutant controls.
DanioVision data were analyzed using two-sided t tests. NMJ data were analyzed using either
an ordinary one-way ANOVA with Tukey’s multiple comparisons test or a Kruskal-Wallis test
with Dunn’s multiple-comparison test.** p < 0.01, *** p < 0.001, **** p < 0.0001.

Lastly, survival was tracked in dmd mutants treated with NMES. Survival checks were
performed twice daily. Three sessions of eNMES, sNMES, and pNMES slightly but significantly
extended the median age of survival for dmd mutants compared to unstimulated dmd mutants
(Figure 8A, B, D); with eNMES having the largest beneficial effect. Three sessions of hNMES,
however, did not affect median survival age (Figure 8C). Taken together, these data indicate
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that different NMES paradigms elicit different neuromuscular responses. Furthermore, out of the
four NMES paradigms we tested, only eNMES improves neuromuscular structure, swimming,
and lifespan. Ultimately, these data further support the need to examine multiple components of
muscle health in order to understand how an intervention affects disease severity and
progression. More importantly, though, these data suggest that there are additional mechanisms
underlying neuromuscular plasticity in dmd mutants that are not captured by changes in muscle
structure and function.

Figure 8: Changes in muscle health and swim activity do not predict survival.
Survival was tracked following completion of the three NMES sessions. Survival was
significantly improved in dmd mutants that completed power (C1), strength (C2), and endurance
(C4) NMES. (C3) Hypertrophy NMES had no effect on survival in dmd mutants. DanioVision
data were analyzed using two-sided t tests. Survival data were analyzed using a Mantel-Cox
test. * p < 0.05, *** p < 0.001, **** p < 0.0001.

4.4 Perspective
Currently, individuals with DMD are advised to refrain from resistance training since the
loss of dystrophin causes the DGC to become unstable and the integrity of the sarcolemma to
be weakened. This long-standing consensus stems from the hypothesis that muscle fiber
degeneration would be initiated sooner and greatly accelerated since the magnitude of tensile
forces experienced by the sarcolemma would be increased. From the data presented in the
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Chapter 2, dmd mutants exposed to extended periods of inactivity experience negative
consequences on disease progression, especially regarding muscle structure and survival.
Therefore, this limited understanding of how resistance training affects the structural integrity of
dystrophic muscle may actually be accelerating disease progression. Using NMES as a
mechanism to emulate the four types of resistance training, we found that these four NMES
paradigms do not result in immediate damage the sarcolemma nor negatively affect survival,
suggesting that NMES may be a better recommendation for care. However, these four NMES
paradigms differentially affect muscle structure and function, supporting our idea that
neuromuscular plasticity is a delicate balance between numerous components that may not be
reflected in muscle fiber structure.
Our understanding of neuromuscular plasticity in healthy muscle encompasses this idea
that improvements in structure are likely to lead to improvements in muscle function. Thus, if
muscle structure becomes compromised, it will likely lead to compromised muscle function.
However, in dmd mutants, the above data suggest that neuromuscular plasticity may not share
this same relationship. Previous studies often expect improvements in structural components to
translate into improvements in functional components but, based on our initial investigations
with inactivity and NMES, this is not the case. Collectively, our experiments suggest that dmd
muscle exhibits a delicate, intricate equilibrium with several factors influencing muscle structure,
swimming activity and survival. Therefore, we next asked what are these additional factors?
What additional components of muscle and organism health are at play in defining
improvements in function and survival? To begin to answer these questions, we examined the
effects of eNMES in more detail since this paradigm positively improved all three outcome
measures.
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CHAPTER 5
MECHANISMS MEDIATING IMPROVEMENT FOLLOWING ENDURANCE NMES IN DMD
MUTANT ZEBRAFISH

5.1 Relevant Background
While previous studies have found positive benefits of NMES on dystrophic muscle in
humans and in mdx mice, the cellular and molecular mechanisms underlying these
improvements are poorly understood. In muscle atrophy studies, NMES is capable of preventing
decreases in muscle mass and muscle fiber cross-sectional area, and it is suggested that these
improvements are due to the absence of the typical slow to fast heavy chain isoform
transitioning observed with muscle atrophy as well as the decrease in expression of atrophyrelated genes [424]. In aging studies, NMES significantly improved functional tests and
increased the diameter of fast muscle fibers, which may be driven by an upregulation in markers
for satellite cell activation (myogenin, miR-206 and miR-1), muscle growth (IGF-1), and cell
adhesion (collagen I, III, and VI), but, more importantly, the down-regulation of markers for
atrophy-related ubiquitin ligases (MuRF-1) [425]. Lastly, in active versus sedentary males, 8
weeks of NMES training (3 sessions per week) significantly increased maximum voluntary
contraction force, neural activation, and muscle fiber cross-sectional area for both slow and fast
muscle fibers, which was likely achieved through enhanced gene and protein expression
patterns indicative of both resistance and endurance training, including oxidative and glycolytic
metabolism, antioxidant defense systems, and myofibrillar proteins [403,426]. Further, NMES
demonstrated profound effects on elements of the contractile apparatus, excitation-contraction
coupling machinery, ion homeostasis, metabolism, and the NMJ [427,428]. The goal for this
chapter is to dive deeper into understanding the mechanisms that underly the improvements in
muscle structure, function and survival following eNMES.
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5.2 Experiment Overview
We used a multi-discipline approach to understand the basic biology of neuromuscular
plasticity observed in dmd mutants following eNMES. We leveraged the unparalleled imaging
capabilities of the zebrafish larval model to shed light on the structural mechanisms that may
lead to the increased birefringence and decreased muscle detachments following eNMES. In
most zebrafish studies, muscle detachments are counted as a method to quantify changes in
muscle health. When we quantified the percentage of muscle segments with detachments, we
observed that eNMES significantly reduced this percentage in dmd mutants (Figure 6F2). While
these data suggest that muscle fiber health is improved, we elected to capture a more detailed
assessment of muscle fiber organization after noticing that while some muscle segments did not
have visibly detached fibers, these segments contained disorganized muscle fibers with a
characteristic ‘waviness’. Therefore, we elected to use machine learning and trained the
computer to identify, pixel-by-pixel, ‘healthy’ versus ‘sick’ with 97% accuracy. Next, we asked
the computer to identify the percentage of healthy muscle in the same phalloidin images in
which fiber detachments were counted on. A detailed description of the methodology used for
machine learning is provided in Appendix B.9.
We used second harmonic generation (SHG) imaging as a label-free mechanism to
visualize sarcomeres at 8 dpf. SHG is a nonlinear optical microscopy technique that captures
highly polarizable matter in a non-centrosymmetric molecular organization (Plotnikov et al.
2005). One such structure is the rod domain of myosin that constructs the sarcomere. A detailed
description on how zebrafish were prepared for SHG imaging is provided in Appendix B.8.
We also utilized two types of time-lapse analyses, the taco time-lapse and the
longitudinal time-lapse, to follow the extent of degeneration/regeneration occurring in each dmd
mutant as well as the health of their muscle nuclei during the training and recovery periods. For
these experiments we used transgenic 3MuscleGlow dmd mutants (sapjeta222a; myog:H2BmRFP; mylpfa:lyn-Cyan; smyhc1:EGFP) to visualize fast and slow muscle fibers and muscle
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nuclei (Hromowyk et al. 2020). For this zebrafish line, disease onset is at 3 dpf rather than 2 dpf
even though both lines harbor the same point-mutation. Therefore, NMES was performed at 3, 4
and 5 dpf, and the recovery period ensued from 6 to 9 dpf. A detailed description on how
zebrafish were prepared for live imaging is provided in Appendix B.7 and how muscle nuclei
were quantified is provided in Appendix B.9. For the taco time-lapse experiments, imaging
began at the same time each day and each zebrafish was imaged at least three times. During
the training period, imaging began immediately following the NMES session. Once all zebrafish
were imaged, the second round of imaging began followed by the third and/or fourth round.
Zebrafish were imaged each day from 3 to 7 dpf. For the longitudinal time-lapse experiments,
imaging began immediately after the NMES session and zebrafish were imaged continuously for
12 hours.
Alongside these imaging experiments, we performed RNAseq to uncover potential
molecular mechanisms that may be eliciting the improvements observed in dmd muscle
following eNMES. At 7 dpf, RNA was extracted from two zebrafish per tube. In each tube,
zebrafish were paired according to their initial mean gray value (severe versus mild) as well as
their change in mean gray value from 5 to 7 dpf. The protocol for RNA extraction and data
analysis are presented in Appendix B.11.
5.3 Results
5.3.1 eNMES Improves Muscle Structure and Sarcomere Length
As demonstrated previously, eNMES significantly reduced the percentage of muscle
segments with muscle fiber detachments, suggesting that muscle fiber health is improved.
However, after noticing that while some muscle segments did not have visibly detached fibers,
these segments contained disorganized muscle fibers with a characteristic ‘waviness’, we
elected to use machine learning to better capture muscle health. We observed that dmd
mutants completing three sessions of eNMES trend towards having higher percentages of
health muscle compared to control dmd mutants (Figure 9A4). The contribution of these
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disorganized, wavy muscle fibers to overall muscle structure and function in dmd mutants is
currently unknown.
Using SHG microscopy, we analyzed muscle fibers at the level of the sarcomeres. The
length of a sarcomere is extremely important to muscle function [429]. As described previously,
a sarcomere produces force through the cross-bridges formed between actin and myosin, and
the amount of force generated is dependent upon the amount of overlap between these thick
and thin filaments. More specifically, force production can be predicted using the force-length
relationship, which states that there is an optimal sarcomere length required for maximal force
and power production [430]. At 8 dpf, wild-type siblings exhibited a mean sarcomere length of
1.853 ± 0.1071 micrometers (Figure 9B4), matching lengths previously published in 3 dpf wildtype zebrafish (1.86 ± 0.15 micrometers; [431]). Compared to wild-type siblings, dmd mutants
have significantly shorter sarcomeres with a mean length of 1.575 ± 0.1567 micrometers (Figure
9B4). While no study has directly measured sarcomere lengths using SHG imaging in dmd
mutants, other studies have reported shorter sarcomere lengths in mutants versus wild-type
siblings [386]. Notably, three sessions of eNMES significantly increased mean sarcomere
lengths (1.707 ± 0.1710) compared to dmd mutant controls, and these values are nearing wildtype lengths, but still significantly shorter (Figure 9B4). These data suggest that eNMES may
improve muscle structure and function by restoring sarcomere lengths to more optimal lengths,
which may allow stronger cross-bridges to form and more success in generating force and
power.
5.3.2 Muscle Nuclei Return to a More Ellipsoidal Shape With eNMES
The above improvements in sarcomere lengths prompted us to next ask whether muscle
nuclei are also changing in response to eNMES. The role of myonuclear size and shape on
muscle health is becoming more prevalent especially since changes in these parameters as well
as their positioning are becoming more evident in skeletal muscle diseases [13,432,433]. We
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measured three components of nuclear size and shape: volume, surface area, and filament
index. Filament index is a measure that quantifies the departure of an object from a circle.
Specifically, a circle has a filament index of 1 and a higher filament index indicates a departure
to a more ellipsoidal shape. Therefore, in terms of muscle nuclei, a higher filament index
suggests that the nuclei are more elongated, which is suggested to be healthier [434]. Muscle
nuclei in dmd mutants have significantly lower volumes, surface areas, and filament indices
compared to wild-type siblings (Figure 9C4-C6). Interestingly, eNMES significantly increased
these measures, especially for filament index, which is restored to wild-type values (Figure
9C6). Additionally, these nuclei appear more organized along the length of individual muscle
fibers, similar to the pattern observed in wild-type siblings (Figure 9C3). These data suggest that
dmd mutants have smaller, spheroidal nuclei compared to wild-type siblings, and eNMES is
capable of elongating the nuclei, and increasing their volumes and surface areas. Since nuclear
size affects DNA organization, transcriptional and translational processes, and nuclear import
and export activities [435], minor changes in size correlate with reduced muscle function and
fiber performance [436]. Therefore, these improvements in muscle nuclei following eNMES may
direct improvements in the muscle structure and function that we observed.
5.3.3 Time-Lapse Analyses Suggest Less Muscle Degeneration and Improved Regeneration
Capabilities With eNMES
From the changes in sarcomere lengths and muscle nuclei at 8 dpf, we next asked what
is happening daily in the muscle structure that lead up to these improvements. We performed
confocal time-lapse analyses using transgenic zebrafish to track individual fast-twitch muscle
fibers immediately following each session of eNMES as well as the days following completion of
eNMES training. Again, disease onset in these transgenic zebrafish is at 3 dpf; thus, NMES
sessions are at 3, 4 and 5 dpf while the recovery period extends from 6 through 9 dpf. At 3 dpf,
there was not a clear difference in muscle degeneration between treated and control mutants.
However, by 4 dpf, control mutants exhibited initial signs of muscle degeneration (Figure 9D1c
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and D1d). eNMES mutants showed less degeneration, suggesting that eNMES delays
degeneration (Figure 9D2c and D2d). Whereas degenerated fibers persist in control mutants for
days (Figure 9D1f - g), degenerated segments are cleared more quickly in eNMES-treated
mutants (Figure 9D2f - g). Finally, more robust regeneration was observed in eNMES-treated
mutants (Figure 9D2h). Taken together, these data suggest that eNMES improves muscle
homeostasis. To elucidate potential molecular mechanisms that may underly these
improvements in muscle health and function, as well as determine whether eNMES is
enhancing regeneration, we performed RNAseq at 7 dpf.

Figure 9: eNMES improves multiple components of muscle health in dmd mutants.
(A) Machine learning was used to quantify muscle health pixel-by-pixel. Green indicates healthy
pixels while red indicates unhealthy pixels. (A4) The percent of healthy muscle following eNMES
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trends to be higher in dmd mutants compared to dmd mutant controls. Scale bar is 50
micrometers. (B) Second harmonic generation microscopy was used to quantify sarcomere
length at 8 dpf. Representative SHG images of WT sibling control (B1), dmd mutant controls
(B2), and dmd mutants that completed eNMES training. Anterior left, dorsal top, side mounted.
Scale bars are 10 micrometers. (B4) Sarcomere length is significantly shorter in dmd mutant
controls compared to WT sibling controls. However, eNMES significantly improves sarcomere
length, bringing it closer to WT lengths. Each point represents a single sarcomere along a
predetermined length of a muscle fiber. Multiple muscle fibers were measured per zebrafish. (C)
Muscle nuclei were imaged at 8 dpf as a potential mechanism for improved muscle health.
Anterior left, dorsal top, side mounted. Scale bar is 50 micrometers. (C1) Representative image
of WT sibling control demonstrates healthy ellipsoidal nuclei organized along the length of the
muscle fibers. (C2) Representative image of dmd mutant control demonstrates fragmented
punctae as well as more spherical nuclei that clustering within the muscle segments. (C3)
Representative image of dmd mutant that completed eNMES training demonstrates healthier,
ellipsoidal nuclei that appear more organized within the muscle segments. Quantification of
nuclear size indicates that eNMES significantly increases the volume (C4) and surface area
(C5) of muscle nuclei compared to dmd mutant controls. However, nuclei are still significantly
smaller compared to WT sibling controls. visually appear to have an increased number of
myonuclei compared to unstimulated dmd mutants. (C6) Filament index was used to assess
circularity, specifically the departure from a circle. Filament index is significantly higher in dmd
mutants that completed eNMES training, indicating that nuclei are more elongated compared to
dmd mutant controls. Each point represents a single nuclei within a z-stack. (D) Transgenic dmd
mutants (mylpfa:lyn-cyan, smych1:GFP) were used to visualize changes in structural integrity of
fast- and slow-twitch muscle fibers across three days. Anterior left, dorsal top, side mounted.
Scale bar is 50 micrometers. Images were taken around the 12th myotome. (D1)
Representative dmd mutant control. (D1a – D1b) At 3 dpf, there is no dystrophy in the imaged
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myotomes. (D1c – D1e) At 4 dpf and the beginning of 5 dpf, dystrophy is minimal with relatively
few detaching muscle fibers. (D1f) However, massive muscle degeneration occurs between the
first found of imaging and the third round of imaging at 5 dpf. (D1g – D1h) Fiber degeneration is
present, suggesting that the damaged muscle fibers have not been cleared and regeneration is
unlikely. (D2) Representative dmd mutant that is undergoing eNMES training. (D2a – D2b) The
first session of eNMES at 3 dpf does not result in immediate damage to the muscle. (D2c –
D2d) Similarly, following the second session of eNMES at 4 dpf, there is no immediate muscle
damage occurring in the imaged myotomes. (D2e) At 5 dpf, following the third session of
eNMES, muscle fiber degeneration is evident but by the third round of imaging (D2f), these
damaged areas are being cleared and there is evidence of regeneration. (D2g – D2h) At 6 dpf,
previously damaged muscle segments have new muscle fibers present. All data were analyzed
using either an ordinary one-way ANOVA with Tukey’s multiple comparisons test or a KruskalWallis test with Dunn’s multiple-comparison test.* p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001.

5.3.4 eNMES Elicits a Molecular Response in Wild-Type Siblings Indicative of Exercise
In our RNAseq analysis, we first asked whether eNMES initiates a molecular response
that emulates exercise in wild-type siblings. PCA analysis revealed that wild-type siblings that
underwent three sessions of eNMES cluster completely separate from those in the control group
(Figure 17), suggesting that wild-type siblings that complete three sessions of eNMES have an
unique expression profile compared to controls. Of the total 25,863 genes identified across the
RNAseq analysis, 932 genes were differentially expressed between wild-type siblings in the
eNMES and control groups (Figure 10A1). Of these 932 genes, 306 genes were upregulated
and 626 genes were downregulated (Figure 10A3). Using Gene Ontology (GO) enrichment
analysis, 24 enriched categories were identified, including regulation of metabolic processes,
regulation of MAP kinase activity, regulation of transcription, and circadian rhythms. Future
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studies will compare these differentially expressed genes to those identified in human NMES
studies to better understand these eNMES-induced molecular patterns.
5.3.5 DMD Zebrafish Do Not Respond to eNMES in the Same Manner as Wild-Type Siblings
Interestingly, the differentially expressed genes suggest that eNMES may be eliciting
changes in WT versus dmd mutants through different mechanisms. Based on the number of
genes differentially expressed, dmd mutants do not respond to eNMES in the same manner as
wild-type siblings (Figure 10A2). Specifically, 123 genes were differentially expressed (FDR <
0.1 and abs(log2(Fold Change)) > 0.6) between dmd mutants that completed three eNMES
sessions versus dmd mutant controls (Figure 10A4). This is much lower than the 932
differentially expressed genes in wild-type siblings. Additionally, dmd mutants have more genes
that are increased (n = 84) than decreased (n = 39), which is the opposite of wild-type siblings,
further suggesting that dmd mutants do not respond through the same signaling pathways as
their healthy counterparts. Unfortunately, GO analyses did not reveal specific cellular processes
in which these genes may participate in to positively impact muscle health. Therefore, we chose
to examine genes individually, looking specifically at how their increase or decrease could
influence dmd muscle.
Only 4 genes of the 1,048 differentially expressed genes elicited by eNMES in both dmd
mutants and wild-type siblings shared the same expression pattern (Figure 10B). Three genes,
including heme oxygenase 1a (hmox1a), calcium release activated channel regulator 2Ab
(cracr2ab), and retinaldehyde binding protein 1b (rlbp1b) were increased and 1 gene,
melanotransferrin (meltf), was decreased with eNMES. This lack of overlap between
differentially expressed genes further indicates that dmd mutants do not respond similarly to
eNMES as wild-type siblings.
Interestingly, we found 3 genes that exhibited opposite expression between genotypes
(dmd mutants vs wild-type) and eNMES (dmd mutants vs wild-type siblings after eNMES)
(Figure 10C). That is, a gene may be decreased in dmd mutants compared to wild-type siblings,
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but eNMES increased its expression in dmd mutants while decreasing its expression in wildtype siblings. These genes included interferon induced transmembrane protein 1 (ifitm1),
gamma-glutamyltransferase 1a (ggt1a), and Cabz01046949.1. Additionally, 3 genes were
decreased in dmd mutants compared to wild-type siblings but eNMES decreased its expression
in dmd mutants and had no effect in wild-type siblings. These genes included serpin peptidase
inhibitor, clade B (ovalbumin), member 1, like 4 (serpinb1l4), kazal-type serine peptidase
inhibitor domain 3 (kazald3), and cystathionase (cystathionine gamma-lyase), like (cthl). Lastly,
1 gene, si:ch1073-13h15.3, was increased in dmd mutants compared to wild-type siblings and
was decreased in both wild-type siblings and dmd mutants following eNMES (Figure 10C7.
Altogether, these data suggest the possibility that eNMES may partially improve dmd muscle
structure and function by returning dmd mutants to more wild-type-like expression profiles.
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Figure 10: dmd mutants do not respond to eNMES in the same manner as WT siblings.
RNAseq analysis was performed at 7 dpf in wild-type siblings and dmd mutants that completed
eNMES training and their expression patterns were compared with their respective controls.
(A1) Volcano plot showing significantly and biologically increased (blue dots) and decreased
(red dots) genes in WT siblings that completed eNMES versus those that did not. (A2) Volcano
plot showing significantly and biologically increased (blue dots) and decreased (red dots) genes
in dmd mutants that completed eNMES versus those that did not. (A3 – A4) Summary of
differentially expressed genes in WT siblings (A3) and dmd mutants (A4). WT siblings had 932
differentially expressed genes compared to 123 differentially expressed genes in dmd mutants,
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suggesting that dmd muscle responds differently to eNMES and the genes responsible for
eliciting beneficial effects on muscle structure and function are different. (B) Differentially
expressed genes in WT siblings versus dmd mutants following eNMES that increased in
expression (B1), decreased in expression (B2). Values are presented as Fold Change (FDR).
The relatively few genes that were significantly differentially expressed in both data sets further
suggests that dmd mutants respond differently to eNMES than WT siblings. (C) Selected
differentially expressed genes in dmd mutants following eNMES to show how expression levels
return to those of wild-type controls.
5.3.6 eNMES May Alter the ECM in dmd Mutants
The ECM surrounding muscle fibers is a critical component of muscle fiber health.
Protein complexes spanning the sarcolemma and ECM serve as mechanical linkages and allow
the muscle fiber to attach to the skeleton via the MTJ and to each other via the costamere [42].
Additionally, ECM proteins play a prominent role in muscle regeneration by promoting satellite
cell division, differentiation and fusion into mature muscle fibers [437]. More importantly, though,
many ECM proteins play dual roles in improving cell adhesion and promoting fibrosis. Since
changes to the ECM, especially its mechanical stiffness, are well documented during disease
and following exercise, we next asked whether ECM proteins are differentially expressed in our
dmd mutants following eNMES and what consequences these expression patterns may have on
muscle health. It should be noted that our RNAseq data represent a snapshot in time, and since
the ECM is a highly dynamic tissue, mRNA expression is not the best way to capture physical
changes to the ECM. Further, since zebrafish larvae are a developmental model, it is possible
that we are capturing developmental changes rather than responses to eNMES. However, for
the genes being discussed below, we see similar changes in wild-type siblings and dmd
mutants, suggesting that expression changes may be more in response to eNMES than
development.
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Transforming growth factor beta induced (TGFBI) is an extracellular matrix protein that
accumulates at the MTJ in high levels as well as in the ECM where it is associated with microfibrillar structures, and responsible for collagen deposition. In our RNAseq data, transforming
growth factor beta induced (tgfbi) is significantly higher in dmd mutants compared to wild-type
controls. However, eNMES reduces the levels of tgfbi in both dmd mutants and wild-type
siblings (Figure 11A1). In studies looking at molecular signatures characterizing DMD muscle,
tgfbi is highly upregulated compared to healthy muscle [438,439]. This is also true when
comparing tgfbi expression in mdx muscle versus muscle from fiona mice (mdx mice
overexpressing utrophin) [440]. TGFBI binds to type I, II and IV collagens as well as several
integrins. In vitro, TGFBI mediates integrin a7-dependent adhesion of myoblasts and myotubes
[441]. In zebrafish, morpholino-mediated knockdown of tgfbi resulted in normal MTJ formation
and myofibril assembly in the sarcolemmal space but these myofibrils did not remain attached to
the sarcolemma, leading to a significant reduction in myofibril content [442]. Therefore, TGFBI
plays an intricate role in balancing fibrosis and cell adhesion. In our dmd mutants, the
downregulation of tgfbi following eNMES may reflect a decrease in excessive ECM deposition
and fibrosis rather than a loss in cell adhesion.
Periostin (postnb) is a TGFBI-related protein that is highly involved in modeling the ECM
and connective tissue architecture during development and regeneration, serving specifically as
a mediator of fibrosis in injury and disease [443]. Notably, RNAseq data indicate that postnb
shares a similar expression pattern to tgfbi with increased expression in dmd mutants compared
to wild-type siblings and a reduction in this expression following eNMES in both groups (Figure
11A2). Morpholino-mediated knockdown in zebrafish results in disrupted myoseptum formation
and muscle fiber attachment [444]. Periostin directly interacts with other ECM proteins, including
fibronectin, tenascin-C, collagen I and V, and heparin, to alter the ECM by changing the
properties and/or assembly of these proteins [445]. In adult muscle, periostin is maintained at
very low levels but becomes strongly expressed in fibroblasts and secreted into the ECM upon
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acute injury [446,447]. Interestingly, periostin is linked to fibrosis induced by eccentric exercise
[448]. Similarly, in individuals with DMD, periostin mRNA is significantly upregulated, especially
in young children [439], and muscle biopsies confirm that periostin is upregulated and
accumulates in the ECM, especially in areas of muscle fiber degeneration and dropout [449]. In
periostin-deficient mice, however, the strength of the collagen network is significantly reduced
as a result of disorganized and dysfunctional collagen fibrils [450,451]. Further, in dsarcoglycan-null mice, deletion of Postn resulted in significant reductions in muscle pathology of
the diaphragm, gastrocnemius and quadriceps muscles at 6 weeks and 6 months of age [449].
Also, the pseudohypertrophy observed in the muscles of d-sarcoglycan-null mice, which is often
the result of extensive fibrosis, was no longer present in the absence of periostin [449]. These
data suggest that while periostin negatively impacts disease pathogenesis, its absence
significantly enhances muscle fiber health in dystrophic muscle [449]. Therefore, in combination
with the downregulation of tgfbi, it is likely that eNMES decreases ECM deposition and fibrosis
in dmd mutants without altering cell adhesion.
Integrin-b1 (itgb1b.2) is also significantly upregulated in dmd mutants compared to wildtype siblings, but is reduced with eNMES (Figure 11A3). In skeletal muscle, integrins represent
the family of cell surface adhesion molecules that mediate cell-matrix interactions. Integrins are
heterodimeric, transmembrane glycoproteins that are made up of an a and b subunit. Notably,
the integrin-b1 family constitutes the largest group of receptors in the ECM, including at the
costameres, NMJ, and MTJ, during development and in mature muscle [452]. Integrin-a5b1 is
the classical fibronectin receptor while a6b1 and a7b1 are laminin receptors [452]. During
development, a5b1, a6b1, and a7b1 mediate aspects of myoblast fusion and myotube
formation [453–457]. In adult muscle, however, a7b1 is the major integrin receptor located
peripherally around muscle fibers and is highly enriched at the MTJs [458] and NMJ [459].
Notably, integrin-a7b1 participates in both outside-in and inside-out signal transduction
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processes and is involved in several muscle diseases [460]. In individuals with DMD and in mdx
mice, integrin-a7b1 is increased compared to healthy muscle, and it is suggested that this
increase may compensate for the absence of dystrophin [460]. In mdx muscles, activating
integrin-b1 ameliorates the dystrophic pathology, restores muscle strength, and improves
regeneration [461]. Similarly, in mdx-utrophin double knockout mice, overexpression of integrina7b1 ameliorates the development of muscular dystrophy and increases lifespan [462]. These
improvements are likely the consequences of enhanced fiber integrity, especially at the MTJ
and NMJ, which is suggested by the restoration of the highly folded sarcolemmal structure
unique to these locations [462]. Additionally, the enhanced laminin organization in the ECM may
support satellite cell proliferation and regenerative capacity [462]. In healthy muscle, integrina7b1 is increased at the MTJ following injury-producing exercise [463]. Interestingly,
overexpression of integrin-a7b1 prior to exercise protected the muscle from this exerciseinduced damage [463]. These data suggest that integrin may serve as a mechano-sensor and
likely plays an important role in muscle regeneration [462,464]. The downregulation of itgb1b.2
in dmd mutants as a consequence of eNMES is puzzling since we would expect that it would
play a protective role in dmd muscle. Further studies should unravel the role that integrin-b1
may play in improving muscle health in dmd mutants following eNMES. Altogether, though,
these data suggest that cell-ECM interactions and the composition of the ECM are changed with
eNMES.
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Figure 11: Modulation of ECM genes involved in regeneration and fibrosis following
eNMES may lead to observed improvements in muscle resilience in dmd mutants.
We identified three ECM genes, tgfbi (A1), postnb (A2), itgb1b.2 (A3) that are significantly
upregulated in dmd mutants compared to WT siblings and trend to be downregulated with
eNMES in dmd mutants. (B) Experiment overview. At 3 dpf (disease onset), birefringence
images are taken followed by the first session of eNMES. At 4 and 5 dpf, zebrafish undergo the
second and third NMES sessions, respectively. At 7 dpf, muscle resilience was tested using an
electrical stimulation paradigm intended to cause fiber detachments. (C) Birefringence images
were taken at 3 dpf, before the first session and after the first and second sessions. (C1) No
visible changes in birefringence are observed in WT siblings after the two stimulation sessions.
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(C2) For dmd mutant controls, the first round of stimulation did not result in visible changes to
birefringence (C2c) but, after the second round, areas of muscle degeneration are visible (C2d).
Conversely, in dmd mutants that completed three sessions of eNMES, the first (C3c) and
second (C3d) rounds of stimulation did not result in visible changes to birefringence. (C4, C5)
Change in birefringence from before to after the first round (C4) and second (C5) of stimulation
suggests that eNMES training may improve muscle resilience. (D) Phalloidin was used to
visualize individual muscle fibers. (D1a) Representative image of a WT sibling control
demonstrates healthy, organized muscle fibers and myotomes. (D2a) Representative image of a
dmd mutant control highlights disorganized and wavy muscle fibers and fiber detachments.
(D3a) Representative image of a dmd mutant that completed eNMES demonstrates some wavy
muscle fibers and detached fibers intermixed with relatively healthy myotomes. (D4) The
percent of muscle segments with detached fibers following the hard stimulation is reduced in
dmd mutants that complete eNMES training compared to dmd mutant controls. A muscle
segment is defined as half of a myotome. (D1b, D2b, D3b) Machine learning was used to
quantify muscle health pixel-by-pixel. Green indicates healthy pixels while red indicates
unhealthy pixels. (D5) The percent of healthy muscle following the hard stimulation is
significantly higher in dmd mutants that completed eNMES compared to dmd mutant controls.
All data were analyzed using two-sided t tests. * p < 0.05.
5.3.7 eNMES May Reduce Susceptibility to Contraction-Induced Injury in dmd Mutants
As mentioned above, analysis of expression levels of cell-matrix adhesion proteins does
not always indicate the physiological impact of these changes because the ECM supports
muscle homeostasis but can also result in fibrosis. Cell-matrix adhesion is often negatively
affected in various models of muscular dystrophy and restoration of adhesion improves muscle
structure and function [465,466]. Therefore, the downregulation of key cell adhesion proteins
following eNMES was puzzling and led us to ask whether muscle cell-matrix adhesion was
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altered by eNMES. We did this by subjecting zebrafish to a hard stimulation paradigm designed
to make muscle fibers detach from the MTJ [467] for two back-to-back sessions (Fig. 11B).
For this experiment, zebrafish completed three sessions of eNMES. Two days after
completing the third session, zebrafish were subjected to a relatively hard stimulation paradigm
designed to make muscle fibers detach from the MTJ for two back-to-back sessions (Figure
12A). This stimulation paradigm was defined by a frequency of 4 pulses per second, a delay of
60 ms, a duration of 2 ms, and a voltage of 30 volts, which is similar to that known to initiate
muscle fiber detachment from the MTJ [467]. Dmd mutants were stimulated for 1 minute.
Birefringence images were taken before and after each session. To ensure consistency in
imaging, zebrafish were mounted laterally with the head on the left and dorsal up, and the same
imaging parameters were used for each zebrafish across all imaging sessions. We then
analyzed the change in mean gray values before stimulation compared to after the first or
second session. Nearly half of control mutants (10/22) had decreased mean gray values after
the first session (Figure 11C4), and slightly over half (13/22) had decreased mean gray values
after the second session (Figure 11C5). In contrast, just under 25% of eNMES treated mutants
(5/22) had a decreased mean gray value after the first session (Figure 11C4) and slightly under
a third had a decreased mean gray value after the second session (7/22; Figure 11C5). While
there are no differences in absolute mean gray values between control and eNMES mutants
before and after the first round of stimulation (Fig. 11C4), the change in mean gray values for
eNMES-treated dmd mutants is higher following the second round of stimulation (Fig. 11C5).
These data suggest that eNMES may improve cell-adhesion.
In order to examine the impact of eNMES on muscle homeostasis in response to a hard
stimulation more thoroughly, zebrafish were immediately fixed and stained with phalloidin after
the last round of birefringence imaging. Similar to the birefringence data, the percent of muscle
segments with detachments is lower in dmd mutants that completed eNMES compared to
control dmd mutants (Figure 11D4). Notably, when we used machine learning to assess overall
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muscle health, dmd mutants that completed eNMES had a significantly higher percentage of
healthy muscle compared to control dmd mutants (Figure 11D5). These data suggest that dmd
mutants that complete eNMES can withstand contraction-induced injury better than dmd mutant
controls.
5.3.8 Paxillin Overexpression Does Not Improve the Benefits of Endurance NMES in dmd
Mutants
With the improved cell adhesion following eNMES, we next asked if paxillin
overexpression would further improve muscle resilience. Paxillin is an important mediator of
cell-matrix adhesion and costamere formation [468,469]. For this experiment, we used
transgenic dmd mutants that overexpress paxillin (actb2:pxn-EGFP) [470]. Zebrafish completed
three sessions of eNMES at 2, 3 and 4 dpf. Three days after completing the third session,
zebrafish were subjected to the cell adhesion stimulation paradigm for two back-to-back
sessions with birefringence images taken before and after each session (Figure 12A).
Surprisingly, paxillin overexpression negatively affected dmd muscle resilience in both groups,
as indicated by the negative changes in mean gray values before versus after the second round
of stimulation (Figure 12B4 and B5). Further, dmd mutants that completed eNMES have a
higher percentage of muscle segments with detachments (Figure 12C4), suggesting that paxillin
overexpression resulted in significant deterioration of muscle health and cell adhesion. These
data also suggest that eNMES finely tunes the ECM, and any interference, such as
overexpression of a cell adhesion protein, may negatively disrupt muscle’s response to
stimulation.
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Figure 12: Paxillin overexpression decreases muscle resilience in dmd mutants.
(A) Experiment overview. Transgenic dmd mutants that overexpression paxillin completed 3
sessions of NMES at 2, 3, and 4 dpf. On 7 dpf, dmd mutants completed two back-to-back
sessions of the cell adhesion stimulation paradigm. (B) Birefringence images were taken at 2
dpf, before the first session and after the first and second sessions of the hard stimulation. (B1)
No visible changes in birefringence are observed in WT siblings after the two stimulation
sessions. (B2) For dmd mutant controls, the first round of stimulation did not result in visible
changes to birefringence (B2c) but, after the second round, new areas of muscle degeneration
are visible (B2d). Similarly, in dmd mutants that completed three sessions of eNMES, the first
(B3c) round of stimulation did not result in visible changes to birefringence but the second round
(B3d) resulted in significant fiber damage. (B4, B5) Change in birefringence from before to after
the first round (B4) and second (B5) of stimulation suggests that overexpression of paxillin does
not protect the muscle from damage and may negatively affect its resilience. (C) Phalloidin was
used to visualize individual muscle fibers. (C1a) Representative image of a WT sibling control
demonstrates healthy, organized muscle fibers and myotomes. (C2a) Representative image of a
dmd mutant control highlights some wavy muscle fibers with few fiber detachments. (C3a)
Representative image of a dmd mutant that completed eNMES demonstrates vast muscle
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disorganization and detached fibers. (C4) The percent of muscle segments with detached fibers
following the hard stimulation is increased, but not significantly, in dmd mutants that complete
eNMES training compared to dmd mutant controls. A muscle segment is defined as half of a
myotome. All data were analyzed using two-sided t tests.
5.3.9 Genes in Our RNAseq Data Correspond With Those Identified in Pathway-Based
Approaches for Developing Therapies for DMD
We next asked whether differentially expressed genes in our RNAseq datasets coincide
with those being investigated as potential therapeutic targets in pre-clinical models.
Immediately, we found three genes of interest: heme oxygenase 1a (hmox1a), inducible nitric
oxide synthase 2a (nos2a), and beta-1,3-N-acetylglucosaminyltransferase 3 (b3gnt3) (Figure
13). These three genes are either being targeted directly or share unique features with those
under investigation. A discussion of their current roles in DMD and how eNMES may initiate
these same roles is provided below.

Figure 13: Potential genes that may be initiating the beneficial effects in muscle structure
and function coincide with those identified in DMD drug studies.
Genes targeted in DMD drug studies. We identified two genes, hmox1a (A1) and nos2a (A2),
that were significantly upregulated in dmd mutants following eNMES, and have been identified
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as potential drug targets in pre-clinical trials to ameliorate disease progression in DMD. (A3 –
A4) We also identified two genes, b3gnt3.1 (A3) and b3gnt3.3 (A4), with glycosyltransferase
activity that is share to those responsible for the glycosylation of alpha-dystroglycan, which is
another therapeutic target for DMD.

5.3.9.1 Sildenafil Citrate Targets NOS and HMOX1 and Improves DMD Phenotype
Sildenafil citrate is a phosphodiesterase-5 inhibitor that catalyzes the breakdown of
cGMP, which is the primary player in smooth muscle relaxation [471]. Sildenafil citrate was
initially introduced as a potential therapy for DMD due to its role as a potent vasodilator and its
ability to enhance nitric oxide (NO) signaling. In dystrophic muscle, NO production is
significantly reduced as a consequence of the mis-localization of neuronal nitric oxide synthase
(nNOS) at the sarcolemma. Specifically, the absence of dystrophin disrupts the recruitment of
nNOS to the sarcolemma, and therefore, negatively affects NO production [472]. Ultimately, the
reduction in NO leads to functional ischemia [473–477] due to persistent vasoconstriction.
Additionally, the lack of nNOS results in hyper-nitrosylation of ryanodine receptors, which
causes a persistent Ca+2 leak [478]. Both of these events result in muscle damage, reduced
force production and contraction-induced injury [475,476]. Numerous studies have
demonstrated positive effects of the administration of sildenafil citrate on respiratory [479] and
cardiac dysfunction [480–482], as well as sarcolemmal integrity and muscle fibrosis in the
diaphragm muscles of mdx mice [479]. Further, sildenafil citrate was shown to reduce muscle
damage following a single bout of downhill running and improve exercise performance in these
mice, possibly through enhanced microvascular function [483]. Similarly, studies have shown
that sildenafil citrate ameliorates the dmd phenotype in zebrafish and enhances survival
[484,485]. These positive results have led to clinical trials in humans [486]. Notably, two genes
targeted by sildenafil citrate, nos2a and hmox1a, are significantly upregulated following eNMES
in dmd mutants (Figure 13A1 and A2).
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5.3.9.2 HMOX1 is a Strong Therapeutic Target for DMD
HMOX1 is an anti-inflammatory and cytoprotective enzyme that attenuates both
oxidative stress and inflammatory reaction, and increases cell survival [487]. Kawahara and
colleagues (2014) [485] identified HMOX1 as a target of sildenafil citrate in zebrafish,
demonstrating a second mechanism in which sildenafil citrate elicits beneficial effects on
dystrophic muscle. Specifically, overexpression of HMOX1 significantly reduced the ability to
distinguish dmd mutants from wild-type siblings using birefringence, indicating improved muscle
structure and fewer muscle detachments. More importantly, though, overexpression of HMOX1
significantly extended survival in these zebrafish. Conversely, by administrating a morpholino
targeting the hmox1 transcript, these improvements were no longer observed. Similarly, in mdx
mice, pharmacological inhibition or genetic ablation of hmox1 aggravated muscle damage and
inflammation, and severely impaired exercise capacity compared to control mdx mice [488].
HMOX1 has been shown to play numerous roles in the body, including the regulation of blood
vessel formation and angiogenesis as well as muscle regeneration [489,490]. In regards to
muscle regeneration, the timing of hmox1 expression is critical. Specifically, short-term
expression of hmox1 promotes myoblast proliferation and subsequent muscle regeneration
[489], but long-term expression inhibits myoblast differentiation and negatively affects
regeneration [491]. Further, in hmox1-deficient satellite cells, higher activation and proliferation
rates are observed following injury, suggesting that hmox1 may prevent exhaustion of the
satellite cell niche [490]. Similarly, enhanced activation and differentiation is observed in satellite
cells isolated from mdx-hmox1 double knockout mice, but satellite cell activity was normalized
by supplementing cells with carbon monoxide, which is the product of HMOX1 activity [488].
Lastly, HMOX1 may play a protective role from oxidative stress by regulating mitochondrial
quality and influencing the processes of biogenesis, dynamics, and mitophagy, especially in the
cardiac muscle [492,493]. In our dmd mutants and wild-type siblings, eNMES significantly
increased hmox1a expression compared to their respective controls (Figure 13A1), suggesting
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a potential role for heme oxygenase signaling in eliciting the beneficial effects of eNMES on
muscle structure, function, and survival. Preliminary data suggest that dmd mutants have
impaired mitochondrial activity prior to disease onset (data not shown). Additionally, eNMES
increases mitochondrial copy number at 8 dpf (data not shown). From these data, combined
with our time-lapse analyses suggesting improved regeneration, we hypothesize that eNMES
reduces oxidative stress by improving mitochondrial function and this could improve
regeneration and muscle function. Future experiments should test whether eNMES and HMOX1
improve angiogenesis, mitochondrial activity, and/or regenerative capacities in dmd mutants.
5.3.9.3 Role of iNOS in DMD Pathology is Not Well Understood
nNOS is the principle isoform, or isozyme, expressed in skeletal muscle and has been
extensively studied in DMD research. Transgenic expression of nNOS in the mdx mouse
normalized NO production and reduced the occurrence of disease pathology, including the
number of centrally located nuclei, inflammation, variability in muscle fiber size and the amount
of sarcolemmal damage [274]. Similar results, including reduced fibrosis and increased lifespan, were obtained in the mdx-utrophin double knockout mice [494]. Conversely, nNOS
deficiency in mdx muscle exacerbated disease pathology, and it was hypothesized that
disrupted blood flow and/or angiogenesis were the underlying mechanisms leading to this
phenotype [126,495]. The role of iNOS, however, as a potential target for improving the
dystrophic phenotype is less studied [496–498]. Inducible NOS is upregulated in DMD muscle
fibers [496,498], suggesting a potential compensatory mechanism for maintaining homeostatic
levels of NO [496]. Inducible NOS is also upregulated in infiltrating macrophages responsible for
NO-dependent lysis of muscle fibers [497,499]. These studies suggest that iNOS-expressing
macrophages may accelerate inflammation and disease pathology in dystrophic muscle.
Conversely, it was recently shown that iNOS is required for effective muscle regeneration
following acute injury in healthy muscle and that iNOS-derived NO plays a non-redundant role in
skeletal muscle repair by regulating myogenic precursor cell function and shaping the
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inflammatory infiltrate [500]. Surprisingly, healthy fast-twitch muscles subjected to electrical
stimulation exhibit enhanced vasodilation via the NO-cGMP cascade [501,502], but whether
nNOS or iNOS is responsible for the production of NO has yet to be determined. Therefore, the
increased expression of nos2a transcript in dmd mutants following eNMES (Figure 13A2)
should be investigated further to unravel its potential role in eliciting the positive benefits
observed in muscle structure, function and survival. Specifically, is the upregulation in iNOS
after eNMES supporting regeneration by regulating satellite cell activation or is iNOS
maintaining homeostatic NO levels that support improved muscle function?
5.3.9.4 Glycosylation Events are Emerging as Major Players in Muscular Dystrophy Research
Mutations in proteins responsible for glycosylation and the production of glycosidic
linkages are responsible for multiple types of muscular dystrophy [503,504]. Additionally, these
proteins are also emerging as potential therapeutic targets for various muscular dystrophies,
including DMD, since many of these proteins target a-dystroglycan and enhance its ability to
bind to ECM ligands [503,504]. In our RNAseq data, two isoforms of b-1,3-Nacetylglucosaminyltransferase 3 (B3GNT3) are downregulated following eNMES in dmd
mutants, including b3gnt3.1 and b3gnt3.3 (Figure 13A3 and A4). Currently, there are no studies
linking these proteins to skeletal muscle health or neuromuscular diseases. However, their
similarity with two well-established proteins in muscular dystrophy research warrants further
discussion and future experiments to unravel their potential roles.
5.3.9.5 B3GNT3 and B3GNT1 Synthesize the Same Disaccharide
The B3GNT1 gene encodes a type II transmembrane protein essential for the synthesis
of poly-N-acetyllactosamine residues. Interestingly, mutations in b3gnt1 gene result in WalkerWarburg Syndrome, which is the most severe clinical form of secondary dystroglycanopathies
[505]. Secondary dystroglycanopathies are a group of muscular dystrophies caused by
abnormal glycosylation of a-dystroglycan. Knockdown of b3gnt1 in zebrafish results in skeletal
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muscle defects, including disrupted MTJs, compromised structural integrity, as well as reduced
a-dystroglycan expression [505]. Studies have proposed that B3GNT1 forms a complex with
LARGE and this interaction is required for LARGE’s glycosyltransferase activity, especially the
laminin-binding glycans on a-dystroglycan [506–508]. Interestingly, mutations in the Large gene
also result in secondary dystroglycanopathy. Therefore, the significance of downregulating
b3gnt3.1 and b3gnt3.3 following eNMES should be evaluated, especially to determine whether
this protein plays an important role in glycosylation or cell-ECM interactions. Additionally, since
glycosidic linkages are important for cell-adhesion, we further question how downregulating key
ECM proteins following eNMES improves cell adhesion and allows for improvements in muscle
function and survival.
5.3.9.6 B4GALNT2 is a Targeted Therapy for DMD
Similar to B3GNT1, the B4GALNT2 gene encodes a type II transmembrane protein
essential for the synthesis of N-acetylgalactosamine residue, which is responsible for
glycosylating a small number of glycoproteins, including a-dystroglycan [291,509]. More
importantly, though, B4GALNT2 is confined to the neuromuscular junction in adult animals
[509]. The B4GALNT2 (formerly GALGT2) protein plays an important role in improving DMD
muscle phenotype [291,293,510,511] and is now undergoing clinical trials. B4GALNT2 is a great
example for highlighting the fine balance in protein expression in muscle health. Specifically, in
healthy muscle fibers, transgenic overexpression of B4GALNT2 in extra-synaptic regions
dramatically reduced muscle fiber diameter and increased satellite cell activation [509].
Additionally, these muscle fibers exhibited significantly reduced numbers of secondary folds at
the NMJ that were often misaligned with active zones as well as mis-localization of critical
synaptic proteins, including laminin a4 and a5, utrophin and NCAM [509]. However,
overexpression of B4GALNT2 in mdx muscle from embryonic time points onward is extremely
effective at delaying the onset of dystrophy [291]. These same effects are also observed with
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postnatal overexpression, delaying muscle pathology up to 18 months of age [510]. Early
embryonic expression of B4GALNT2 increased the expression of utrophin and many dystrophinassociated proteins, including dystroglycan, sarcoglycans, and dystrobrevins along the length of
the muscle fibers in mdx mice [291]. These improvements translated to protection from
eccentric contraction-induced injury in mdx mice [293]. Interestingly, postnatal overexpression of
B4GALNT2 may or may not require utrophin or a-dystroglycan to initiate the positive benefits on
muscle health [510,511]. These data further support the idea that diseased muscle responds
differently to treatments, whether it is a pharmacological or non-pharmacological intervention.
Again, while there is no direct evidence establishing an interaction between or overlapping role
of B3GNT3 and B4GALNT2, further investigations should be conducted to evaluate the
significance of its downregulation following eNMES, especially since glycosylation proteins
demonstrate a significant impact on skeletal muscle health and disease progression, and may
require precise dosing to elicit beneficial versus detrimental effects.
5.4 Perspective
Basic fundamental studies are necessary to elucidate both the positive and negative
physiological adaptations at the molecular, cellular, and tissue levels to resistance training and
inactivity in dystrophic muscle. Our results demonstrate that dmd mutants play an integral role in
understanding neuromuscular plasticity in dystrophic muscle. Specifically, by employing the
zebrafish model to understand how eNMES impacts dystrophic muscle we have identified
numerous potential mechanisms for improving muscle structure and function in dystrophic
muscle. The data presented above demonstrate that eNMES positively benefits disease
progression by increasing sarcomere lengths, improving muscle nuclei health, and creating an
environment that supports regeneration. RNAseq data identify potential molecular mechanisms
that may allow us to see these improvements, and often these mechanisms are simply restoring
gene expression levels back to wild-type levels.

120

Re-evaluating the impact of NMES on the progression of DMD is critical for three
reasons: (1) there are still extremely limited gene therapies, (2) inactivity negatively impacts
disease progression, and (3) when an effective gene therapy is available, the next step will be to
strengthen these muscles. Therefore, having an established NMES training program that
improves muscle health is highly beneficial as it creates a starting point for when these gene
therapies become available. The results from this study demonstrate that eNMES improves
muscle health and is better for disease progression in dmd mutants, and that the zebrafish
model is an extremely valuable tool in elucidating the mechanisms of skeletal muscle plasticity
in healthy and diseased muscle.
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CHAPTER 6
ANSWERING THE UNKNOWNS: HOW CAN WE LEVERAGE ZEBRAFISH TO
UNDERSTAND NEUROMUSCULAR PLASTICITY?

6.1 Summary
The experiments conducted within this dissertation demonstrate that
•

The zebrafish model for DMD exhibits phenotypic variation in disease progression.

•

Periods of inactivity are extremely detrimental to dmd muscle health and survival.

•

NMES initiates changes in gene expression in wild-type siblings, indicating that the
zebrafish model is a valuable model to study skeletal muscle plasticity.

•

Endurance NMES positively benefits muscle health, function, and survival in dmd
mutants, and these changes are accompanied by improvements in NMJ abundance,
nuclear shape and size, and sarcomere lengths.

•

Dmd mutants respond to NMES differently than wild-type siblings, indicating that healthy
and diseased muscle use different mechanisms to maintain homeostasis.

We created an experimental design that leverages the power of the zebrafish model’s ability
to perform in-vivo analyses of numerous components of organismal health across time in
individual zebrafish. Ultimately, this design should be applied to pre-clinical drug studies for
various zebrafish models of muscular dystrophy as it provides a more comprehensive
understanding of the impacts an intervention may have immediately and across time. Further,
no studies to our knowledge have established zebrafish as a model for studying NMES. By
establishing zebrafish as a model for studying NMES, we can conduct comprehensive analyses
at the functional, structural, and molecular levels using a well-controlled experimental set-up
with high power analyses. These analyses will provide a more in depth understanding of the
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effects of NMES on skeletal muscle with the potential of unveiling new mechanisms and key
components in muscle growth. Most importantly, though, these findings indicate that the
zebrafish model is a valuable tool for studying skeletal muscle plasticity.
6.2 How Can We Leverage Zebrafish to Understand Neuromuscular Plasticity?
6.2.1 Elucidate Mechanisms for Disease Variation and Response to Interventions
No two individuals are alike. This statement is easily accepted when discussing the
human population but it is most often refuted when discussing animal models, such as the
mouse and zebrafish. While humans, mice and zebrafish are all very different from each other in
their size and biomechanics, it is possible that clinical trials, especially for muscular dystrophies,
are less successful because researchers tend to not address the possibility of variation in inbred
organisms.
The implications of variation in disease progression are not fully understood but make it
difficult to predict response to potential treatments. As demonstrated in Chapter 2, we see two
visibly and quantitatively distinct phenotypes at disease onset in our dmd mutants. We see a
mild phenotype, where very few muscle segments have visible signs of dystrophy, and a severe
phenotype, where multiple muscle segments have muscle fiber detachments and disorganized
fibers. Additionally, we see that in our transgenic zebrafish, which harbor the same pointmutation, disease onset is delayed from 2 dpf to 3 dpf but the same mild and severe
phenotypes are still present. This variation at disease onset is extremely important to be aware
of since disease progression, especially in the first three days after disease onset, is different.
Specifically, mild dmd mutants are degenerating while severe dmd mutants are regenerating.
Even though mild and severe mutants arrive at the same muscle structure at 8 dpf, their initial
severity level continues to affect their muscle function. Further studies will determine whether
initial disease severity also affects survival.
Studies have identified disease modifiers in the human population, and these genes
correlate with severity and muscle function, suggesting that our dmd mutants may also harbor
123

disease modifiers. We performed a preliminary investigation using RNAseq data from the
eNMES experiment. Since we paired the zebrafish based on their birefringence at disease
onset, we were able to compare differentially expressed genes in mild versus severe dmd
mutants. To perform this analysis, we combined all of the mild replicates, regardless if they were
in the control or eNMES group, into an analysis group (n = 9 replicates), and combined all of the
severe replicates, regardless if they were in the control or eNMES group, into another analysis
group (n = 7 replicates), and compare these two groups directly. Overall 76 genes were
statistically and biologically significant in their increase or decrease between mild and severe
mutants. These genes were associated with multiple GO terms, most notably are those
associated with memory and learning (or more broadly neurological) and the regulation of
transcription by RNA polymerase II. Two genes that immediately piqued our interest were
npas4, which regulates gene transcription for genes controlling inhibitory synapse development
and plasticity as well as cdkn1a, which stimulates protein breakdown and inhibits anabolic
signaling, protein synthesis, and PGC1-alpha expression. Both were decreased in severe dmd
mutants. Further, klf2a was decreased in severe mutants compared to mild mutants while il1b
and cd83 were upregulated. Interestingly, klf2a is involved in NO biosynthesis process while il1b
and cd83 are involved in the immune response. While these data are preliminary and represent
only a snapshot in disease progression, they suggest that the zebrafish model may be a great
model for studying variation and the underlying mechanisms of variation in disease.
To better understand neuromuscular plasticity in dmd muscle, future studies should look
at gene expression changes at 2, 5, and 8 dpf, since these time points are found to be most
critical in disease progression for mild versus severe dmd mutants. Differentially expressed
genes could unveil potential biomarkers for neuromuscular plasticity and their potential roles in
muscle structure, function and survival. Most importantly, though, these data could be valuable
when evaluating pharmacological interventions as some may have differential effects based on
the current expression levels of the targeted proteins in mild versus severe dmd mutants.
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Combined with the potential biomarker data, it may be possible to predict responders from nonresponders or create a drug program that targets specific genes at certain times depending on
the disease stage.
6.2.2 Model Inactivity and Exercise to Unravel the Delicate Equilibrium in Diseased Muscle
Zebrafish have been used to study various components of the exercise response [512–
515] as well as the impact of mechanical loading on development and tissue architecture
[514,516,517]. In adult zebrafish, swimming at an optimal speed for 6 hours per day for 20 days
significantly increased muscle fiber cross-sectional area, perimeter, and density, and promoted
capillarization within the muscle [512]. These adaptations to swim training were also observed
at the gene expression level. Specifically, swim training modulated the expression of genes
involved in the activation of neuromuscular communication, excitation-contraction coupling,
sarcomere contraction, cytoskeletal transmission of contractile force to the sarcolemma, and
ECM remodeling [512]. Genes involved in muscle growth and development, angiogenesis,
metabolism, inflammation, and protein synthesis and degradation were also altered by swim
training [512]. Lastly, adult swim training increased the expression of genes involved in
generating the slow muscle fiber phenotype [516]. Similarly, zebrafish larvae demonstrate these
same adaptations to swim training [513]. Beginning at 5 dpf, zebrafish completed three 3-hour
training sessions each day for up to 10 days. Following swim training, qPCR, in situ
hybridization and whole genome microarray analyses were performed, and data suggest that
molecular adaptations occurred in the brain, kidneys, pancreas, intestines and skeletal muscle.
Molecular changes in the gastrointestinal system suggest that larvae were able to
physiologically adapt to the increasing energy demands of the active muscles. Most importantly,
though, zebrafish larvae exhibited molecular changes that support muscle growth and shift in
muscle fiber types to support aerobic training. Most importantly, growth and survival were not
affected by swim training. Collectively, these data support the idea that zebrafish are a valuable
model for assessing the immediate and long-term physiological effects of aerobic exercise. In
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addition to being a valuable model for aerobic exercise, we believe zebrafish are exceptional
animals for elucidating mechanisms of neuromuscular plasticity in response to inactivity and
NMES, especially in healthy and diseased muscle.
NMES allows us to employ a concrete definition of exercise that can easily translate
across studies and across animal models. In Chapter 4, we explored how four NMES paradigms
influence components of muscle structure, function and survival and in Chapter 5, we explored
potential mechanisms that could lead to improvements in all three of these components in
response to only one NMES paradigm. There are numerous questions that remain unanswered,
such as how NMES improves structure but not function, or how NMES negatively affects
function but enhances survival. Performing additional analyses from Chapter 5 in dmd mutants
that underwent hypertrophy, strength and power NMES could help define the delicate
equilibrium we observe for neuromuscular plasticity in dmd mutants.
6.2.3 Understand the Importance of Time in Neuromuscular Plasticity
We created a high-throughput system to test the effects of electrical stimulation on
numerous components of muscle health but focused solely on a single time point, which is 8
dpf. We know that critical changes occur in dmd muscle from disease onset to this point. Thus,
it is important to look at additional time points in order to paint a better picture of how dmd
mutants arrive at this 8 dpf stage. Specifically, we have the ability to perform live SHG imaging
to elucidate changes in sarcomeres during and after NMES and utilize transgenic zebrafish
harboring fluorescent markers for pre- and post-synaptic proteins to monitor changes in NMJ
distributions. Additional confocal time-lapse analyses using our transgenic fish will also help
capture critical periods in which the muscle’s response to NMES is decided.
The ECM is highly dynamic and is constantly responding to signals from outside the cell
as well as to signals from inside the cell. In muscle, the ECM incorporates these signals to
provide a scaffold that supports regeneration or fibrosis to prevent further damage. Our RNAseq
data suggest that ECM remodeling is critical to dmd mutant phenotype and response to
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eNMES. Unfortunately, though, a single measure of gene expression at 8 dpf, does not allow us
to elucidate how the ECM responds to eNMES and if this response is the same immediately
following NMES versus three days post-NMES. In most exercise studies, gene expression is
evaluated at multiple time points after exercise to capture the evolving ECM dynamics. Based
on our taco time-lapse analysis, there is a critical period between 5 and 6 dpf where dmd mutant
controls are slow to respond to damaged muscle segments while dmd mutants that underwent
eNMES respond to and repair the damage. Evaluating gene expression during these time points
could shed light on what determines the fate of the ECM. Ultimately, these could identify
therapeutic targets that may support improvements in structure, function, and survival.
6.2.4 Target Newly Identified Genes to Understand Their Roles in Improving Muscle Structure,
Function, and Survival in dmd Mutants
Our RNAseq data provide us with a foundation to begin testing how certain genes
influence neuromuscular plasticity, especially in response to eNMES. First, we must confirm that
these genes and their respective proteins are differentially expressed using qPCR and Western
blot. Additionally, we need to identify where these genes are being expressed using in-situ
hybridization. Once these data are confirmed, the next step is to perform studies that examine
how manipulating their expression impacts eNMES-induced benefits in dmd muscle. For
example, 1400W dihydrochloride is a potent, highly selective iNOS inhibitor. Our data
demonstrate that nos2a is significantly upregulated in dmd mutants following eNMES. By
administering this drug during the training period, we would be able to determine whether iNOS
plays a fundamental role in eliciting the benefits observed with eNMES. Specifically, if eNMES is
no longer beneficial, we know that nos2a expression is important and additional experiments
can then be performed to determine the underlying mechanisms in which iNOS is driving these
improvements. Also, if nos2a is responsible, we can perform overexpression studies with our
inactivity paradigm to determine whether iNOS preserves muscle resilience. Similar studies can
be performed for HMOX1.
127

6.3 Moving Forward
The purpose of this project stemmed from questions concerning the limitations of
previous studies addressing the effects of exercise in dystrophic muscle and the difficulties of
accepting inactivity as the best recommendation for care. Disease-modifying therapies are
within the drug development pipeline for DMD. However, we are still unsure what the underlying
mechanisms for neuromuscular plasticity in dystrophic muscle are and how these muscles may
respond to changes in the demands imposed upon it, especially after the restoration of
dystrophin. We believe that identifying these basic mechanisms is a crucial first step for
evaluating potential therapies and driving research forward. The long-term impact of this project
is the establishment of a model system that provides a sustained and powerful influence within
the field of neuromuscular plasticity in healthy versus diseased muscle. It is likely that the
mechanisms in which our NMES programs benefit muscle health in dmd muscle may have
therapeutic potential in non-dystrophic muscle wasting conditions, including cardiovascular
disease, chronic obstructive pulmonary disease, diabetes, cancer, and long-term inactivity due
to trauma. Therefore, we believe that our study will help guide future efforts in the more timeand resource-intensive mouse model studies and human patient trials.
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APPENDIX A: MATERIALS
This section provides detailed protocols for making the solutions used throughout the
experiments performed in the above chapters.

A.1 1X ERM
To prepare a 20X stock solution the following was added to 800 mL of ddH2O: 17.5 g
NaCl, 0.75 g KCl, 2.9 g CaCl-2H2O, 0.41 g KH2PO4, 0.142 g Na2HPO4 anhydrous, and 4.9 g
MgSO4-7H2O. Once in solution, ddH2O was used to fill up to 1 L. This solution was then filter
sterilized into an autoclaved 1-L flask and stored at +4C. 1X ERM was prepared by adding 50
mL of the 20X stock solution, 0.3 g of NaHCO3, and one drop of methylene blue to 950 mL of
autoclaved ddH2O. 1X ERM was stored at room temperature.

A.2 Tricaine
A stock solution of triciane (MS-222) was prepared by adding 400 mg of powered
tricaine and 800 mg of Na2HP04 (Anhydrous) to 100 mL ddH20. The pH was adjusted to 7.0 if
necessary with 1M HCl or 1M NaOH. The stock solution was aliquoted and stored at -20C.
Working solutions were prepared daily for live imaging and/or NMES by adding 400 µL of the
stock solution to 10 mL of 1X ERM (612 µM). For the inactivity studies, working solutions were
prepared daily by adding 200 µL of the stock solution to 10 mL of 1X ERM (306 µM).

A.3 Agarose
For long-term live imaging on the confocal, we found the best concentration for agarose
to be 0.05%. In a 50-mL conical, 50 mg of low-melt agarose (Boston Bioproducts) was added to
10 mL of 1X ERM. The solution was then warmed in the microwave until the agarose was
completely dissolved. After the agarose cooled, but before it solidified, 400 µL of tricaine was
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added. For confocal imaging of fixed zebrafish, 50 mg of low-melt agarose was added to 10 mL
of 1X PBS and warmed in the microwave until it was dissolved.

A.4 Evan’s Blue Dye
Evan’s Blue Dye (EBD) was prepared in 0.9% saline solution. To make the 0.9% saline
solution, 9 g NaCl was dissolved in 700 mL dd H2O, and the final volume was brought to 1 L
using ddH2O and filter sterilized into an autoclaved 1 L flask. To make 1% EBD stock solution,
100 mg of EBD powder was added to 10 mL of 0.9% saline solution. This stock solution was
diluted to a final working solution of 0.1% by adding 1 mL of stock solution to 9 mL of 0.9%
saline solution. EBD remained wrapped in tin foil to avoid exposure to light.

A.5 Buffers
A 10X PBS stock solution was made by adding 74.0 g NaCl, 19.4 g Na2HPO4•7H2O, and
4.37 g NaH2PO4•H2O to 800 mL ddH2O. Once dissolved, ddH2O was used to fill up to 1 L and
the pH is adjusted to 7.4. This solution is then autoclaved. A 1X PBS solution was made by
adding 100 mL of 10X PBS to 900 mL of ddH2O. Similarly, a 2X PBS solution was made by
adding 200 mL of 10X PBS to 800 mL of ddH2O.
The 1X PBS-0.01% tween (PBS-tw) solution was prepared by adding 10 mL of
Tween20 to 990 mL of 1X PBS. Similarly, the 1X PBS-2% triton (PBS-tx) solution was prepared
by adding 20 mL of Triton X-100 to 980 mL of 1X PBS.

A.6 Paraformaldehyde
To prepare a 4% solution, 15 mL of ddH2O and 10 drops of 1M NaOH was added to 2 g
of powdered PFA in a 50-mL conical. The conical was placed in a hot bath with a stir bar until
the PFA was dissolved. Once dissolved, ddH2O was added up to 25-mL line, and the solution
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was filtered into a clean 50-mL conical. Next, 25 mL of 2X PBS was added followed by 12 drops
of 1M HCl. The pH was further adjusted until it was between 7.2 and 7.4.

A.7 Antibody Block
In a 50-mL conical, 2.5 g of Bovine Serum Albumin was dissolved in 30 mL of 1X PBS.
Once BSA was in solution, 500 µL of DMSO, 500 µL of Triton and 100 mg of saponin was
added. The final volume was brought up to 50-mL mark on the conical with 1X PBS.
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APPENDIX B: METHODS
This section provides detailed descriptions for the assays and analyses performed throughout
the experiments described in the above chapters. For every experiment, the same protocol was
followed unless explicitly stated.

B.1 Zebrafish Husbandry and Handling
Zebrafish embryos were retrieved from natural spawns of adult zebrafish maintained on
a 14-h light/10-h dark cycle. We used sapjeta222a zebrafish [390] for most experiments. For live
imaging studies, we used a transgenic sapjeta222a zebrafish expressing mylpfa:lyn-cyan,
smych1:GFP, myog:H2B:RFP (gift from Drs. Sharon Amacher and Jared Talbot). For the cell
adhesion study, we used sapjeta222a zebrafish overexpressing paxillin (actb2:pxn-EGFP) [470].
Embryos were grown in embryo rearing media (ERM) with methylene blue at 28.5 degrees
Celsius. Embryos were manually dechorionated at 1 day post fertilization (dpf). Zebrafish were
fed once daily beginning at 5 dpf. For survival studies, zebrafish were housed in 20 mm petri
dishes with 10 mL of system water per dish beginning at 8 dpf. Survival checks were performed
in the morning and at night. All protocols conform to the University of Maine Institutional Animal
Care and Use Committee’s Guidelines.

B.2 Birefringence Analysis
Birefringence is unique, physical property of highly organized matter, such as
sarcomeres, in which light is rotated as it passes through it [518]. The optical transparency of
zebrafish larvae allows birefringence to be used as a quick, rudimentary assessment of muscle
defects [518,519], and we use it in our experiments to quantitatively assess the daily
progression of dystrophy. Zebrafish were placed in tricaine (612 µM in 1X ERM) immediately
prior to imaging and then transferred to a 35-mm glass bottom dish. Birefringence images were
taken on a Leica MZ10 F Stereomicroscope with a Zeiss AxioCam MRm or Leica DMC5400
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camera attached. An analyzer in a rotatable mount (Leica) was attached to the objective and the
glass-bottom petri dish was placed on the polarized glass stage. Larvae showing consistently
bright (white in color), well organized myotomes are classified as unaffected, wild-type siblings.
Those displaying patchy areas (gray to black in color) of disrupted and disorganized myotomes
are classified as affected dmd mutants. These gaps or lesions are the result of muscle fiber
detachments from the myotendinous junction or disorganized and wavy muscle fibers [389].
Images were taken at the same time every day within an experiment. Imaging parameters were
consistent for all zebrafish and across all days.
Mean gray values were calculated using FIJI software as described previously [519]. All
images were blinded prior to measurements. Briefly, the body of the zebrafish was outlined from
the 6th to the 25th myotome using the “Polygon selections” tool and then the mean gray value
was measured. Three separate outlines were drawn to obtain three separate measures, and the
average was used for calculations. All birefringence data were normalized to the average wildtype birefringence in each imaging session. Mean gray values are presented as a percentage of
the average mean gray value of wild-type siblings in the control group (equation in Figure 1A).
Birefringence was used as the metric to assess changes in overall muscle structure from 5 dpf
to 8 dpf. A positive change in birefringence (increase in mean gray value) meant that there was
increased birefringence at 8 dpf compared to 5 dpf and thus muscle structure improved. A
negative change (decrease in mean gray value) meant that there was decreased birefringence
and that muscle structure was worse.

B.3 DanioVision Analysis
The DanioVision system and EthoVision XT 13.0 software (Noldus Information, Inc) was
used to conduct high-throughput locomotion tracking studies to better characterize the impact of
NMES on zebrafish swimming activity. DanioVision uses a high-speed, infrared-sensitive
camera to track individual zebrafish movement. For experiments, we kept zebrafish in their
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respective wells of a 12-well plate and placed the 12-well plate into the DanioVision observation
chamber. The temperature control unit was set to 28 degrees Celsius, ensuring that the
temperature of the ERM in the well plate was maintained throughout the recording period. All
zebrafish had five minutes to acclimate to the chamber. Using the EthoVision software, we
created a white-light routine that included a 5 minute period in the dark followed by two lighton/off cycles, where the white light turned on at 100% intensity for 5 minutes and then turned off
for 5 minutes. The total recording time was 25 minutes. Recordings were made at the same
time each day.
At the end of the recording period, the raw data for each well was exported as an Excel
file. This raw data file includes the distance moved and mean velocity across 0.033-second
periods. For each fish, the average total distance and mean velocity across 1 minute intervals
were calculated. Total distance and mean velocity during the dark periods (when fish are most
active) was then calculated for each experimental group using the average total distance and
mean velocity for each fish across the three 5-minute intervals.

B.4 Evan’s Blue Dye Analysis
Evan’s blue dye is a membrane impermeable dye used to assess membrane damage. In
dmd mutants, EBD is used to assess muscle fiber integrity [520]. We used EBD to assess fiber
integrity pre- and post-NMES using the methods described by [520]. Zebrafish were placed in
tricaine (612 µM) for 4 minutes. At the end of the 4 minutes, zebrafish were aligned on a 1%
agarose-lined Petri dish in a minimal volume of ERM. EBD was loaded into an injection needle
pulled from glass capillary tubes on a Sutter Flaming/Brown Micropipette Puller. The needle was
gently inserted into the peri-cardial space and EBD was ejected using a MPPI-3 pressure
injector (ASI). Zebrafish were allowed to recover for 3 hours, providing ample time for the dye to
circulate the body and enter damaged muscle fibers. Zebrafish were prepared for live imaging
as described above for birefringence. An ET DSR fluorescent filter (Leica) was used to visualize
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EBD. After imaging the initial dye amount in each zebrafish, zebrafish underwent 1 session of
NMES as described above. Immediately after the NMES session, zebrafish were again
prepared for live imaging. This allowed us to observe whether NMES caused additional dye
entry into the muscle. The next day, zebrafish were imaged pre- and post-NMES using the
same methods. Imaging parameters remained the same for all zebrafish and imaging sessions.
Zebrafish were mounted laterally with the head on the left and dorsal up. To quantify EBD entry,
mean gray values were calculated using the same methods described for birefringence except
the outline was drawn from the first visible somite to the last visible somite. All images were
blinded prior to analysis using a Perl script. Data is presented as the average mean gray value
of the three separate measurements.

B.5 NMES
Zebrafish were subjected to NMES in groups of four using our 3D printed ‘gym’ (Figure
4B). The rectangular gym is divided into 6 rectangular wells that measure 4.7625 mm (length),
1.5875 mm (width), and 1.5875 mm (depth). Two tunnels run parallel to the smaller sides of the
rectangular wells and the positive and negative electrodes slide through these tunnels such that
they are exposed only in the wells. This allows the delivery of electrical pulses to each zebrafish
simultaneously. Prior to the NMES session, zebrafish were transferred to tricaine solution (612
µM in 1X ERM) for 4 minutes. At the end of the 4 minutes, each zebrafish was placed into a well
with its head facing the positive electrode and its tail facing the negative electrode. The positive
and negative electrodes are attached to a Grass SD9 Stimulator, which is used to generate the
electrical pulses. Each NMES session lasts 1 minute. Following each NMES session, zebrafish
are removed from the gym and placed back into their respective well plates.

B.6 Immunostaining
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Zebrafish were fixed in 4% Paraformaldehyde (PFA) for 4 h at room temperature. After
fixation, embryos were rinsed in PBS-0.1% Tween 20 (PBS-tw). For visualizing muscle
structure, phalloidin was used. Zebrafish were first permeabilized in PBS-2% Triton-X-100 for
1.5 h and then placed in 1:20 phalloidin (Invitrogen) in PBS-tw for 4 hours on the rocker at room
temperature. Zebrafish were rinsed out of phalloidin using PBS-tw and stored in PBS-tw until
imaged. For visualizing neuromuscular junctions, zebrafish were stained with alphabungarotoxin and SV2. Zebrafish were first permeabilized in 1 mg/ml collagenase in 1X PBS for
1.5 h, and then stained with 1:500 alpha-bungarotoxin-647 (Molecular Probes) and 1:20
phalloidin in antibody block for 2 h at room temperature. Zebrafish were rinsed using PBS-tw,
and placed in antibody block overnight at 4°C. Zebrafish were then stained with 1:50 SV2
(DSHB) in antibody block for 3 days at 4°C. Upon removal from SV2, zebrafish were rinsed
using PBS-tw and then placed in antibody block for 8 h at room temperature. This was followed
by an overnight incubation in 1:200 GAM (Invitrogen) in antibody block. Zebrafish were then
rinsed out of secondary antibody using PBS-tw and stored in PBS-tw until imaged. Phalloidin488 or -546 and GAM-488 or -546 were used interchangeably with no differences in staining
observed.

B.7 Confocal Imaging
Confocal imaging was used to visualize phalloidin and NMJ staining. Fixed and stained
zebrafish were deyolked and then mounted in 0.5% low-melt agarose in 1X PBS in a 24-well
glass bottom plate. Fluorescent images were captured using a 25x water objective on a Leica
SP8 confocal microscope.
For live imaging, zebrafish were anesthetized in tricaine solution (612 µM in 1X ERM) for
4 minutes and then mounted 24-well glass bottom plate using 0.5% low-melt agarose in 1X
ERM (with 612 µM tricaine). Two or three zebrafish were placed in each well. Zebrafish were
mounted anterior left and dorsal up to ensure the same side of the fish was imaged each day.
178

Finally, a small amount of tricaine solution (612 µM in 1X ERM) was added to prevent the
agarose from evaporating and to ensure the zebrafish remained anesthetized throughout the
imaging session. Upon completion of imaging, zebrafish were gently removed from the agarose
using fine fishing line and returned to their respective wells.

B.8 Second Harmonic Generation
Fixed zebrafish were deyolked and then mounted in 1.0% low-melt agarose in 1XPBS
glass bottom 30-mm petri dish. The petri dish was then filled with PBS. Images were acquired
using a custom-built two-photon microscope. This system uses a modified Olympus FV300
system with an upright BX50WI microscope stand and a mode-locked Ti:Sapphire laser. Laser
power was modulated via an electro-optic modulator.
The SHG signals were collected in a non-descanned geometry using a single PMT.
Emission wavelengths were separated from excitation wavelengths using a 665 nm dichroic
beam splitter followed by a 448/20 nm bandpass filters for SHG signals. Images were acquired
using circular polarization with excitation power ranging from 1 to 50 mW and a 40x 0.8 NA
water immersion objective with 3x optical zoom and scanning speeds of 2.71s/frame. All images
were 512 x 512 pixels with a field of view of 85 micrometers.
To calculate sarcomere distance, SHG images were first imported into ImageJ, and
then, using the Freehand selection tool, two lines were drawn to indicate the outer boundaries
(top and bottom) of the muscle fiber being analyzed. The Freehand selections were converted
into .txt files and imported into LabVIEW VI. Using LabVIEW, the midline of the two selections
(top and bottom) was determined. The midline was then imported back into ImageJ over the
original photo, and positioned in the center of the sarcomeres. Next, the Plot Profile tool and
Peak Finder tool were then used to determine the peaks, which correspond to sarcomere
length. Since the Peak Finder tool gives distance in pixels, a conversion factor was used to
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convert pixels to micrometers based on the objective and optical zoom used. Multiple muscle
fibers are analyzed for each zebrafish.

B.9 Image Analysis
All images were blinded using a Perl script prior to analysis. Phalloidin images were
used to assess muscle fiber degeneration. The percent of myotomes with muscle fiber
detachments was calculated manually by counting the number of muscle segments with visibly
detached fiber(s). Muscle segments are defined as half myotomes. Additionally, we used
machine learning to identify healthy versus unhealthy muscle fibers. For these analyses, we
used MATLAB to implement a deep learning approach to segment images of phalloidin stained
fish into healthy muscle, sick muscle, and background. We used the DeepLab v3+ system with
an underlying Resnet18 network [521,522]. We defined the ground truth dataset manually using
LabelBox (labelbox.com). Training images and ground truth images were broken down into 256
x 256 pixel images for training. The training dataset was divided into 60% training, 20%
validation and 20% test data. Median frequency weighting was used to balance the classes.
Each fish was oriented such that the head of the fish would be at the left of the image. Data was
augmented to translate the images by 10 pixels vertically and horizontally. Rotation was found
to make the network less accurate as orientation angle of the muscle fibers relative to the body
orientation is important to assessing their health. The stochastic gradient descent with
momentum (SGDM) optimizer was selected with 0.9 momentum. The maximum number of
epochs was 100, and the mini-batch size was 8. In every epoch, the training dataset was
shuffled. The number of iterations between evaluations of validation metrics was 315. The
patience of validation stopping of network training is set up to 4. The initial learning rate used for
training was 0.001. The learning rate was dropped 0.3 fold piecewise during training every10
epochs. The Factor for L2 regularization (weight decay) was 0.005. The training set reached an
accuracy of 97%. Images were then segmented by the MATLAB semanticseg command, which
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produced 8-bit unsigned integer segmentations. The fraction of each fish that was determined to
be healthy was reported as a fraction of the total muscle. Pixels determined to be background
(i.e. not muscle) were excluded from this calculation.
For NMJ analyses, we used the method that was recently published by our laboratory
[523]. To prepare images for analysis, a custom Fiji macro was written in order to keep image
processing consistent throughout all experiments. First, the raw .lif file is opened in FIJI and the
image is split into its respective channels (phalloidin, AChR, and SV2). The phalloidin channel is
immediately saved as a .tif file and closed. For the AChR and SV2 channels, duplicate z stacks
are created and a 10 pixel radius Gaussian blur is applied. These blurred images are then
subtracted from their original images, respectively. The resulting images are then merged to a
single image and a maximum intensity projection is generated. This maximum intensity
projection is saved as a .tif file and closed. For each experiment, the maximum intensity
projections are combined into a single .tif file using a custom MATLAB script. This file is then
opened in FIJI and three separate masks, marking the fish body, horizontal myoseptum and
myoseptal innervation, are drawn on the projected images using the Pencil tool. These masks
were used to define muscle segments, where a muscle segment represents half of a single
myotome. Using a custom MatLab script, skeleton number and skeleton length were then
calculated for each muscle segment across all zebrafish analyzed. To do this, masks were
imported back into MATLAB for segmentation of the AChR and SV2 channels. Images were
further processed using the adaptive histogram equalization (“adapthisteq” function) to enhance
the images followed by a 1 pixel radius Gaussian blur (‘imguassfilt’ function) to denoise the
images. The now defined muscle segments were then skeletonized, cleaned, and despurred
(“bwmorph” function). Finally, skeleton number and length were calculated within each muscle
segment of a single fish and averaged across all fish within each experimental group.
Muscle nuclei were analyzed using FIJI’s 3D Object Counter as well as the basic
Measure tool. To prepare images for analysis we first reduced background noise by duplicating
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the image (z stack), performing a 10 pixel Gaussian blur on the duplicated image, and
subtracting the blurred image from the original image. We then performed a 1 pixel Gaussian
blur on this image and set a threshold using ‘max entropy’ setting. With this image, we used the
“Analyze Particles” tool to generate masks to use with “3D Object Counter” tool as well as the
“Measure” tool. The 3D Objects Counter tool provided surface area and volume measurements
while the Measure tool provided perimeter, area, and major axis measurements. These latter
measurements were used to calculate filament index.

B.10 Statistical Analysis
All statistical analyses were performed in Graphpad Prism. Normality was first assessed
for all data using the Shapiro-Wilk test. If data passed this normality test, an unpaired two-tailed
t test was performed between two data sets (i.e., dmd mutant control vs dmd mutant eNMES)
while an ordinary one-way ANOVA was performed followed by a Tukey’s multiple comparison
test between three data sets (i.e., WT sibling control vs dmd mutant control vs dmd mutant
eNMES). Conversely, if data failed the normality test, a Mann-Whitney U test was performed for
comparing two data sets while a Kruskal-Wallis test was performed for comparing three data
sets. Significance for all tests was set to p < 0.05.

B.11 RNA Extraction and Analysis
Total RNA was extracted from whole zebrafish at 7 dpf from replicate samples using the
Zymo Direct-zol RNA microprep kit. Each biological replicate consisted of two zebrafish. For
wild-type siblings, there were 4 replicates for the control group and 3 replicates for the eNMES
group, and for dmd mutants, there were 8 replicates for the control group and 10 replicates for
the eNMES group. Prior to performing RNA extractions, zebrafish within the eNMES and control
groups were paired based on their severity at disease onset and the calculated change in their
birefringence from 5 dpf to 7 dpf. RNA was kept at -80°C until it was shipped to Quick Biology
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(Pasadena, CA) for sequencing. Following RNA quality control using an Agilent BioAnalyzer
2100 (), polyA+ RNA-seq libraries were prepared for each sample using the KAPA Stranded
RNA-Seq Kit (KAPA Biosystems, Wilmington, MA). Final library quality and quantity were
analyzed by Agilent Bioanalyzer 2100 and Life Technologies Qubit3.0 Fluorometer. 150 bp
reads were sequenced on Illumina HighSeq 4000 (Illumnia Inc., San Diego, CA). Each library
was sequenced using 150bp paired-end reads using an Illumina HiSeq4000.
Analyses of RNA-Seq reads were completed on the Advanced Computing Group Linux
cluster at the University of Maine. To determine the quality of the RNA sequencing reads before
further processing, FastQC version 0.11.8 was utilized [524]. Following this quality assessment,
reads were concatenated tail-to-head to produce one forward FASTQ file and one reverse
FASTQ file for each replicate sample. These FASTQ files were then trimmed of adapter
sequences, and low quality leading and trailing ends were removed using Trimmomatic version
0.36.0 [525]. Trimmed paired-end reads mapped to the Ensembl-annotated zebrafish
transcriptome [526] (Ensembl version 95) to generate read counts per gene using RSEM
version 1.2.31 [527] with bowtie version 1.1.2 [528]. Read counts were analyzed using the
DESeq2 version 1.22.2 [529] to analyze gene expression, p-value, and false discovery rate
(FDR). Genes with fewer than ten mapped reads across all samples were excluded. For each
pairwise comparison of treatment groups, differentially expressed genes were determined using
FDR p-value cutoff of 0.1 and requiring at least a 0.6 log2 fold-change (in either direction).
Resulting lists were used for Gene Ontology enrichment analysis and set analysis for each pairwise comparison.
Sets of differentially expressed genes (both up and down regulated) were analyzed to
test for enriched GO Biological Process terms (FDR < 0.1) using GOrilla [530,531] (http://cblgorilla.cs.technion.ac.il/) for enrichment in Biological Processes. For this analysis, the entire set
of expressed genes were used a background. In cases where Gorilla found no enriched terms,
PantherDB’s overrepresentation test on Biological Processes [532] (http://pantherdb.org/) was
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used. Again, the entire set of expressed genes list was used as the backround, and results were
evaluated using Panther’s Fisher’s Exact Test and p-values were adjusted for multiple testing
using FDR.
Ensembl gene IDs were mapped to gene symbols and names using zebrafishMine’s
Analyse feature [533] (http://www.zebrafishmine.org/). In some cases, manual mapping was
used by comparing Zfin.org gene search and Ensembl gene search results. Summarized gene
expression data are available at the Gene Expression Omnibus (accession number
GSE155465), and FASTQ files are available at the Short Read Archive (accession number
SRP274405).
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APPENDIX C: SUPPLEMENTAL FIGURES
Figure 14: Variation at disease onset in dmd mutants affects swimming activity
throughout disease progression.

Figure 15: Swimming activity is negatively affected by extended inactivity at 5 dpf.

Figure 16: Percentage of dmd mutants that exhibited a negative change in mean gray
value from 5 to 8 dpf following NMES or extended inactivity.

Figure 17: Principal component analysis highlights clustering of replicates for WT
siblings and dmd mutants with and without eNMES.
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